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SREBP: A Key Effector of mTORC1 Signaling in Metabolism and Cancer  
 
ABSTRACT 
 The mammalian target of rapamycin complex 1 (mTORC1), a master regulator of 
cell growth and proliferation, is aberrantly activated in cancer, genetic tumor syndromes 
and obesity. Much progress has been made to understand the upstream pathways that 
regulate mTORC1, most of which converge upon its negative regulator, the Tuberous 
Sclerosis Complex (TSC) 1-TSC2 complex. However, the cell intrinsic consequences of 
aberrant mTORC1 activation remain poorly characterized. Using systems in which 
mTORC1 is constitutively activated by genetic loss of TSC1 or TSC2 and 
pharmacologically inhibited by treatment with an mTORC1-specific inhibitor rapamycin, 
we have identified that mTORC1 controls specific aspects of cellular metabolism, 
including glycolysis, the pentose phosphate pathway, and de novo lipogenesis. Induction 
of the pentose phosphate pathway and de novo lipogenesis is achieved by activation of 
a transcriptional program affecting metabolic gene targets of sterol regulatory element-
binding protein (SREBP). We have demonstrated that mTORC1 stimulates the 
accumulation of processed, active SREBP, although details of the molecular mechanism 
remain to be elucidated.  
To understand the physiological and pathological relevance of mTORC1-
dependent activation of SREBPs and lipogenesis, we explored these findings in the liver 
and in cancer. While we find that the induction of hepatic SREBP1c and lipogenesis by 
insulin requires mTORC1, mTORC1 activation is not sufficient to stimulate hepatic 
SREBP1c in the absence of Akt signaling, revealing the existence of an additional 
downstream pathway also required for this induction. We demonstrate that this 
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mTORC1-independent pathway involves Akt-mediated suppression of Insig2a, a liver-
specific transcript encoding the SREBP1c inhibitor INSIG2. In cancer, our initial findings 
demonstrate that mTORC1 plays a role downstream of TSC-deficiency and oncogenic 
PIK3CA and K-Ras to activate lipogenic SREBP targets and de novo lipogenesis. 
Further studies of the connection between mTORC1 and SREBPs in disease may offer 
insights into novel therapeutic approaches.    
 
 
 
 
 
 
	   v	  
TABLE OF CONTENTS 
 
CHAPTER 1 
Introduction 
Summary……………….………..……………………………………………………….2 
 
Background…………….………..……………………………………………………....2 
 
Common oncogenic signaling events activate mTORC1…………………………...3 
 
mTORC1 signaling and the metabolic reprogramming of tumor cells…………….6 
 Protein Synthesis  
  Autophagy 
Glucose Uptake and Glycolysis 
Mitochondrial Metabolism 
Lipid Synthesis 
The Pentose Phosphate Pathway 
 
Implications for the treatment of tumors with aberrant mTORC1 activation…….14 
 
Beyond cancer: the role of mTORC1 in metabolic disorders……………………..16 
 
Acknowledgements.…………..……………………………………………………….17 
 
References……………………..………………………………………………………17 
 
 
 
CHAPTER 2 
mTOR Complex 1 Controls Cellular Metabolism 
Summary……………….………..……………………………………………………..23 
 
Background…………….………..……………………………………………………..23 
 
Results……………….………..………………………………………………………..26 
A genomic approach to identify transcriptional targets downstream of 
mTORC1 
mTORC1 induces genes encoding the enzymes of specific metabolic 
pathways 
Identification of enriched transcription factor-binding elements in 
mTORC1-regulated genes 
HIF1a is responsible for the glycolytic response downstream of mTORC1 
	   vi	  
CHAPTER 2 continued 
 
SREBP is responsible for increased lipid biosynthesis, the pentose 
phosphate pathway, and cell proliferation downstream of mTORC1 
mTORC1 activates SREBP1 through S6K1 
 
Discussion…………….………..………………………………………………………65 
 
Materials and Methods………..………………………………………………………68 
 
Acknowledgements.…………..……………………………………………………….75 
 
References……………………..………………………………………………………75 
 
 
CHAPTER 3 
mTORC1-Dependent and Independent Control of Hepatic SREBP1c 
Summary……………….………..……………………………………………………..81 
 
Background…………….………..……………………………………………………..81 
 
Results……………….………..………………………………………………………..84 
Insulin stimulates hepatic SREBP1c in an mTORC1-dependent manner 
Liver-specific deletion of Tsc1 results in insulin-independent activation of 
mTORC1 
LTsc1KO mice are protected from age- and diet-induced hepatic steatosis 
LTsc1KO mice have defects in hepatic induction of SREBP1c and 
lipogenesis 
Elevated hepatic mTORC1 signaling attenuates insulin signaling to Akt 
Restoration of Akt signaling to LTsc1KO hepatocytes rescues SREBP1c 
induction 
INSIG2a suppression is an mTORC1-independent mechanism regulating 
SREBP1c downstream of Akt  
 
Discussion…………….………..…………………………………………………….117 
 
Materials and Methods………..…………………………………………………….119 
 
Acknowledgements.…………..……………………………………………………..123 
 
References...………………………………………………………………………….124  
 
 
	   vii	  
CHAPTER 4 
Discussions and Future Directions 
 SREBP as a key effector of mTORC1 signaling………………………………….130 
 mTORC1-dependent regulation of SREBP in hepatic lipid metabolism………..133 
Transcriptional Control of Cellular Metabolism by mTOR Signaling:  
Implications for mTORC1-driven cancer…………………………………………..136 
  Transcriptional control of tumor cell metabolism 
 Toward understanding the consequences of aberrant mTORC1 signaling 
 Transcriptional control of metabolic pathways downstream of mTORC1 
Normoxic induction of HIF1α by mTORC1 
Implications for tumor development, progression, and treatment 
 
Studies toward defining the role of the mTOR-SREBP connection in tumor cell 
metabolism……………………………………………………………………………145 
 
Future Directions………………………..……………………………………………152 
 
References……………………..……………………………………………………..153 
 
 
APPENDIX 
Chewing the Fat on Tumor Cell Metabolism 
Summary………………………………………………………………………………160 
Discussion…………………………………………………………………………….160  
References...………………………………………………………………………….164  
 
 
  
	  	   viii	  
 
 
 
 
 
 
 
 
For Derek, Mom, Dad and Justin 
 
In memory of Pete Curtin 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   ix	  
ACKNOWLEDGEMENTS 
 
 
I have had a wonderful Ph.D. experience thanks to Brendan, who has been an 
incredibly supportive advisor. I learned so much from Brendan, who has taught me not 
only how to do great science but also to effectively communicate my work to others. I am 
so grateful for the tremendous opportunities Brendan has provided me with, whether to 
pursue exciting projects, to write papers and reviews, and to speak at conferences. I am 
really appreciative of his caring guidance and willingness to always provide insightful 
and thoughtful feedback. I will miss our chats that quickly went off topic towards some 
exciting discussion of new future directions. I have also to thank him for my acquisition of 
a liking for both coffee and good beer.  
I would like to especially thank my family. My husband, Derek, has always been 
there to support me, in both the happy and difficult times throughout graduate school 
and always. I could not have accomplished my Ph.D. without him – and I also mean this 
literally, as he worked as my very talented technician for a few months. I would like to 
express my upmost appreciation for my mom, who inspired me to study science and 
pursue a Ph.D. She has accompanied me throughout my Ph.D. on the other end of the 
phone during my daily journeys to and from the lab. She has always been there to offer 
suggestions and advice, both scientific and personal. Thanks also, to my Mom, Dad and 
brother, Justin, who made long trips up from New York to visit for dinner, which were 
always a fun escape from weekends in the lab. 
Finally, I would like to thank the members of my Dissertation Advisory and 
Dissertation Defense Committee Drs. Lewis Cantley, Gökhan Hotamisligil, Chih-Hao 
Lee, Tiffany Horng, Marianne Wessling-Resnick, and David Sabatini for their time, 
advice, and support.  
CHAPTER 1. Introduction 
	   1	  
 
CHAPTER 1 
Introduction  
 
Adapted from: 
Yecies, J.L.1 and Manning, B.D1. (2011). mTOR links oncogenic signaling to tumor cell 
metabolism. J Mol Med 89, 221-8.  
 
1Department of Genetics and Complex Diseases, Harvard School of Public Health, 
Boston, MA 02115, USA 
 
 
 
 
 
 
 
 
CHAPTER 1. Introduction 
	   2	  
SUMMARY 
The mammalian target of rapamycin (mTOR) complex 1 (mTORC1) is aberrantly 
activated in a wide variety of disease states, including cancer, genetic tumor syndromes, 
and metabolic disorders. As a key regulator of cell growth and proliferation, mTORC1 
has been the subject of intense investigation for its role in tumor development and 
progression. This research has revealed a signaling network of oncogenes and tumor 
suppressors lying upstream of mTORC1, and oncogenic perturbations to this network 
result in the aberrant activation of this kinase complex in the majority of human cancers. 
However, the molecular events downstream of mTORC1 contributing to tumor cell 
growth and proliferation are just coming to light. In addition to its better-known functions 
in promoting protein synthesis and suppressing autophagy, mTORC1 has emerged as a 
key regulator of cellular metabolism. Recent studies have found that mTORC1 activation 
is sufficient to stimulate an increase in glucose uptake, glycolysis, and de novo lipid 
biosynthesis, which are considered metabolic hallmarks of cancer, as well as the 
pentose phosphate pathway. mTORC1’s novel role as a regulator of cellular metabolism 
also has implications for its role in metabolic disorders, such as type 2 diabetes. Here, 
we focus on the molecular mechanisms of metabolic regulation by mTORC1, and the 
potential consequences for anabolic tumor growth and therapeutic strategies. We will 
also briefly summarize the current knowledge of mTORC1’s control of systemic 
metabolism. 
  
BACKGROUND 
The successful tumor cell must overcome the metabolic demands of an 
increased rate of growth and proliferation, often in the face of diminishing access to 
certain nutrients. In order to adapt and thrive under such conditions, tumor cells 
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inevitably acquire oncogenic mutations in growth factor and nutrient-sensing signaling 
pathways that disconnect metabolic regulation from physiological signals. The 
mammalian target of rapamycin (mTOR) is an evolutionarily conserved Ser/Thr kinase 
that could play a major role in the metabolic reprogramming of tumor cells. A complex of 
mTOR with at least two other essential core components (Raptor and mLST8), known as 
mTOR complex 1 or mTORC1, responds to signals relaying the status of extrinsic and 
intrinsic cellular growth conditions and has emerged as an upstream control point for 
cellular metabolism. Importantly, the mTORC1 pathway is aberrantly activated in the 
majority of human tumors (reviewed in [1]), making it poised to influence the metabolic 
changes common to tumor cells. 
 
Common oncogenic signaling events activate mTORC1 
As a key regulator of cell growth and proliferation, mTORC1 is activated by the 
predominant signaling pathways that promote these processes. These include both the 
PI3K-Akt and Ras-Erk pathways, which are the most common oncogenic signaling 
pathways activated in human cancers. These pathways regulate mTORC1 by 
converging on a small G protein switch, involving the tuberous sclerosis complex (TSC) 
tumor suppressors TSC1 and TSC2 and the Ras-related small G protein Rheb (Figure 1-
1; reviewed in [2]). TSC2, when in a complex with TSC1, acts as a GTPase-activating 
protein (GAP) for Rheb, thereby stimulating its conversion to the inactive GDP bound 
form. GTP-bound Rheb is thought to bind directly to mTORC1 and is essential for the 
stimulation of mTORC1 kinase activity [3]. Protein kinases downstream of Ras and PI3K, 
including Akt, Erk, and RSK, directly phosphorylate TSC2 on a variety of inhibitory sites, 
thereby blocking the ability of the TSC1-TSC2 complex to act as a GAP for Rheb. This 
results in accumulation of GTP-bound Rheb and acute activation of mTORC1. In 
addition to these growth factor signaling pathways, mTORC1 signaling is sensitive to  
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Figure 1-1. A network of oncogenes and tumor suppressors lie upstream of 
mTORC1. Growth factors bind to and stimulate receptor tyrosine kinases (RTKs), which 
can activate mTORC1 through both the PI3K-Akt and Ras-Erk signaling pathways. 
These pathways converge to inhibit the TSC1-TSC2 complex, allowing Rheb-GTP to 
accumulate and activate mTORC1. Cellular energy depletion is sensed by mTORC1 
through a rise in intracellular AMP leading to LKB1-dependent activation of AMPK. 
AMPK also signals through the TSC1-TSC2 complex, but enhances the activity of this 
complex, thereby inhibiting mTORC1 in response to energy stress. Within this upstream 
signaling network lie many oncogenes (depicted in green) and tumor supressors 
(depicted in red). Oncogenic mutations within this network are common in human 
tumors, resulting in aberrantly elevated mTORC1 activity contributing to uncontrolled cell 
growth and proliferation. 
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intracellular nutrients and energy. While the sensing mechanisms are poorly understood, 
mTORC1 senses amino acids in a manner dependent on the Rag GTPases, which 
under amino acid replete conditions recruit mTORC1 to lysosomal membranes for 
activation by Rheb [4]. Cellular energy levels are sensed by mTORC1, at least in part, 
through the AMP-activated protein kinase (AMPK). In response to ATP consumption and 
a rise in intracellular AMP levels, AMPK inhibits mTORC1 by phosphorylating TSC2 on 
activating sites [5] and the mTORC1 component Raptor on inhibitory sites [6]. Therefore, 
the activation status of mTORC1 is influenced by a network of signaling pathways that 
sense cellular growth conditions. Aberrantly elevated mTORC1 signaling is detected in 
40 to 90% of the ten most frequently occurring human cancers [1]. This is consistent with 
the fact that the signaling network lying upstream of mTORC1 is comprised of some of 
the most commonly mutated oncogenes and tumor suppressors (Figure 1-1). In addition 
to common activating mutations in PI3K and K-Ras, upstream receptor tyrosine kinases 
(RTKs) are often subjected to activating mutations and amplifications, and tumor 
suppressors that negatively regulate these pathways, such as PTEN and NF1, are 
frequently lost. Through activation of the PI3K and/or Ras signaling pathways, these 
events lead to growth factor-independent activation of mTORC1. In addition, the LKB1 
tumor suppressor, which is mutated in a large percentage of lung cancers, is required for 
AMPK activation in response to energy stress, and its loss also leads to aberrant 
mTORC1 signaling [7]. In addition to sporadic cancers, mTORC1 is activated in a large 
number of genetic tumor syndromes, classified as hamartoma syndromes or 
phakomatoses, caused by loss of upstream tumor suppressors, including tuberous 
sclerosis complex (TSC1, TSC2), Cowden syndrome (PTEN), neurofibromatosis (NF1, 
NF2), and Peutz-Jeghers syndrome (LKB1) (reviewed in [1]). Therefore, as a 
convergence point for numerous oncogenes and tumor suppressors, mTORC1 is well-
positioned to control cellular processes common to all tumor cells. 
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mTORC1 signaling and the metabolic reprogramming of tumor cells 
Given the pervasive upregulation of mTORC1 in human tumors, it is important to 
establish a better understanding of the downstream consequences of mTORC1 
activation under both physiological and pathological states. Studies using the mTORC1-
specific inhibitor rapamycin have revealed an evolutionarily conserved role for mTORC1 
orthologs in the control of cell growth (i.e. an increase in cell size) and proliferation (i.e., 
an increase in cell number) in organisms from yeast to humans [8]. However, these are 
complex biological processes, and the specific molecular functions of mTORC1 
contributing to these gross physiological outcomes are still being elucidated. Below, we 
focus on metabolic processes found to be regulated downstream of mTORC1 and their 
potential to contribute to the bioenergetic and anabolic demands of rapidly growing and 
proliferating tumor cells. 
 
Protein synthesis 
The most recognized function for mTORC1 is the promotion of protein synthesis, 
which it controls at several levels. While the mechanisms are poorly understood in 
mammalian cells, mTORC1 plays a conserved role in stimulating ribosome biogenesis. 
A major point of control for the production of new ribosomes is the translation of mRNAs 
encoding ribosomal proteins, which share the characteristic of 5’ untranslated regions 
(UTRs) containing sequences rich in pyrimidines, commonly referred to as 5’-terminal 
oligo pyrimidine (5’TOP) tracts. The translation of these mRNAs, which also include 
those encoding translation factors, is stimulated by mTORC1 signaling through an 
unknown mechanism (e.g., reference [9]). In addition, the transcription of rRNA genes 
can be induced downstream of mTORC1 [10]. Apart from enhancing the protein 
synthetic capacity of the cell by increasing the number of ribosomes, mTORC1 signaling 
controls specific aspects of mRNA translation initiation through at least two classes of 
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direct downstream substrates (reviewed in [11]). mTORC1 phosphorylates and activates 
the ribosomal S6 kinases (S6K1 and S6K2), which in turn phosphorylate a number of 
downstream targets involved in translation initiation, including ribosomal protein S6, 
eIF4B, and PDCD4 (programmed cell death 4). mTORC1 also phosphorylates the 
eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BP1 and 4E-BP2), which 
triggers their release from eIF4E at the 5’-cap of mRNAs, thereby allowing translation 
initiation factors to bind (Figure 2-2). However, mTORC1 activation appears to acutely 
stimulate the translation of only a subset of mRNAs. Aside from 5’TOP sequences, the 
molecular properties dictating this selectivity are poorly defined, but many of the mRNAs 
that are particularly sensitive to mTORC1 signaling contain highly structured 5’UTRs. 
Importantly, this includes mRNAs encoding proteins that control cell proliferation and 
metabolism (e.g., cyclin D1, c-Myc, HIF1α). While the individual translational targets of 
mTORC1 signaling will contribute to tumor development and progression, the stimulation 
of ribosome biogenesis leading to an overall increase in protein synthesis is likely to be a 
major mechanism by which mTORC1 promotes anabolic cell growth and proliferation in 
tumor cells.  
 
Autophagy  
Autophagy is a catabolic cellular process that facilitates the recycling of 
organelles and proteins into their nutrient components (reviewed in [12]). Autophagy 
serves as both a quality control process and a mechanism to replenish intracellular 
nutrients under conditions of poor nutrient availability. Under nutrient rich conditions, 
mTORC1 signaling suppresses autophagy, at least in part, by inhibiting a conserved 
protein complex containing the protein kinases ULK1 or ULK2, which is required for the  
CHAPTER 1. Introduction 
	   8	  
 
Figure 1-2. mTORC1 regulates many aspects of cellular metabolism. Physiological 
or pathological activation of mTORC1 results in changes to cellular metabolic processes. 
In addition to its well-known roles in promoting protein synthesis and inhibiting 
autophagy, mTORC1 has been found to stimulate glucose uptake, its conversion to 
glucose 6-phosphate (G6P), and metabolic flux through both glycolysis and the oxidative 
arm of the pentose phosphate pathway (PPP). Through activation of SREBP, mTORC1 
also stimulates the production of cytosolic acetyl-CoA and subsequent lipid and sterol 
synthesis. The products of these metabolic processes that are most likely to contribute 
to anabolic growth and proliferation downstream of mTORC1 are depicted in green. See 
text for details. 
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induction of autophagy [13]. Autophagy is thought to have prosurvival effects on cells 
experiencing metabolic and nutritional stress within established tumors, enabling them to 
evade apoptosis [14]. However, autophagy also has tumor suppressive effects, as 
defective initiation of autophagy promotes tumorigenesis. Therefore, aberrant activation 
of mTORC1 and inhibition of autophagy in the early stages of tumorigenesis could 
promote tumor progression. 
 
Glucose Uptake and Glycolysis 
One of the most well appreciated metabolic differences between cancer cells and 
their cell of origin is a greatly enhanced rate of glucose uptake and its glycolytic 
conversion to lactate (reviewed in [15]). This glycolytic switch is driven, in part, by the 
hypoxic tumor microenvironment, which dampens the capacity for oxidative metabolism 
in the mitochondria. However, this switch to glycolysis is generally maintained when 
tumor cells are returned to normoxic conditions following angiogenesis or, as seen most 
often, when cultured in the laboratory, suggesting underlying genetic or epigenetic 
changes. This phenomenon, known as aerobic glycolysis or the “Warburg effect”, 
provides tumor cells a proliferative advantage over normal cells under conditions of 
intermittent hypoxia within the growing tumor. However, aerobic glycolysis also more 
readily provides both the energy (ATP) and building blocks (carbon intermediates) for 
rapid anabolic growth and proliferation. The switch to aerobic glycolysis occurs, in large 
part, through the global upregulation of genes encoding the enzymes of glycolysis, and 
these genes are amongst the most overexpressed in human cancer [16].  
Oncogenic events, most notably the activation of the PI3K-Akt-mTORC1 
pathway, have been found to promote expression of genes involved in glucose uptake 
and glycolysis through normoxic upregulation of the hypoxia-inducible factor (HIF1α) 
transcription factor [17-22]. Importantly, activation of mTORC1 increases translation from 
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the 5’UTR of the mRNA encoding HIF1α and is sufficient to stimulate glycolytic gene 
expression and a corresponding increase in flux through glycolysis (Chapter 2; [23]). 
Another known translational target of mTORC1 is the oncogenic transcription factor c-
Myc, which can also promote glycolytic gene expression and might contribute to the 
induction of glycolysis downstream of mTORC1 in some settings [24, 25]. Therefore, 
through its effects on specific transcription factors, mTORC1 activation by upstream 
oncogenic signaling pathways could be an underlying mechanism driving the Warburg 
effect in some tumors. In the clinic, monitoring glucose uptake into tumors, through FDG-
PET imaging, could serve as an important tool to predict the efficacy of mTORC1 
inhibitors [22]. 
 
Mitochondrial Metabolism 
The glycolytic program of tumor cells is generally accompanied by upregulation 
of enzymes involved in further funneling pyruvate, the end product of glycolysis, away 
from oxidation in mitochondria. This is achieved in large part through HIF1α-mediated 
expression of lactate dehydrogenase (LDH1), which converts pyruvate to lactate, and 
pyruvate dehydrogenase (PDH) kinase (PDK1), which inhibits the conversion of 
pyruvate to acetyl-CoA by phosphorylating and inhibiting a subunit of PDH (reviewed in 
[25]). Activation of mTORC1 promotes the HIF1α-dependent expression of both LDH1 
and PDK1 (Chapter 2; [23]) and, therefore, would be predicted to decrease oxidative 
metabolism in the mitochondria. However, in some cellular settings, mTORC1 appears 
to promote mitochondrial biogenesis and oxidative metabolism [26, 27], and in one 
study, short-term inhibition of mTORC1 with rapamycin actually led to an increase in 
lactate production and decrease in oxygen consumption [28]. A genetic mouse model 
ablating mTORC1 activity specifically in skeletal muscle has also suggested a role for 
mTORC1 in mitochondrial function [29]. Further studies focused on the importance of 
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mTORC1-mediated effects on the mitochondria in tumor models are clearly needed to 
understand potential contributions of this regulation to tumor cell metabolism. 
 
Lipid Synthesis 
Like the Warburg effect, an increased rate of de novo lipid synthesis is another 
nearly ubiquitous metabolic change in tumor cells [30]. In contrast to metabolic cell types 
designed to produce lipids, such as those comprising the liver and adipose tissue, most 
normal cells have very low rates of lipid synthesis, instead obtaining essential lipids from 
the diet. The acquired ability of cancer cells to generate their own lipids facilitates the 
increased demand for new membranes to support rapid growth and proliferation. The 
sterol regulatory element-binding protein (SREBP) transcription factors (SREBP1a, 
SREBP1c, and SREBP2) are master regulators of genes involved in lipid and sterol 
synthesis. In order to prevent the metabolically costly processes of lipid and sterol 
synthesis under conditions of low demand, the SREBPs are tightly regulated through a 
complex series of events that have yet to be fully delineated [31]. SREBPs reside as 
inactive precursors in the endoplasmic reticulum (ER) in complex with SREBP cleavage-
activating protein (SCAP). Growth factor signaling or depletion of intracellular cholesterol 
stimulate SREBP trafficking from the ER to the golgi, where two sequential proteolytic 
cleavage events release the mature, active form, which translocates to the nucleus to 
turn on target genes.  
The PI3K-Akt pathway has been shown to upregulate lipogenic gene expression 
in an SREBP-dependent manner [32], and mTORC1 has recently been identified as the 
critical downstream effector responsible for SREBP activation (Chapter 2; [23, 33]). 
Although the molecular mechanism(s) remains to be elucidated, current data support a 
role for mTORC1 signaling in promoting the trafficking or processing of SREBP. 
mTORC1 activation has been demonstrated to stimulate de novo lipogenesis in an 
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SREBP-dependent manner, and this contributes to both the growth and proliferation of 
cells downstream of mTORC1 (Chapter 2; [23, 33]). Interestingly, fatty acid synthase 
(FASN) is encoded by an SREBP target gene and is upregulated at the mRNA level in 
most types of human cancer [30]. Activation of the PI3K-Akt pathway has been 
implicated in the increased expression of FASN in prostate cancer cell lines and primary 
tumors [34, 35]. Future studies will focus on determining whether mTORC1 is primarily 
responsible for elevated FASN expression and de novo lipid synthesis in some classes 
of tumors, such as those driven by the PI3K-Akt pathway. However, one recent study 
has suggested that the elevated activation of SREBP in at least some tumors is resistant 
to rapamycin [36]. FASN expression can also be readily detected in biopsy samples, and 
its sensitivity to treatment with mTORC1 inhibitors may prove to be a useful biomarker to 
predict clinical response to these inhibitors. 
 
The Pentose Phosphate Pathway 
  While increases in protein synthesis, glycolysis, and de novo lipogenesis are 
metabolic hallmarks of cancer, contributions from altered regulation of the pentose 
phosphate pathway are more poorly understood. Increased activity of the rate limiting 
enzyme of the oxidative arm of the pentose phosphate pathway, glucose 6-phosphate 
dehydrogenase (G6PD), has been reported in a variety of human tumors (e.g., 
references [36-38]). Similarly, overexpression and increased activity of transketolase 
(TKTL1), a key enzyme of the non-oxidative branch of the pentose phosphate pathway, 
has been found to correlate with increased invasiveness and patient mortality in several 
cancer types (e.g., references [40-42]). A recent study has found that mTORC1 
activation is sufficient to stimulate the expression of genes encoding the enzymes of 
both the oxidative and non-oxidative branches of the pentose phosphate pathway 
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(Chapter 2; [23]), although the relevance to cancers displaying elevated mTORC1 
signaling remains to be explored. 
Activation of the pentose phosphate pathway could contribute to many of the 
unique metabolic requirements of tumor cells. Through its generation of NADPH, the 
oxidative arm of the pentose phosphate pathway provides reducing power to drive 
anabolic metabolism. For instance, large amounts of NADPH are required and 
consumed during de novo lipid synthesis. In support of a link between the pentose 
phosphate pathway and lipogenesis, G6PD has been suggested to be a transcriptional 
target of the lipogenic transcription factor SREBP1 [43-45]. Importantly, the induction of 
G6PD expression downstream of mTORC1 was found to be dependent on the ability of 
mTORC1 to activate SREBP1 (Chapter 2; [23]). How mTORC1 signaling stimulates the 
other pentose phosphate genes is currently unknown. Pentose phosphate pathway-
generated NADPH also protects against oxidative stress by sustaining levels of reduced 
glutathione. This could be particularly important in tumor cells that might have elevated 
levels of reactive oxygen species due to metabolic fluctuations influenced by intermittent 
access to oxygen and nutrients within the tumor. In support of this idea, a recent study 
demonstrated that the PI3K-Akt pathway reduces oxidative stress and promotes cell 
survival of mammary epithelial cells detached from the extracellular matrix by increasing 
flux through the oxidative pentose phosphate pathway [46]. It has been demonstrated 
that mTORC1 activation is sufficient to stimulate an increase in flux through the oxidative 
pentose phosphate pathway (Chapter 2; [23]), and future studies will determine the role 
of this regulation in tumor cell adaptation to the dynamic tumor microenvironment. 
Both the oxidative and non-oxidative branches of the pentose phosphate 
pathway generate ribose, an essential precursor for de novo nucleotide biosynthesis. 
Rapidly dividing tumor cells must generate their own nucleotides to sustain DNA 
replication and the increased demand for RNA, especially ribosomal RNA. While 
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mTORC1 stimulates expression of genes encoding enzymes of both branches of the 
pentose-phosphate pathway, the increase in production of ribose 5-phosphate 
stimulated by mTORC1 activation was found to come primarily from increased flux 
through the oxidative branch (Chapter 2; [23]). There is some debate over the relative 
contributions of the oxidative and non-oxidative arms of the pentose phosphate pathway 
to the production of ribose for nucleotide biosynthesis within tumor cells. This is an 
important area for future study in the field of tumor cell metabolism, as it is likely that 
distinct oncogenic events could differentially regulate the pentose phosphate pathway at 
various stages of tumor progression. In general, a more detailed understanding of how 
metabolic flux through the pentose phosphate pathway affects other bioenergetic and 
anabolic processes, including glycolysis and lipid and nucleotide synthesis are required. 
 
Implications for the treatment of tumors with aberrant mTORC1 activation 
Given that mTORC1 activity is elevated in the majority of human tumors, there 
has been much interest in targeting this kinase complex with highly specific inhibitors, 
such as rapamycin (sirolimus) and its analogs (e.g., temsirolimus and everolimus). 
However, while studies are ongoing, these inhibitors have had limited success as cancer 
therapeutics thus far, and they generally elicit cytostatic rather than cytotoxic responses. 
An important recent finding is that rapamycin-derived compounds, which are allosteric 
inhibitors of mTOR, only partially inhibit mTORC1 function [47]. Another potential 
contributing factor to the limited effectiveness of these compounds as single anti-tumor 
agents is that they can potently activate the upstream PI3K-Akt pathway by blocking 
mTORC1-dependent feedback mechanisms. One way around such effects is to target 
key processes downstream of mTORC1, rather than mTORC1 itself. Downstream 
metabolic pathways are excellent candidates for such an approach, as mTORC1 
activation is sufficient to drive the metabolic changes most common to tumor cells, 
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including increased rates of glycolysis and protein and lipid synthesis. An increased 
dependence on these metabolic pathways distinguishes tumor cells from normal cells 
and presents therapeutic opportunities to selectively kill tumor cells. 
The coordinated activation of specific metabolic processes by mTORC1 signaling 
could represent a mechanism of cellular adaptation to the potentially deleterious effects 
of uncontrolled mTORC1 signaling in tumor cells. For example, increased lipid synthesis 
may be as important for expanding ER membranes to accommodate an increase in ER 
load due to mTORC1-driven protein synthesis as it is for promoting membrane 
biogenesis to facilitate cell growth and proliferation. Likewise, activation of the pentose 
phosphate pathway may be more critical for maintaining cellular redox homeostasis than 
for directly supporting the anabolic processes of de novo lipid and nucleotide 
biosynthesis. Therefore, while mTORC1 inhibitors might block adaptive metabolic 
processes, they also alleviate the metabolic stress induced by hyperactivation of 
mTORC1. To this end, rapamycin has been found to have pro-survival effects on cells 
with aberrantly high mTORC1 activity [5, 48, 49]. The induction of autophagy by 
rapamycin might also facilitate tumor cell survival under some conditions. Therefore, 
targeting the metabolic pathways important for adaptation to the stress of elevated 
mTORC1 signaling could elicit potent tumor-specific responses. In support of this idea, 
knockdown of SREBP, the transcription factor responsible for the induction of lipid 
synthesis and the oxidative pentose phosphate pathway downstream of mTORC1, can 
block mTORC1-driven growth and proliferation in cell culture models (Chapter 2; [23, 
33]). It will be important to identify the key enzymes induced by SREBP that underlie this 
effect and to test the in vivo response of tumor cells exhibiting uncontrolled mTORC1 
activity to knockdown or genetic ablation of these targets. In theory, the enzymes 
comprising the major metabolic pathways downstream of mTORC1 are so-called 
druggable targets. Novel and specific pharmacological inhibitors of the rate-limiting and 
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branch-point enzymes of these pathways will be important for validating these targets in 
preclinical tumor models. However, it is clear that a deeper understanding of how 
metabolic pathways are interconnected with and altered by oncogenic signaling 
pathways is needed to design therapeutic strategies to target tumor cell metabolism. 
 
Beyond cancer: the role of mTORC1 in metabolic disorders 
In addition to cancer, elevated mTORC1 activity has also been implicated in 
states of obesity and insulin resistance that are characterized by dysregulated lipid 
metabolism [50]. In mouse models of HFD-induced obesity, mTORC1 activity is elevated 
in insulin-responsive tissues, like the liver and muscle, which correlates with increased 
IRS phosphorylation and the development of hepatic insulin resistance [51]. The findings 
from studies of whole body S6K1 and 4E-BP1/2 knockout mice challenged with a HFD 
suggest that mTORC1-dependent activation of S6K1 and inhibition of 4E-BPs promotes 
cell intrinsic insulin resistance [52, 53]. S6K1 knockout mice are protected from obesity 
when fed a HFD or crossed to genetic models of obesity, while 4E-BP double knockouts 
are more susceptible to HFD-induced adiposity and increased hepatic triglyceride levels.  
Additional studies have been performed in genetic models that modulate 
mTORC1 signaling in a tissue-specific manner to further understand the role of 
mTORC1 in physiology and disease. mTORC1 coordinates nutrient utilization by 
promoting insulin secretion from the pancreas and promoting mitochondrial biogenesis in 
skeletal muscle, while mTORC1 functions to suppress continued food intake in the 
hypothalamus and to prevent lipolysis in adipose tissue (reviewed in [54]). Although we 
are beginning to understand the cell intrinsic functions and regulation of mTORC1, 
further work is needed to completely understand how it is connected to and exerts 
control over systemic metabolic homeostasis.  
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SUMMARY 
Aberrant activation of the mammalian target of rapamycin complex 1 (mTORC1) 
is a common molecular event in a variety of pathological settings, including genetic 
tumor syndromes, cancer, and obesity. However, the cell intrinsic consequences of 
mTORC1 activation remain poorly defined. Through a combination of unbiased genomic, 
metabolomic, and bioinformatic approaches, we demonstrate that mTORC1 activation is 
sufficient to stimulate specific metabolic pathways, including glycolysis, the oxidative arm 
of the pentose phosphate pathway, and de novo lipid biosynthesis. This is achieved 
through the activation of a transcriptional program affecting metabolic gene targets of 
hypoxia-inducible factor (HIF1α) and sterol regulatory element-binding protein (SREBP1 
and SREBP2). We find that SREBP1 and 2 promote proliferation downstream of 
mTORC1, and the activation of these transcription factors is mediated by S6K1. 
Therefore, in addition to promoting protein synthesis, mTORC1 activates specific 
bioenergetic and anabolic cellular processes that are likely to contribute to human 
physiology and disease. 
 
 BACKGROUND 
The mammalian target of rapamycin (mTOR) is an evolutionarily conserved 
Ser/Thr kinase that has been implicated in a diverse array of physiological processes 
and pathological states. Aberrantly elevated mTOR activity is a common molecular 
defect detected in the majority of human cancers [1], under conditions of obesity [2], and 
in genetic syndromes with a high incidence of cognitive deficits and autism spectrum 
disorders [3]. While this increased activation of mTOR is believed to contribute to the 
development and progression of these diseases, the downstream consequences of 
mTOR activation at the molecular, cellular, and organismal levels are poorly understood. 
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The mTOR kinase exists within two physically and functionally distinct protein 
complexes, mTORC1 and mTORC2, which differ in their regulation, downstream targets, 
and sensitivity to the allosteric mTOR inhibitor rapamycin [4]. mTORC1 consists of the 
core essential components mTOR, Raptor, and mLST8 and is acutely sensitive to 
rapamycin. Pharmacological and genetic studies have demonstrated that mTORC1 
activation increases cell growth (i.e., an increase in cell mass) in diverse organisms from 
yeast to human [5]. However, mTORC1 inhibition using rapamycin causes most 
mammalian cells to arrest in the G1 phase of the cell cycle, thereby demonstrating that 
mTORC1 activity also promotes cell proliferation. While the molecular mechanisms by 
which mTORC1 promotes anabolic cell growth and proliferation are not fully understood, 
two classes of direct downstream targets of mTORC1 have been well characterized. 
Specifically as part of mTORC1, mTOR directly phosphorylates the ribosomal protein S6 
kinases (S6K1 and S6K2) and the eukaryotic initiation factor 4E (eIF4E)-binding proteins 
(4E-BP1 and 4E-BP2), both of which control specific steps in the initiation of cap-
dependent translation [6]. Phosphorylation of the S6Ks downstream of mTORC1 leads 
to their activation, whereas phosphorylation of the 4E-BPs lead to their inhibition and 
release from eIF4E at the 5’ cap of mRNAs. mTORC2 is comprised of the core essential 
components mTOR, Rictor, mSIN1, and mLST8. Within this complex, mTOR is not 
directly inhibited by rapamycin, but mTORC2 assembly is blocked by prolonged 
exposure to this compound [7]. The known downstream targets of mTORC2 are all AGC 
family kinases, including Akt, SGK1, and PKCα [4]. The focus of this current study is on 
downstream events specific to mTORC1 signaling. 
The aberrant increase in mTORC1 signaling detected in a variety of human 
disease states is due to genetic or environmental factors leading to frequent 
misregulation of upstream signaling pathways that, in large part, converge on a small G 
protein switch essential for the proper control of mTORC1 activation. In its GTP-bound 
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state, the Ras-related GTPase Rheb is a potent and essential activator of mTORC1 
[8,9]. Rheb is tightly regulated by a GTPase-activating protein (GAP) called TSC2 (or 
tuberin). Along with its binding partner TSC1 (or hamartin), TSC2 is encoded by a tumor 
suppressor gene mutated in the genetic tumor syndrome tuberous sclerosis complex 
(TSC; [10]). TSC2 has specific GAP activity toward Rheb, which is greatly enhanced by 
binding to TSC1, thereby inactivating Rheb and, in turn, mTORC1. As a key regulator of 
anabolic growth and proliferation, mTORC1 is exquisitely sensitive to cellular growth 
conditions, such as the presence or absence of growth factors, nutrients, energy, and 
stress. Many of the signaling pathways that relay the status of these conditions to 
mTORC1 do so, at least in part, through specific phosphorylation events on the TSC1-
TSC2 complex that affect the ability of this complex to act as a GAP for Rheb [9]. 
Reciprocal to its inhibitory effects on mTORC1, the TSC1-TSC2 complex promotes the 
activation of mTORC2 through an as yet unknown mechanism that can be separated 
from its effects on Rheb and mTORC1 [11, 12]. 
Importantly, genetic loss of either TSC1 or TSC2 leads to constitutive activation 
of mTORC1 that is largely insensitive to perturbations in cellular growth conditions [9]. 
This is most obvious under conditions of growth factor withdrawal, where mTORC1 
signaling is attenuated in normal cells but remains fully stimulated in cells lacking a 
functional TSC1-TSC2 complex or overexpressing Rheb (e.g., [13-16]. Consistent with 
its role in the activation of mTORC2, TSC-deficient cells exhibit defects in mTORC2 
activity, even in the presence of growth factors [11, 12]. In this study, we take advantage 
of these major differences in mTOR signaling between Tsc1 and Tsc2 null cells and their 
wild-type counterparts to isolate mTORC1 activity from mTORC2 and other growth 
factor-stimulated signaling pathways. By comparing TSC-deficient cells to wild-type cells 
in the absence of growth factors, we have an mTORC1 gain-of-function model that, 
when combined with rapamycin, can be used to reveal cellular processes that mTORC1 
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activation is sufficient to induce. Through a combination of genomic, metabolomic, and 
bioinformatic analyses, we find that mTORC1 activation on its own can stimulate a gene 
network that alters specific metabolic pathways. 
 
RESULTS 
A genomic approach to identify transcriptional targets downstream of mTORC1 
Cells lacking TSC1 or TSC2 exhibit growth-factor independent activation of 
mTORC1 (Figure 2-1A). In order to identify mTORC1-dependent transcriptional 
changes, we compared wild-type MEFs to Tsc1-/- and Tsc2-/- MEFs following serum 
starvation, where mTORC1 signaling is off in wild-type cells and fully active in TSC-
deficient cells (P-S6K1; Figure 2-1B). Importantly, under these conditions, mTORC2 
targets are off in all of these cell lines, as Akt-S473 phosphorylation is lost and SGK1 
protein levels are nearly undetectable. All cell lines were serum-starved for 24 h, and the 
Tsc1-/- and Tsc2-/- cells were treated with a time course of rapamycin prior to the isolation 
of mRNA for microarray analysis. The use of both Tsc1 and Tsc2 null cells provides an 
added degree of stringency and controls for non-specific differences in these 
independently derived lines [14,16]. In order to be classified as an mTORC1-regulated 
transcript in this study, a gene probe must meet four independent criteria at a P-
value<0.01: 1) different in Tsc1-/- versus wild-type; 2) different in Tsc2-/- versus wild-type; 
3) reverted toward wild-type levels by rapamycin in Tsc1-/-; 4) reverted toward wild-type 
levels by rapamycin in Tsc2-/- (Figure 2-1C). Strikingly, only 239 of the 39,000 gene 
probes analyzed, representing 205 genes, met these conditions (available online). 
These are shown in the scatter plot in Figure 2-1D (blue dots) in relation to all others 
(gray dots). These 205 genes include those that are decreased in TSC1- and TSC2-
deficient cells and stimulated by rapamycin (75 mTORC1-repressed genes) and those  
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Figure 2-1.  A genomics approach to identify mTORC1-regulated transcripts. 
A) Model of mTORC1 regulation downstream of growth factors. 
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Figure 2-1 continued 
B) Growth factor-independent mTOR signaling in Tsc1-/- and Tsc2-/- MEFs.  MEF lines 
were serum starved for 24 h in the presence of vehicle (-) or 20-nM rapamycin (12 or 24 
h) and, where indicated, were stimulated with 10% serum for the final 1 h. (JLY) 
C) Hypothetical Venn diagram of the four major changes in gene expression detected in 
this study. mTORC1-regulated transcripts were classified as those that met all four of 
these criteria at a statistical cut of p<0.01 (*).  
D) Scatter plot of the expression levels (log2) of the 39,000 gene probes comparing 
vehicle-treated Tsc2-/- cells to vehicle-treated wild-type controls (x-axis) and vehicle-
treated Tsc2-/- cells to rapamycin-treated (24 h) Tsc2-/- cells (y-axis).  The larger blue 
dots depict the pattern of the 239 gene probes meeting the criteria described in (B).  The 
gray dots depict the expression pattern of the whole dataset. (PR) 
E) Heat map of the 239 probes found to be regulated by mTORC1 signaling in this 
study, showing their expression levels and response to a rapamycin time course in Tsc2-
/- cells.  Expression levels shown are representative of the log2 average obtained from 
independent replicates per time point.  The brightness of green and red represents the 
degree to which expression is respectively lower or higher in the Tsc2-/- cells relative to 
vehicle treated wild-type cells. (AIL, PR) 
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that are increased in these cells and inhibited by rapamycin (130 mTORC1-induced 
genes). The rapamycin time course revealed that the majority of these mTORC1-
regulated genes were responsive to rapamycin at 6 to 12 h of treatment in both Tsc2-/- 
(Figure 2-1E) and Tsc1-/- (Figure 2-2) cells. 
 
mTORC1 induces genes encoding the enzymes of specific metabolic pathways 
To identify functional groups that are enriched amongst the mTORC1-regulated 
genes, a gene set enrichment analysis (GSEA) was performed on a larger set of genes 
meeting the above criteria for being induced or repressed by mTORC1 signaling at a P-
value<0.05 (Table 2-1). Interestingly, within the top 20 mTORC1-induced gene sets are 
specific metabolic pathways, including the pentose phosphate pathway (P<7x10-8), fatty 
acid biosynthesis (P<5x10-6), glycolysis (P<0.0002), and cholesterol biosynthesis 
(P<0.0031). Indeed, a survey of mTORC1-induced genes found many encoding the 
enzymes of glycolysis (Figure 2-3A), the pentose phosphate pathway (Figure 2-3B), and 
sterol and fatty acid biosynthesis (Figure 2-3C) to be elevated in both Tsc1-/- and Tsc2-/- 
cells and rapamycin sensitive. The mTORC1-dependent induction of many of these 
genes was verified by qRT-PCR (representative genes shown in Figures 2-3D-F). In 
addition, the regulation of representative genes from these metabolic pathways was 
further confirmed in three independent genetic settings of mTORC1 activation, including 
Tsc2-/- MEFs reconstituted with empty vector or human TSC2 (Figure 2-4A), HeLa cells 
with a stable shRNA-mediated knockdown of TSC2 (Figure 2-4B), and HEK-293 cells 
over-expressing Rheb (Figure 2-4C). In all three systems, activation of mTORC1 
signaling led to increased expression of genes of glycolysis, the pentose phosphate 
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Figure 2-2. Expression pattern of mTORC1-regulated transcripts in Tsc1 null cells.  
Heat map of the stringent 239 probes, representing 209 genes, found to be regulated by 
mTORC1 signaling in this study, showing their expression levels and response to a 
rapamycin time course in Tsc1-/- cells. Expression levels shown are the log2 averages 
obtained from independent replicates per time point. The brightness of green and red 
represents the degree to which expression is respectively lower or higher in the Tsc1-/- 
cells relative to vehicle treated wild-type cells. The list of genes and normalized log2 
expression levels are available online. (AIL, PR) 
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Table 2-1: Gene-set enrichment analysis of mTORC1-regulated genesa 
 
Gene Set (MAP)        P-value 
mTORC1 Induced: 
Neurodisease – Parkin disorder under Parkinson disease   2.36E-09 
Pentose phosphate pathway       6.64E-08 
Transcription – Ligand-dependent transcription of retinoid-target genes  1.92E-07 
Immune response – Antigen presentation by MHC class I   6.15E-07 
Unsaturated fatty acid biosynthesis      4.89E-06 
Apoptosis and survival – Regulation by mitochondrial proteins   8.09E-05 
Glycolysis and gluconeogenesis      1.36E-04 
Galactose metabolism        2.00E-04 
n-3/n-6 Polyunsaturated fatty acid biosynthesis    2.40E-04 
Glycine, serine, cysteine, and threonine metabolism    3.98E-04 
ATP/ITP metabolism        9.86E-04 
Aminocyl-tRNA biosynthesis in cytoplasm     1.07E-03 
Signal transduction – AKT signaling      1.10E-03 
Apoptosis and survival – Endoplasmic reticulum stress response pathway 1.16E-03 
Regulation of degradation of wt-CFTR      1.43E-03 
Development – PACAP signaling in neural cells     2.69E-03 
Cholesterol biosynthesis       3.01E-03 
Signal transduction – PTEN pathway      6.42E-03 
Cell Cycle – Role of Nek in cell cycle regulation     6.56E-03 
Regulation of lipid metabolism – Insulin regulation of fatty acid metabolism 6.84E-03 
 
mTORC1 Repressed: 
Apoptosis and survival - Anti-apoptotic TNFs/NF-kB/IAP pathway  3.11E-03 
Apoptosis and survival - Lymphotoxin-beta receptor signaling   6.94E-03 
Transcription - Role of heterochromatin protein1 family in transcriptional silencing 9.56E-03 
Cardiac Hypertrophy - NF-AT signaling in Cardiac Hypertrophy   1.15E-02 
Cell adhesion - Plasmin signaling      1.16E-02 
Development - VEGF signaling and activation     1.51E-02 
Cell cycle - Role of Nek in cell cycle regulation     1.56E-02 
Cytoskeleton remodeling - Cytoskeleton remodeling    1.63E-02 
Translation - Regulation activity of EIF4F     2.21E-02 
Immune response - CD40 signaling      2.40E-02 
Development - Role of HDAC and CaMK in control of skeletal myogenesis 2.46E-02 
Translation - (L)-selenoaminoacids incorporation in proteins during translation 2.68E-02 
Development - Cross-talk between VEGF and Angiopoietin 1 signaling pathways 2.75E-02 
Immune response - MIF-mediated glucocorticoid regulation   2.81E-02 
G-protein signaling - K-RAS regulation pathway     2.94E-02 
Cytoskeleton remodeling - TGF, WNT and cytoskeletal remodeling  3.00E-02 
Immune response - IL-10 signaling pathway     3.14E-02 
Regulation of metabolism - Triiodothyronine and Thyroxine signaling  3.21E-02 
Immune response - IL-6 signaling pathway     3.98E-02 
Cooperation between Hedgehog, IGF-2 and HGF pathways in medulloblastoma 4.66E-02 
 
aGSEA was performed using MetaCore on genes that were up or down regulated and responsive 
to rapamycin in both Tsc1 and Tsc2 null cells at a P-value<0.05. The top 20 non-redundant gene 
sets are shown for each. 
 
(PR) 
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Figure 2-3. Transcriptional induction of metabolic genes downstream of mTORC1 
activation.   
A-C) mTORC1 activation leads to the induction of genes encoding the enzymes of 
glycolysis (A), the pentose phosphate pathway (B), and lipid and sterol biosynthesis (C) 
in Tsc1-/- (upper graphs) and Tsc2-/- (lower graphs) cells.  The log2 expression levels 
shown are the average obtained from independent replicates per time point of rapamycin 
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Figure 2-3 continued 
treatment normalized to the expression levels in vehicle-treated wild-type cells. (KD) 
D-F) Confirmation of mTORC1-induced metabolic genes.  The expression levels of 
representative genes from (D) glycolysis, (E) the pentose phosphate pathway, and (F) 
lipid and sterol biosynthesis was measured by qRT-PCR.  MEFs were serum starved for 
18 h in the presence of vehicle (-) or 20-nM rapamycin (+) and, where indicated, were 
subjected to a proliferation arrest via double thymidine block (DTB).  Expression levels 
are presented as mean±SD relative to vehicle-treated Tsc2+/+ cells and are 
representative of at least three independent experiments. (See data in Figure 2-4) (JLY) 
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Figure 2-4. Confirmation that mTORC1 regulates metabolic gene expression.  
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Figure 2-4 continued 
A) Confirmation of mTORC1-induced metabolic genes in Tsc2-deficient cells 
reconstituted with TSC2 or empty vector.  Tsc2-/- MEFs stably reconstituted human 
TSC2 or empty vector were serum starved for 16 h in the presence of vehicle or 20 nM 
rapamycin (Rap).  The expression levels of representative genes from the three 
metabolic pathways, including glycolysis (Glut1 and Pfkp, left), the pentose phosphate 
pathway (G6pd and Pgd, middle), and lipid and sterol biosynthesis (Scd1 and Mvk, right) 
were measured by qRT-PCR.  Expression levels are presented as mean±SD relative to 
vehicle-treated TSC2-reconstituted cells over three independent experiments. (KD) 
B) Confirmation of mTORC1-induced metabolic genes in human epithelial cells with 
stable knockdown of TSC2.  HeLa cells stably expressing shRNAs targeting TSC2 or 
firefly luciferase (Ctl) treated as in (A).  An immunoblot control is provided.  The 
expression levels of representative human genes from the three metabolic pathways, 
including glycolysis (GLUT1 and PFKP, left), the pentose phosphate pathway (G6PD 
and RPE, middle), and lipid and sterol biosynthesis (SCD1 and MVK, right) were 
measured by qRT-PCR.  Expression levels are presented as mean±SD relative to 
untreated cells expressing control shRNAs and are representative of three independent 
experiments. (SM) 
C) Confirmation of mTORC1-induced metabolic genes in human epithelial cells 
overexpressing Rheb.  HEK-293 cells were transiently transfected with FLAG-Rheb or 
empty vector and serum starved for 16 h in the presence or absence of rapamycin (20 
nM).  An immunoblot control is provided.  Representative metabolic genes were 
analyzed as in (B). Expression levels are presented as mean±SEM relative to untreated 
vector-transfected cells over three independent experiments. (KD) 
D) Like rapamycin, Leucine starvation blocks the enhanced expression of metabolic 
genes in Tsc2-/- MEFs. Cells were serum-starved overnight in DMEM or DMEM lacking  
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Figure 2-4 continued 
Leucine (-Leu) in the presence of vehicle or rapamycin (20 nM, Rap).  Expression levels 
are presented as mean±SD relative to Tsc2+/+ cells and are representative of two 
independent experiments. (KD) 
E) Comparison of the effects of rapamycin and the double thymidine block (DTB) on the 
proliferation of Tsc2-/- MEFs.  2x105 cells were plated and upon attachment, thymidine 
(2mM) or vehicle (PBS) was added to the normal growth medium for 20 h. Cells were 
restored to their normal growth medium for 12 h prior to a second treatment with 
thymidine or vehicle in serum-free medium in the presence or absence of rapamycin (20 
nM) for 18 h.  Viable cell counts per well are shown at the end of the experiment, when 
cells were harvested for expression analysis.  Lysates were prepared in parallel to 
determine effects on mTORC1 signaling (P-S6K1-T389 in the accompanying blot). (JLY) 
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pathway, and lipid/sterol biosynthesis and rapamycin reversed this effect. Finally, 
consistent with these genes being downstream of mTORC1, withdrawal of the essential 
amino acid leucine from Tsc2-/- cells led to a repression of these metabolic genes similar 
to that seen with rapamycin (Figure 2-4D). 
Due to sustained mTORC1 signaling, cells lacking the TSC1-TSC2 complex can 
proliferate in the absence of growth factors ([17]; see below). This raises the possibility 
that the differences in metabolic gene expression between wild-type and TSC-deficient 
cells are due to differences in proliferation. This was addressed by arresting the 
proliferation of Tsc2-/- cells through a standard double thymidine block (DTB). The DTB 
had a more pronounced effect on proliferation than rapamycin in these cells, but did not 
inhibit mTORC1 signaling (Figure 2-4E). While the DTB-mediated arrest of Tsc2-/- cells 
led to a modest decrease in the expression of representative metabolic genes, their 
expression remained significantly higher than in wild-type cells and fully sensitive to 
rapamycin (Figure 2-3D-F). Therefore, the mTORC1-induced expression of these 
metabolic genes is independent of cell proliferation. 
 
mTORC1 activation is sufficient to induce specific metabolic processes 
As depicted in Figure 2-3A, mTORC1 signaling activates the expression of genes 
encoding nearly every step of glycolysis and the pentose phosphate pathway, as well as 
critical enzymes in the de novo synthesis of sterols, isoprenoids, and fatty acids. To 
investigate whether these transcriptional changes are also reflected by changes in 
cellular metabolism, we measured effects on both specific metabolic processes and 
global metabolites. Consistent with the gene expression profile, Tsc2-/- cells exhibit a 
rapamycin-sensitive increase in glucose uptake (Figure 2-5B), lactate secretion (Figure 
2-5C), and de novo lipid biosynthesis (Figure 2-5D). To obtain a more global and 
unbiased analysis of mTORC1-mediated changes in intracellular metabolites, a liquid  
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Figure 2-5. Alterations in cellular metabolism induced by mTORC1 activation. 
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Figure 2-5 continued 
A) Placement of the mTORC1-induced metabolic genes within their metabolic pathways. 
Genes found to be regulated by mTORC1 are shown in red, with those in the most 
stringent set indicated (*). 
B) mTORC1 signaling stimulates glucose uptake. MEFs were serum starved for 16 
hours in the presence of vehicle or rapamycin (20 nM).  Glucose uptake was measured 
as the incorporation of 2-deoxy-D-[3H]-glucose over 4 minutes and normalized to cell 
number.  Levels are presented as mean±SD relative to Tsc2+/+ cells from four 
independent experiments.  *p<0.002 versus Tsc2+/+; **p<0.009 versus Tsc2-/-. (KD) 
C) mTORC1 signaling increases lactate production.  Cells were grown as in (B), and 
lactate secretion into the media was measured over the final hour.  Lactate 
concentrations normalized to cell number are presented as mean±SD relative to Tsc2+/+ 
cells from three independent experiments. *p<0.00001 versus Tsc2+/+; **p<0.006 versus 
Tsc2-/-. (JLY) 
D) mTORC1 signaling stimulates de novo lipid biosynthesis.  MEFs were serum starved 
for 24 h in the presence of vehicle or rapamycin (20 nM) and were incubated with D-[6-
14C]-glucose for the final 4 h.  14C incorporation into the lipid fraction was measured and 
is presented as mean±SD relative to Tsc2+/+ cells.  These data are representative of 
three independent experiments. *p<0.006 versus Tsc2+/+; **p<0.004 versus Tsc2-/-. (JLY) 
E) Metabolomic profiling demonstrates that mTORC1 activation increases metabolites of 
glycolysis and the pentose phosphate pathway. MEFs were grown as in (B) and 
metabolites were extracted and profiled by LC-MS.  Relative levels of specific 
metabolites, normalized to cell number, from three independent samples for each cell 
line and treatment are shown in the heat map.  Metabolites showing a pattern consistent 
with mTORC1 regulation are indicated (*).  The complete metabolomic profile is provided 
as supplemental Figure 2-6. (KD, ALS, CBC) 
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Figure 2-5 continued 
F) mTORC1 signaling increases flux through glycolysis.  MEFs were grown as in (B) and 
incubated with [1,2-13C]-glucose for 15 min prior to metabolite extraction and LC-MS 
analysis.  Levels of dually 13C-labeled glycolytic intermediates, normalized to cell 
number, are presented as mean±SD over three independent samples. (KD, ALS, CBC) 
G) mTORC1 signaling increases flux through the oxidative branch of the pentose 
phosphate pathway.  The ratio of singly (1x) and doubly (2x) 13C-labeled to unlabeled 
(12C) pentose phosphate pathway metabolites were measured by LC-MS in the samples 
from (F).  P-values for pair-wise comparisons in (F) and (G) are listed in the 
accompanying table. (KD, ALS, CBC) 
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chromatography mass spectrometry (LC-MS)-based metabolomics approach was 
employed. As with our genomic study, we compared littermate-derived wild-type and 
Tsc2-/- MEFs under growth factor-free conditions, where mTORC1 signaling is off in wild-
type cells but fully active and rapamycin sensitive in the Tsc2 null cells. Only 21 of the 
119 metabolites measured showed a pattern consistent with mTORC1-induced changes 
(i.e., elevated in Tsc2-/- cells relative to Tsc2+/+ and decreased by rapamycin; Figure 2-6). 
Of these, only the intermediates of glycolysis and the pentose phosphate pathway 
showed a pathway-specific pattern of increase by mTORC1 signaling (Figure 2-5E). 
To determine whether the steady state increase in these intermediates reflects 
an increase in flux through these pathways, we measured metabolite levels following a 
15 min pulse of [1,2-13C]-glucose. Indeed, we found increased 13C-labeling of glycolytic 
and pentose phosphate pathway intermediates in Tsc2-/- cells, which was blocked by 
rapamycin treatment (Figure 2-5F and G). The use of doubly labeled [1,2-13C]-glucose 
allowed us to determine whether the increase in ribulose 5-phosphate and ribose 5-
phosphate was the result of increased flux through the oxidative (glucose 6-phosphate 
dehydrogenase (G6PD)-mediated) or non-oxidative branches of the pentose phosphate 
pathway. If ribulose 5-phosphate and ribose 5-phosphate are singly labeled, they are 
produced through the oxidative arm, as phosphogluconate dehydrogenase (PGD) 
catalyzes decarboxylation and loss of the 1 carbon as CO2, whereas doubly labeled 
intermediates could only come from the non-oxidative branch. Consistent with the 
mTORC1-dependent increase in expression of G6PD and PGD, there was a rapamycin-
sensitive increase in singly labeled ribose and ribulose in the Tsc2-/- cells, while there 
was no difference in levels of doubly labeled pentose phosphate pathway intermediates 
(Figure 2-5G). These data demonstrate that the mTORC1-induced expression of genes 
encoding the enzymes of glycolysis and the oxidative arm of the pentose phosphate 
pathway is accompanied by increased flux through these pathways.  
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Figure 2-6. mTORC1 regulates specific intracellular metabolites. 
Metabolomic profiling of wild-type and Tsc2-deficient MEFs to identify mTORC1-
regulated metabolites.  Littermate-derived Tsc2+/+ and Tsc2-/- MEFs were serum starved 
for 16 h in the presence of vehicle or rapamycin (20 nM).  Small metabolites were 
extracted and profiled by liquid chromatography mass spectrometry (LC-MS).  Relative 
levels of specific metabolites, normalized to cell number, from three independent 
samples for each cell line and treatment are shown in the heat map, with metabolites 
grouped according to metabolic pathways.  Metabolites showing a pattern consistent 
with regulation by mTORC1 signaling (i.e., increased in Tsc2-/- relative to Tsc2+/+ and 
rapamycin sensitive) are indicated (*). (KD, ALS, CBC)
CHAPTER 2. mTOR Complex 1 Controls Cellular Metabolism 
	   43	  
Identification of enriched transcription factor-binding elements in mTORC1-
regulated genes 
To identify candidate transcription factors downstream of mTORC1, we used a 
previously described unbiased bioinformatic approach (MotifADE; [18,19]) to detect 
transcription factor-binding motifs enriched in the promoters of mTORC1-regulated 
genes from the expression array study. This approach identifies over-represented cis 
regulatory elements present in the promoters of specific gene sets. An analysis of all 
genes sensitive to rapamycin at 24 h revealed that binding motifs for only four 
transcription factors are significantly enriched (q-value>0.01) in the data from both Tsc1-/- 
and Tsc2-/- cells (Table 2-2). Interestingly, two of these factors, sterol regulatory element-
binding protein (SREBP) and c-Myc are well known to regulate specific aspects of 
cellular metabolism. C-Myc has been estimated to regulate up to 15% of all genes, 
including the genes of glycolysis [20]. However, the c-Myc protein is very unstable and 
following 24 h of serum deprivation, as performed in our gene expression analysis, it is 
not detectable in the TSC-deficient cells (e.g., Figure 2-7A). Importantly, the transcription 
factor hypoxia-inducible factor (HIF1) stimulates the same genes of glycolysis and, like 
c-Myc, is a basic helix loop helix (bHLH) transcription factor that recognizes an 
overlapping promoter-binding element (Table 2-2; [21, 22]). 
 
HIF1α  is responsible for the glycolytic response downstream of mTORC1 
Given that known targets of HIF1 involved in glycolysis are elevated in an 
mTORC1-dependent manner in the TSC-deficient cells, we analyzed 26 previously 
characterized HIF1 targets in our expression array data. These genes all demonstrated 
a pattern of induction by mTORC1, as they were elevated in both Tsc1 and Tsc2 null 
cells and rapamycin sensitive (Figure 2-8A). These genes included those encoding the 
enzymes of glycolysis as well as non-metabolic targets, several of which were in our 
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Table 2-2. Enrichment of transcription factor binding elements in the promoters of 
mTORC1-induced genesa. 
Transcription Factor Binding Motif 
Rap-Sensitive 
Probes (Total)c p-valued q-valuee 
 
SREBP VNNVTCACCCYA 33 (82) 2.41E-07 1.28E-05 
 
c-Myc (HIF1)b RACCACGTGCTC 385 (1164) 4.52E-06 1.45E-04 
 
HNF4alpha VTGAACTTTGMMB 853 (2084) 2.17E-05 4.34E-04 
 
ATF4 CVTGACGYMABG 18 (30) 5.57E-04 6.36E-03 	  
aOver-represented transcription factor-binding motifs in all rapamycin-sensitive genes from both 
Tsc1-/- and Tsc2-/- MEFs identified using a modified version of the MotifADE method (Mootha et 
al. 2004; Ma et al. 2008).  Only these 4 motifs were in enriched in both cell lines with a q-
value<0.01.  Numbers for the Tsc2 null cells are provided. 
 
bThe HIF1-binding hypoxia response element (bold) overlaps with this motif. 
 
cNumbers are based on 39,000 gene probes analyzed in triplicate with Affymetrix microarrays, 
comparing vehicle-treated versus rapamycin-treated (24 h) Tsc2-/- MEFs.  
 
dTwo-tailed Mann-Whitney rank sum p-value. 
 
eMultiple testing corrected false discover rate (FDR) q-value. 
 
(PR) 
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Figure 2-7. Alternative mechanisms involving C-Myc and mTORC2 are not 
involved and 4EBP is responsible for increased Hif1α  levels. 
A) C-myc is not expressed in Tsc2-/- cells under the prolonged serum-free growth 
conditions used for expression analyses in this study.  MEF lines were serum starved for 
24 h in the presence of vehicle (-) or 20-nM rapamycin (12 or 24 h) and, where indicated, 
were stimulated with 10% serum for the final 1 h. (JLY) 
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Figure 2-7 continued 
B) Levels of Hif1α and processed SREBP1 are not affected by the status of mTORC2.  
Littermate-derived Rictor+/+ and Rictor-/- MEFs, along with Tsc2-/- MEFs, were treated as 
in (A). (JLY) 
C) The elevated level of HIF1α in Tsc2-/- MEFs is dependent on mTORC1 and not 
mTORC2. MEFs were transfected with control non-targeting siRNAs (ctl) or siRNAs 
targeting Raptor or Rictor for 48 h followed by serum starvation for 24 hours.  (SM) 
D) The mTORC1-dependent induction of translation from the 5’-UTR of HIF1α is more 
strongly inhibited by the active phosphorylation-site mutant of 4E-BP1 relative to wild-
type 4E-BP1. The bicistronic reporter encoding Renilla luciferase under translational 
control of the HIF1α-5’-UTR and firefly luciferase under control of a polio-virus IRES was 
cotransfected into either Tsc2+/+ or Tsc2-/- MEFs with empty vector (Vec), 4E-BP1 
(4EBP-WT), or mutant 4E-BP1 lacking two of the mTORC1-regulated phosphorylation 
sites (T37A/T46A; 4EBP-AA).  24 h post-transfection, cells were serum starved for 16 h 
and the ratio of Renilla to firefly luciferase was measured.  The ratios are presented as 
mean±SD relative to Tsc2+/+ cells and are representative of two independent 
experiments.  The accompanying immunoblot shows the relative protein levels of 
exogenous wild-type and mutant 4E-BP1 expressed in this experiment. (SM) 
E) The mTORC1-dependent induction of translation from the 5’-UTR of HIF1α is not 
affected by S6K1 or S6K2.  Tsc2+/+ and Tsc2-/- MEFs were transfected with control non-
targeting siRNAs (ctl) or siRNAs targeting S6K1 and/or S6K2.  24 h post-transfection, 
the cells were transfected with the bicistronic reporter described in (D).  24 h later, the 
cells were serum starved for 16 h in the presence or absence of rapamycin (Rap, 20 
nM), and the ratio of Renilla to firefly luciferase was measured. The ratios are presented  
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Figure 2-7 continued 
as mean±SD relative to Tsc2+/+ cells.  An immunoblot is provided showing the sustained 
effects of the siRNAs at the end of this experiment. (SM) 
F) S6K1 has modest effects on Hif1α protein levels. Tsc2+/+ and Tsc2-/- MEFs were 
transfected with siRNAs targeting the indicated transcripts or control non-targeting 
siRNAs (ctl).  24 h post-transfection, cells were serum starved for 18 h in the presence of 
vehicle or rapamycin (20 nM), where indicated.  (JLY) 
G) Rapamycin is more potent than Raptor siRNAs at inhibiting mTORC1 signaling. Tsc2-
/- MEFs were transfected with control non-targeting siRNAs (ctl) or siRNAs targeting 
Raptor.  48 h post-transfection, cells were serum starved for 24 h in the presence or 
absence of rapamycin (Rap, 20 nM). (SM) 
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Figure 2-8. HIF1α  and its target genes are upregulated by mTORC1 signaling. 
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Figure 2-8 continued 
A) HIF1 target genes are elevated and rapamycin sensitive in Tsc1 (upper graph) and 
Tsc2 (lower graph) null cells. The log2 expression levels shown are the average obtained 
from independent replicates per time point of rapamycin treatment normalized to the 
expression levels in vehicle-treated wild-type cells, with those in the most stringent set 
indicated (*). (KD) 
B) HIF1α protein levels are shown in wild-type and either Tsc1 or Tsc2 null MEFs grown 
in serum-free media and subjected to a time course of rapamycin (20 nM). *non-specific 
band.  (See also Figures 2-7A-C) (AIL) 
C) Induction of translation from the 5’-UTR of HIF1α is regulated by 4E-BP1.  The 
bicistronic reporter was cotransfected with empty vector (Vec), TSC2, or 4E-BP1-AA 
(T37A/T46A).  24 h post-transfection, cells were serum starved for 16 h in the presence 
or absence of rapamycin (Rap, 20 nM), and the ratio of Renilla to firefly luciferase was 
measured.  The ratios are presented as mean±SD relative to Tsc2+/+ cells and are 
representative of three independent experiments.  (See also Figures 2-7D-F) (SM) 
D, E) mTORC1-dependent increase in the expression Hif1α (D) and its glycolytic gene 
targets (E).  MEFs were transfected with siRNAs targeting the indicated transcripts or 
control non-targeting siRNAs (ctl).  32 h post-transfection, the cells were serum starved 
for 16 hours in the presence or absence of rapamycin (Rap, 20 nM).  Transcript levels, 
measured by qRT-PCR, are presented as the mean±SD relative to levels in Tsc2+/+ (Ctl) 
cells over three independent experiments. (See also Figure 2-7G) (KD)  
F) The stimulation of glucose uptake downstream of mTORC1 is dependent on HIF1α. 
MEFs were transfected with siRNAs and treated as in (D). Glucose uptake was 
measured as the incorporation of 2-deoxy-D-[3H]-glucose over 4 min and normalized to 
cell number.  Levels are presented as mean±SD relative to Tsc2+/+ (Ctl) cells over six  
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Figure 2-8 continued 
independent experiments.  *p<0.003 for Tsc2+/+ versus  Tsc2-/- and Tsc2-/- versus 
rapamycin-treated Tsc2-/-; **p<0.03 for Tsc2-/- versus Tsc2-/- with Hif1α knockdown. (KD) 
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most stringent dataset. The HIF1 transcription factor is a heterodimer comprised of the 
constitutively expressed HIF1β/ARNT subunit complexed with either HIF1α or 
HIF2α/EPAS1 [21, 22]. The HIFα subunit appears to dictate the target specificity of the 
HIF1 heterodimer [23], and TSC-deficient cells display mTORC1-dependent 
transcriptional upregulation of targets specific to HIF1α (e.g., glycolysis genes), as well 
as those shared between HIF1α and HIF2α (e.g., VEGF). 
As we are focused here on the metabolic genes, we examined the mechanism 
leading to upregulation of the HIF1α subunit, which activates the genes of glycolysis [23, 
24]. Consistent with the global upregulation of HIF1α targets and the findings from a 
previous study [25], both Tsc1-/- and Tsc2-/- cells have elevated levels of HIF1α protein 
relative to their wild-type counterparts (Figure 2-8B). Similar to its transcriptional targets, 
this increase is blocked following 2 to 6 h of rapamycin treatment. The upregulation of 
HIF1α is specific to mTORC1 and not affected by the status of mTORC2 in these cells. 
Unlike Tsc2-/- MEFs, Rictor-/- MEFs do not show elevated levels of HIF1α (Figure 2-7B), 
and the increased HIF1α in Tsc2-/- cells is sensitive to siRNAs targeting Raptor but not 
Rictor (Figure 2-7C). Through studies using rapamycin, mTORC1 signaling has been 
implicated in the activation of HIF1 (e.g., [26, 27]), in part through selective control of 
translation from the 5’-untranslated region (UTR) of the HIF1α mRNA [28, 29]. To test 
whether mTORC1 activation alone was sufficient to stimulate translation from the HIF1α 
5’-UTR, we utilized a bicistronic reporter in which the translation of Renilla luciferase is 
under control of the HIF1α 5’-UTR and firefly luciferase is translated from an internal 
ribosomal entry sequence (IRES; Figure 2-8C). Tsc2-/- MEFs showed enhanced 
translation from the HIF1α 5’-UTR, and this was rescued by expression of human TSC2 
or rapamycin treatment. Expression of a dominantly active 4E-BP1 mutant lacking two 
mTORC1 inhibitory phosphorylation sites (4E-BP1-T37A/T46A) blocked this selective 
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translation (Figure 2-8C), whereas expression of wild-type 4E-BP1 resulted in a partial 
decrease (Figure 2-7D). We found no effect of siRNAs targeting S6K1 and S6K2 on 
translation from the HIF1α 5’-UTR (Figure 2-7E), but S6K1 knockdown led to a modest 
decrease in HIF1α protein levels (Figure 2-7F). These data suggest that mTORC1 
activation is sufficient to stimulate an increase in HIF1α protein levels, at least in part, 
through mTORC1-mediated inhibition of 4E-BP1 and subsequent activation of 5’-cap-
dependent translation. However, we cannot rule out further contributing effects from 
gene expression, as both Hif1α (Figure 2-8D) and Hif2α (data not shown) mRNA levels 
are increased in an mTORC1-dependent manner (i.e., sensitive to rapamycin or siRNAs 
targeting Raptor) in Tsc2-deficient cells.  
To determine whether HIF1α is the transcription factor downstream of mTORC1 
in the control of glycolytic genes, the expression of representative genes was analyzed 
following the introduction of siRNAs targeting either Raptor or HIF1α (Figure 2-8E). 
Indeed, HIF1α knockdown reduced the mRNA levels of Glut1, Pfkp, and Pdk1 in Tsc2-/- 
cells to wild-type levels, similar to Raptor siRNAs or rapamycin treatment. In this 
experiment and those described below, transient knockdown of Raptor generally elicits a 
weaker inhibitory effect than rapamycin, and this is reflected in an incomplete block of 
mTORC1 signaling by Raptor siRNAs in the Tsc2-/- cells (Figure 2-7G). Consistent with 
the increase in HIF1α and its targets being responsible for the mTORC1-dependent 
increase in glycolysis observed, siRNA-mediated knockdown of HIF1α in Tsc2-/- cells 
significantly blocked the increase in glucose uptake (Figure 2-8F). 
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SREBP is responsible for increased lipid biosynthesis, the pentose phosphate 
pathway, and cell proliferation downstream of mTORC1 
The DNA-binding element recognized by SREBP was found to be the most 
highly enriched motif in the promoters of rapamcyin-sensitive genes in our expression 
array study (Table 2-2). Importantly, SREBP1 and SREBP2 are master transcriptional 
regulators of genes involved in de novo lipid and sterol biosynthesis genes [30]. Full-
length SREBPs reside as inactive, transmembrane precursors in the endoplasmic 
reticulum and are activated by trafficking to the Golgi where they are processed by 
proteases. The active processed form then translocates to the nucleus to turn on its 
target genes. Interestingly, a recent study found that overexpression of an activated 
version of Akt leads to a rapamycin-sensitive increase in the processed form of SREBP1 
[31]. To gain insights into how mTORC1 activation might increase the transcription of a 
large number of known SREBP targets, we compared the protein levels of full length and 
processed SREBP1 in littermate-derived wild-type and either Tsc1-/- or Tsc2-/- cells. 
While modest increases in the levels of full length SREBP1 could be detected, larger 
differences were seen in the processed active form of SREBP1, which were elevated in 
the TSC-deficient lines relative to their wild-type counterparts (Figure 2-9A). This is 
reflected by an increase in the ratio of processed to full length SREBP1 in these cells 
that is sensitive to rapamycin. The increased levels of processed SREBP1 are specific to 
mTORC1 and not affected by the status of mTORC2 in these cells. Unlike Tsc2-/- MEFs, 
Rictor-/- MEFs do not show elevated levels of processed SREBP1 (Figure 2-7B), and the 
increase in Tsc2-/- cells is sensitive to siRNAs targeting Raptor but not Rictor (Figure 2-
9B). However, as with Hif1α and Hif2α, rapamycin-sensitive increases in Srebp1 and 
Srebp2 transcript levels are detected in Tsc2-deficient cells (Figures 2-10A and B) or 
HEK-293 cells overexpressing Rheb (Figures 2-10C and D). Interestingly, siRNAs  
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Figure 2-9. mTORC1 signaling activates SREBP1 to induce de novo lipid 
biosynthesis and growth factor-independent proliferation.  
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Figure 2-9 continued 
A) Levels of full length (fl) and processed (p) SREBP1 are shown from littermate-derived 
pairs of wild-type and either Tsc1 or Tsc2 null MEFs grown in serum-free media and 
subjected to a time course of rapamycin (20 nM).  (Below) The ratio of processed to full 
length SREBP1 at the indicated time points was quantified and plotted relative to 
untreated wild-type cells. (JLY) 
B) MEFs were transfected with control non-targeting siRNAs (ctl) or siRNAs targeting 
Raptor or Rictor, and 48 h post-transfection, cells were serum starved for 24 hours. (SM) 
C, D, E) The mTORC1-induced expression of genes involved in fatty acid (C) and sterol 
(D) biosynthesis and the pentose phosphate pathway (E) is dependent on SREBP.  
MEFs were transfected with control non-targeting siRNAs (ctl) or siRNAs targeting 
Raptor, Srebp1 (Sr1), Srebp2 (Sr2), or both (Sr1/2).  32 h post-transfection, cells were 
serum starved for 16 h in the presence or absence of rapamycin (Rap, 20 nM). The 
expression levels of representative genes were measured by qRT-PCR and are 
presented as the mean±SD relative to levels in Tsc2+/+ cells over three independent 
experiments.  (See also Figures 2-10A and B) (KD) 
F) Overexpression of Rheb or the processed form of SREBP1a induces G6PD 
expression.  HEK-293 cells were transiently transfected with empty vector (Vec), FLAG-
RHEB, or FLAG-processed SREBP1a.  24 h post-transfection, cells were serum starved 
for 16 h in the presence of vehicle or rapamycin (20 nM).  G6PD mRNA levels, 
measured by qRT-PCR, are presented as the mean±SD relative to levels in vector-
transfected cells over three independent experiments. (See also Figures 2-10C and D) 
(KD) 
G) The stimulation of de novo lipid biosynthesis downstream of mTORC1 is dependent 
on SREBP.  MEFs were transfected with siRNAs targeting the indicated transcripts or 
control non-targeting siRNAs (ctl).  24 h post-transfection, cells were serum starved for 
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Figure 2-9 continued 
24 h in the presence of vehicle or rapamycin (20 nM) and were incubated with D-[6-14C]- 
glucose for the final 4 h.  14C incorporation into the lipid fraction was measured and is 
presented as mean±SD relative to Tsc2+/+ (Ctl) cells.  These data are representative of 
three independent experiments. *p<0.004 for Tsc2+/+ versus  Tsc2-/- and Tsc2-/- versus 
rapamycin-treated Tsc2-/-; **p<0.008 versus Tsc2-/- (ctl); ***p<0.002 versus Tsc2-/- (ctl).  
A control immunoblot is provided with numbering matching the samples from the graph.  
(See also Figure 2-10E) (JLY) 
H) The mTORC1-driven proliferation of Tsc2 null cells in the absence of growth factors is 
dependent on SREBP.  Tsc2+/+ (T2+/+) and Tsc2-/- (T2-/-) MEFs were transfected with 
siRNAs targeting indicated genes or non-targeting control siRNAs (siCtl).  24 h post-
transfection, 1X105 cells per well were re-seeded and grown in serum-free medium in 
the presence of vehicle or rapamycin (20 nM, Rap), with daily medium changes.  
Triplicate samples were counted every 24 h, and the mean cell numbers ±SD for a 
representative experiment are shown. (See also Figure 2-10F) (KD) 
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Figure 2-10. SREBP regulates its own expression downstream of mTORC1. 
A, B) mTORC1-dependent up-regulation of Srebp1 and Srebp2 transcript levels in Tsc2-
/- cells.  Tsc2+/+ and Tsc2-/- MEFs were transfected with siRNAs targeting Srebp1 (Sr1), 
Srebp2 (Sr2), or both (Sr1/2) or control non-targeting siRNAs (ctl).  32 h post-
transfection, the cells were serum starved for 16 hours in the presence or absence of 
rapamycin (Rap, 20 nM).  The mRNA levels of Srebp1 (A) and Srebp2 (B), measured by 
qRT-PCR, are presented as the mean±SD relative to levels in Tsc2+/+ cells treated with 
control siRNAs over three independent experiments. (KD) 
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Figure 2-10 continued 
C, D) Induction of SREBP1 and SREBP2 expression by Rheb and the processed form of 
SREBP1.  HEK-293 cells were transiently transfected with empty vector (Vec), FLAG-
RHEB, or FLAG-processed SREBP1a.  24 h post-transfection, cells were serum starved 
for 16 h in the presence of vehicle or rapamycin (20 nM), as indicated.  SREBP1 (C) and 
SREBP2 (D) mRNA levels were measured by qRT-PCR and are presented as the 
mean±SEM relative to levels in vector-transfected cells over three independent 
experiments. (KD) 
E) mTORC1-dependent changes in the levels of enzymes encoded by SREBP-target 
genes.  Protein levels of two SREBP targets are shown in Tsc2+/+ and Tsc2-/- MEFs 
serum starved for 24 h in the presence of vehicle or rapmacyin (20nM) for 12 or 24 h, as 
indicated. (JLY) 
F) The effects of SREBP knockdown on Tsc2-/- viable cell counts following 48 h serum 
starvation.  Tsc2+/+ (T2+/+) and Tsc2-/- MEFs were transfected with siRNAs targeting 
Hif1α, Srebp1, Srebp1 and Srebp2, or non-targeting control siRNAs (siCtl), as indicated.  
24 h post-transfection, 5 x 104 cells per well were re-seeded and grown in serum-free 
medium in the presence of vehicle (DMSO) or rapamycin (20 nM, Rap), with daily 
medium changes.  Viable cell counts (via trypan blue exclusion) were measured for 
triplicate samples at 48 h.  The mean viable cell numbers ±SD are shown and are 
representative of three independent experiments. (KD) 
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specific to Srebp1 strongly down-regulate the transcript levels of Srebp2. These data 
suggest that the mTORC1-dependent increase in Srebp1 and Srebp2 transcript levels 
are due to their transcriptional activation by processed SREBP1. In support of this idea, 
we found that overexpressing the processed form of SREBP1 in HEK-293 cells can 
increase the endogenous transcript levels of both SREBP1 and SREBP2 (Figure 2-10C 
and D). Furthermore, unlike Rheb overexpression, this effect is resistant to rapamycin, 
indicating that the processed form of SREBP1 acts downstream of mTORC1. 
To confirm that the mTORC1-driven expression of fatty acid and sterol 
biosynthesis genes is dependent on the SREBP transcription factors, the expression of 
representative gene were analyzed following siRNA-mediated knockdown of Srebp1 
and/or Srebp2. Similar to Raptor knockdown, siRNAs targeting one or both of these 
transcription factors blocked the expression of genes encoding enzymes involved in de 
novo fatty acid biosynthesis (e.g., Scd1 and Acsl3, Figure 2-9C). Knockdown of either 
Srebp1 or Srebp2 also blocked the expression of genes involved in sterol and isoprenoid 
biosynthesis (e.g., Mvk and Sc5d, Figure 2-9D), with SREBP2 playing a more dominant 
role in the regulation of these genes. Therefore, the SREBP1 and SREBP2 transcription 
factors are required for the mTORC1-induced expression of fatty acid and sterol 
biosynthesis genes. 
The unbiased genomic and metabolomic profiling described above revealed that 
mTORC1 signaling stimulates the oxidative pentose phosphate pathway. To gain insight 
into the regulation of this pathway by mTORC1, we used siRNAs targeting a number of 
candidate transcription factors and measured effects on the mRNA levels of G6pd, 
encoding the rate-limiting enzyme in the oxidative phase of the pentose phosphate 
pathway. Interestingly, we found that siRNA-mediated knockdown of SREBP1 
decreased the rapamycin-sensitive expression of G6pd in Tsc2-deficient cells (Figure 2-
9E). Furthermore, overexpression of the processed form of SREBP1 could induce G6PD 
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expression in HEK-293 cells (Figure 2-9F). Unlike Rheb overexpression, the effects of 
SREBP1 on G6PD transcript levels were largely resistant to rapamycin, suggesting that 
the processed form of SREBP1 is downstream of mTORC1 for the regulation of this 
gene.    
We next determined the role of SREBP in mTORC1-dependent cellular 
processes. The transcriptional activation of SREBP targets encoding the key enzymes of 
fatty acid biosynthesis (FASN) and the pentose phosphate pathway (G6PD) leads to a 
rapamycin-sensitive increase in the level of these enzymes in Tsc2-/- cells (Figure 2-
10E). Importantly, we found that the mTORC1-dependent increase in de novo lipid 
biosynthesis observed in Tsc2-/- cells was dependent on SREBP, but not HIF1α, with 
Srebp1 knockdowns reducing the levels to that of wild-type cells and Srebp1/2 double 
knockdowns reducing it further (Figure 2-9G). Unlike rapamycin, knockdown of neither 
HIF1α nor SREBP1 and 2 affected mTORC1 signaling. Interestingly, the growth factor-
independent, mTORC1-dependent proliferation of the Tsc2-/- cells was blocked by 
siRNAs targeting both Srebp1 and Srebp2, displaying similar effects to that of rapamycin 
(Figures 2-9H and 2-10F). Knocking down Srebp1 alone decreased proliferation to a 
lesser extent, whereas knocking down Hif1α alone or in combination with Hif2α had only 
marginal effects on this phenotype. These findings indicate that the SREBP-dependent 
activation of a lipogenic program is required for mTORC1-driven cell proliferation. 
 
mTORC1 activates SREBP1 through S6K1 
Once processed and released from the Golgi, the active form of SREBP1 is 
susceptible to proteasomal degradation [30]. To gain insight into how mTORC1 signaling 
leads to elevated levels of processed SREBP1, we examined the stability of this active 
form. Following cyclohexamide treatment, the processed form of SREBP1 was degraded 
with similar kinetics in the presence or absence of TSC2 (Figure 2-11). This suggests 
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Figure 2-11. mTORC1 does not regulate the stability of processed SREBP. 
The processed form of SREBP1 displays similar stability in the presence or absence of 
TSC2.  Tsc2-/- cells transfected with FLAG-processed SREBP1a were co-transfected 
with either empty vector or FLAG-TSC2. Cells were serum starved for a total of 24 h and 
treated with either vehicle or cycloheximide (CHX, 50µM) for the indicated time points 
before harvesting.  Immunoblots for FLAG-processed SREBP1a were normalized to the 
actin loading control and their untreated control using densitometry. Graphs show the 
percentage of protein relative to control remaining after various durations of CHX for 
vector- or TSC2-expressing cells. (JLY) 
CHAPTER 2. mTOR Complex 1 Controls Cellular Metabolism 
	   62	  
that the mTORC1-dependent accumulation of processed SREBP1 in Tsc1-/- and Tsc2-/- 
cells is not due to increased protein stability. To further examine potential differences in 
SREBP1 degradation, we tested the effects of a proteasome inhibitor (ALLN) on this 
regulation. While ALLN treatment substantially increased the overall levels of processed 
SREBP1, this active form remained higher in the Tsc2-/- cells and, compared to 
untreated cells, was equally sensitive to rapamycin (Figure 2-12A). Finally, as GSK3-
mediated phosphorylation of SREBP1 has been found to target it for degradation [32], 
we examined a potential role for GSK3. Efficient knockdown of GSK3α and β did not 
alter the levels or rapamycin sensitivity of processed SREBP1 in Tsc2-/- cells (Figure 2-
12B). Collectively, these data suggest that mTORC1 signaling exerts a regulatory input 
into the processing step of SREBP1.  
In order to identify the mTORC1-proximal signaling component responsible for 
the regulation of SREBP1 processing, we tested the effects of siRNAs targeting S6K1 
and S6K2. Interestingly, knockdown of S6K1 or both S6K1 and 2 lead to a substantial 
decrease in the levels of processed SREBP1 in Tsc2-/- cells, even in the presence of the 
proteasome inhibitor (Figure 2-12B). The inhibitory effects of S6K1 knockdown on the 
levels of active SREBP1 is also reflected by a decrease in the expression levels of 
several of its transcriptional targets, including both lipid biosynthesis and pentose 
phosphate pathway genes (2-12C). Finally, loss of S6K1 leads to a partial but significant 
attenuation of the enhanced lipid biosynthesis phenotype of Tsc2-/- cells (2-12D). 
Therefore, S6K1 is the major downstream target of mTORC1 stimulating the activation 
of SREBP1.  
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Figure 2-12. mTORC1 regulates SREBP1 through S6K1 but independent of GSK3 
and effects on proteasomal degradation.   
A) The inhibitory effects of rapamycin on processed SREBP1 (SREBP1(p)) are 
independent of proteasomal degradation.  MEFs were serum starved for 24 h in the 
presence of vehicle or 20-nM rapamcyin (12 or 24 h) and, where indicated, were treated 
with ALLN (25 µg/mL) for the final 1 h.  Light and dark exposures of the same blot of 
SREBP1(p) are shown. (JLY) 
B) Involvement of S6K1, but not GSK3, in the mTORC1-dependent effects on SREBP1.  
MEFs were transfected with siRNAs targeting the indicated transcripts or control non-
targeting siRNAs (ctl).  24 h post-transfection, cells were treated as in (A) with ALLN. 
(JLY) 
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Figure 2-12 continued 
C) S6K1 regulates expression of SREBP1 target genes.  MEFs were transfected with 
the indicated siRNAs, and 32 h post-transfection, cells were serum starved for 16 h in 
the presence or absence of rapamycin (Rap, 20 nM).  Transcript levels were measured 
by qRT-PCR and are presented as the mean±SD relative to levels in Tsc2+/+ (Ctl) cells 
over three independent experiments. (JLY) 
D) S6K1 contributes to stimulation of de novo lipid biosynthesis downstream of 
mTORC1.  Cells were transfected with the indicated siRNAs and serum starved for 24 h.  
For the final 4 h, cells were labeled with D-[6-14C]-glucose.  14C incorporation into the 
lipid fraction was measured and is presented as mean±SD relative to Tsc2+/+ (Ctl) cells. 
*p<0.003 versus WT; **p<0.03 versus Tsc2-/- (ctl). (JLY) 
E) Model of the control of specific metabolic pathways downstream of mTORC1.  See 
text for details. 
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DISCUSSION 
The cell lines and conditions chosen for this study were designed to isolate 
mTORC1 signaling from mTORC2, upstream branching pathways, parallel pathways, 
and feedback mechanisms that all accompany mTORC1 activation downstream of 
growth factors. While studies using rapamycin alone can reveal functions for which 
mTORC1 is necessary, combining rapamycin with an mTORC1 gain-of-function 
approach can identify those processes and pathways for which mTORC1 activity is both 
necessary and sufficient. Previous studies have profiled the effects of rapamycin on 
gene expression in lymphocytes [33, 34], and these studies have identified individual 
genes of glycolysis and lipid biosynthesis that were also classified as mTORC1-
regulated transcripts in our study. Our study demonstrates that the genes of glycolysis, 
the pentose phosphate pathway, and sterol and lipid biosynthesis are amongst the most 
prominently induced by mTORC1. Interestingly, the set of mTORC1-regulated 
transcripts indentified in this study has substantial overlap with gene sets from two 
independent studies that have profiled transcriptional changes induced by forced 
expression of membrane-targeted Akt (myr)-Akt, which is constitutively active and 
potently affects many downstream pathways, including the TSC-mTORC1 pathway [35, 
36]. One of these studies concluded that myr-Akt induces most of the genes of glycolysis 
through increased HIF1α [35], while the other found that myr-Akt induces many genes 
involved in lipid and cholesterol biosynthesis through increased SREBP1 and SREBP2 
[36]. We find that mTORC1 signaling alone is sufficient to activate these transcription 
factors and their many downstream targets.  
Perhaps the most striking finding from our unbiased analyses of mTORC1-
regulated transcripts is the specificity of the effects of mTORC1 activation on HIF1 and 
SREBP, relative to other transcription factors. However, the mechanism by which 
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mTORC1 activates these two sets of transcription factors appears to be quite different 
(see model in Figure 2-12E). Our data support previous studies using rapamycin alone, 
which have concluded that mTORC1 signaling increases HIF1α protein levels by 
promoting mRNA translation from its 5’UTR [28; 29], and we find that this induction 
requires the inhibitory phosphorylation of 4E-BP1. However, we also find an mTORC1-
dependent increase in Hif1α and Hif2α/Epas1 transcript levels, indicating either 
autoregulation of Hifα transcripts or additional mTORC1-dependent inputs into their 
regulation. Our data regarding the mTORC1-driven activation of SREBP1, on the other 
hand, suggests that transcriptional and translational control have only minor effects and 
that the induction involves a specific increase in the processed active form of SREBP1. 
This finding is consistent with that of a recent study on cells overexpressing myr-Akt [31]. 
While we find a modest, but reproducible, increase in the full-length inactive form of 
SREBP1 in TSC-deficient cells, this appears to reflect transcriptional autoregulation. 
Importantly, mTORC1 signaling does not alter the stability of active SREBP1, suggesting 
that this regulation is at the level of SREBP1 processing. This is also supported by our 
finding that exogenous expression of the processed form of SREBP1 renders its gene 
targets resistant to rapamycin. Our data indicate that S6K1 is required for the mTORC1-
driven increase in processed SREBP1 and downstream activation of its transcriptional 
targets. Therefore, S6K1 promotes the processing of SREBP1 through an, as yet, 
unknown molecular mechanism. 
In addition to enhancing the de novo synthesis of lipids through SREBP-
dependent induction of the relevant enzymes, our studies demonstrate that mTORC1 
activity is sufficient to increase metabolic flux through both glycolysis and the oxidative 
arm of the pentose phosphate pathway. Consistent with previous studies [23, 24], we 
find that HIF1α, but not HIF2α, regulates glucose uptake and glycolysis downstream of 
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mTORC1. Interestingly, knockdown of SREBP1 led to an attenuation of the mTORC1-
dependent increase in the expression of G6pd, which encodes the rate-limiting enzyme 
in the oxidative phase of the pentose phosphate pathway. The promoter regions of both 
the rodent and human genes encoding G6PD contain predicted sterol regulatory 
elements, and SREBP1 has been shown to be capable of driving transcription from the 
rat version of this promoter [37]. Furthermore, data from Srebp1 transgenic and 
knockout mice indicate that SREBP1c is involved in the induction of G6pd expression in 
liver [38, 39, 40]. Therefore, mTORC1 signaling increases flux through the oxidative 
pentose phosphate pathway, at least in part, through activation of SREBP1. A large 
amount of NADPH is needed for reducing power during de novo lipid biosynthesis, 
perhaps explaining the regulation of G6PD by SREBP1. In addition, it is likely that this 
connection between mTORC1 and the pentose phosphate pathway, leading to the 
production of NADPH needed for many biosynthetic processes and ribose needed for 
the synthesis of nucleotides, contributes to the promotion of anabolic cell growth and 
proliferation downstream of mTORC1. To this end, knocking down the expression of 
SREBP1 and SREBP2 has the same effect as rapamycin for blocking the proliferation of 
Tsc2-/- cells, suggesting an essential role for lipid biosynthesis and, perhaps, the pentose 
phosphate pathway.  
mTORC1 activation rarely occurs in isolation, but rather cooperates with many 
other signaling events to alter cell physiology. There is a growing appreciation that cell 
intrinsic alterations in nutrient and energy metabolism underlie multiple disease states, 
including cancer, diabetes, and neurological disorders. mTORC1 has been implicated in 
all of these pathological conditions and is a key component in a signaling network that 
regulates metabolism. Together with recent genetic approaches to understand the role 
of mTORC1 in integrated physiology [41, 42], we are gaining important insights into the 
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contributions of mTORC1 to the metabolic reprogramming of cells in response to the 
physiological or pathological activation of upstream signaling pathways.  
 
MATERIALS AND METHODS 
Cell culture, constructs, and RNAi 
Cell lines were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with 
4.5 g/L glucose containing 10% fetal bovine serum (FBS) prior to the described 
experiments in serum-free DMEM. Immortalized littermate-derived pairs of wild-type and 
null Tsc1 (3T3 immortalized) and Tsc2 (p53−/−) MEFs were provided by Dr. D.J. 
Kwiatkowski [14, 16]. The stable pools of Tsc2-/- MEFs reconstituted with human TSC2 
or empty vector were described previously [17]. Previously described pcDNA3-based 
constructs encoding FLAG-tagged versions of the processed nuclear form of SREBP1a 
(gift of Dr. T. Osborne [43]) and Rheb [15] were transfected into HEK293 cells using 
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s protocol. The HA-4E-
BP1 constructs and HIF1α-5’UTR bicistronic reporter were gifts of Dr. J. Blenis, and the 
corresponding methods were described previously [44]. HeLa cells stably expressing 
shRNAs targeting firefly luciferase or TSC2 were described elsewhere [11]. All siRNA-
mediated knockdown experiments were carried out with ON-TARGETplus or siGENOME 
SMARTpool siRNAs (40 nM; Dharmacon). Cells were transfected using Lipofectamine 
RNAiMAX (Invitrogen), according to the manufacturer’s protocol for reverse transfection. 
 
Gene expression array and bioinformatic analyses 
MEFs were grown to 70% confluence in 10 cm plates and were serum starved 
for 24 h in the presence of vehicle (DMSO) for 24 h or rapamycin (20 nM) for 2, 6, 12, or 
24 h. All vehicle-treated samples (0 h time points) were plated in triplicate and all 
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rapamycin time course samples were plated in duplicate. For each replicate, expression 
analysis was performed by hybridization to an Affymetrix Mouse 430_2 oligonucleotide 
microarray chip. The complete microarray data set is available at 
www.ncbi.nlm.nih.gov/geo (accession number GSE21755). Detailed protocols describing 
this analysis and the subsequent bioinformatic approaches, including GSEA and 
MotifAde, are provided with the supplemental materials.  
 
Metabolomic profiling  
To measure the intracellular levels of metabolites, extracts were prepared and 
then analyzed using LC-MS. Triplicate 10-cm plates (~70% confluent) were incubated in 
serum-free medium for 16 h, with a medium change 2 h prior to extraction. For the flux 
studies, cells were washed once with glucose-free DMEM and then incubated in DMEM 
containing a 10-mM 1:1 mixture of D-[1,2-13C]-glucose and unlabeled D-glucose for 15 
min. Metabolites were extracted on dry ice with 5-mL 80% methanol (-80°C). The extract 
was dried down under nitrogen and resuspended in 80 µL water just prior to the LC-MS 
run.  
LC-MS data were acquired using a 4000 QTRAP triple quadrupole mass 
spectrometer (Applied Biosystems/Sciex) equipped with an HTS PAL autosampler (Leap 
Technologies) and an Agilent 1200 Series binary HPLC pump. Water-soluble 
metabolites were profiled using hydrophobic interaction chromatography (HILIC) with MS 
operation in the positive ion mode and ion pairing chromatography (IPC) with MS 
operation in the negative ion mode. Amino acids, biogenic amines and other positively 
charged polar metabolites were separated using an Atlantis HILIC column (150 x 2.1 
mm; Waters) eluted with a 10-min linear gradient, initiated with 100% mobile phase B 
(acetonitrile with 0.1% formic acid, v/v) and concluded with 60% mobile phase A (10 mM 
ammonium formate and 0.1% formic acid, v/v). Central metabolites, purines, 
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pyrimidines, and other negatively charged polar compounds were analyzed using a 
modified version of the IPC method. The mobile phases used in this method were 10 
mM tributylamine/15 mM acetic acid (mobile phase A) and methanol (mobile phase B), 
and the stationary phase was an Atlantis T3 column (150 x 2.1mm; Waters). The column 
was eluted at a flow rate of 300 mL/min using the following program: 100% mobile phase 
A at initiation, 100% A at 4.0 min, 2% A at 34 min, 2% mobile phase A at 39 min, 100% 
mobile phase A at 39.5 min, and 100% mobile phase A at 55 min. Multiple reaction 
monitoring (MRM) was used to acquire targeted MS data for specific metabolites (HILIC: 
53 metabolites measurable of 88 targeted; IPC: 68 metabolites of 148 targeted). 
Declustering potentials and collision energies were optimized for each metabolite by 
infusion of reference standards prior to sample analyses. The scheduled MRM algorithm 
in the Analyst 1.5 software (Applied Biosystems/Sciex) was used to automatically set 
dwell times for each transition. MultiQuant software (Version 1.1; Applied 
Biosystems/Sciex) was used for automated peak integration and metabolite peaks were 
manually reviewed for quality of integration and compared against a known standard to 
confirm identity. For 13C tracer studies, LC-MS sample preparation and analyses were 
carried out as described above with minor modification to the mass spectrometer data 
acquisition method to include specific MRM settings for M+1 and M+2 isotopes. 
 
Measurements of glucose uptake, lactate production, and de novo lipid 
biosynthesis 
Glucose uptake was measured as the incorporation of radiolabeled 2-
deoxyglucose, based on a previously described method [45]. Briefly, cells were grown in 
12-well plates and serum-starved in the presence of vehicle (DMSO) or rapamycin for 16 
h. The cells were then washed twice with KRH buffer (20 mM HEPES, pH 7.4, 136 mM 
NaCl, 4.7 mM KCl, 1.25 mM MgSO4, 1.25 mM CaCl2) containing 0.1% bovine serum 
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albumin (BSA) and incubated for 15 min in 0.45 ml KHR/BSA, followed by addition of 0.1 
mM cold 2-deoxy-D-glucose and 0.5 µCi 2-deoxy-D-[3H] glucose (American 
Radiolabeled Chemicals) for 4 min. Following the 4 min incubation, cells were placed on 
ice, washed twice with ice-cold PBS, and lysed in 0.5 ml of 0.05% SDS. 0.4 ml lysate 
was counted in 5 ml of scintillation fluid using a Beckman LS6500 scintillation counter. 
Rates of non-specific glucose uptake were determined in samples pre-treated for 10 min 
with cytochalasin B (10 mM, Sigma) and were subtracted from the total uptake. The 
specific glucose uptake was normalized to cell number obtained from parallel wells. 
Each cell line and condition was assayed in triplicate. 
For measurements of lactate secretion, cells were plated (four replicates per 
condition) at subconfluent density (4x104 cells/well) in 12 well dishes, and after 24 h, 
cells were switched to serum-free medium containing DMSO or rapamycin (20 nM) for 
16 h. For the final hour, cells were incubated in fresh serum free medium with DMSO or 
rapamycin, and lactate secreted into the medium over this time was measured, in 
triplicate for each sample, using the fluorescence mode of a Lactate Assay Kit (Biovision 
Inc.). Fluorescent readings were averaged for each sample replicate, which were then 
averaged for each condition replicate, and were normalized to cell number obtained from 
parallel wells. 
Following a 20 h incubation in serum-free medium, de novo lipogenesis was 
measured by changing to fresh serum-free, low-glucose medium containing 4 µCi/mL D-
[6-14C]-glucose (Amersham) for 4 h prior to lipid extraction. Cells were incubated with 
vehicle (DMSO) or rapamycin (20 nM) for the duration of the 24 h incubation. As a 
background control, one sample was labeled for just 1 min prior to extraction. Cells were 
washed twice with D-PBS before lysing in 0.5% Triton X-100. The lipid fraction was 
extracted by sequential addition of chloroform and methanol (2:1 v/v) with vortexing. 
After washing with water, phase separation was achieved by low-speed centrifugation 
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(1000 rpm, 15 min), and 14C incorporation into the lower lipid-containing phase was 
counted in 3 ml scintillation fluid using a Beckman LS6500 scintillation counter. Each cell 
line and condition was assayed in duplicate, and after subtracting background values, 
average readings were normalized to cell counts from parallel plates. For all of these 
metabolic assays, a two-tailed Student’s t-test was used to determine the statistical 
significance of the relative differences measured. 
 
Cell Lines 
The littermate-derived pair of immortalized (p53-/-) Rictor+/+ and Rictor-/- MEFs 
were provided by Drs. D.A. Guertin (University of Massachusetts Medical School, 
Worcester, MA) and D.M. Sabatini (Massachusetts Institute of Technology). 
 
Immunoblotting 
Cell lysates and immunoblots were prepared as described previously (Manning 
et al., 2002). Antibodies used include those recognizing mouse SREBP1 (C20 from 
Santa Cruz) and Hif1α (Figure 4B, gift of Dr. M.C. Simon; all other blots, Cayman 
Chemicals), G6PD and Rictor (Bethyl Laboratories), and β-actin (Sigma). All other 
antibodies were from Cell Signaling Technologies. Image J Software was used to 
quantify band intensities. 
 
mRNA expression analysis 
For gene expression analyses, RNA was isolated using the RNeasy Mini Kit 
(Qiagen). cDNAs were generated using the Superscript III First Strand Synthesis System 
for RT-PCR kit (Invitrogen), and SYBR green-based quantitative RT-PCR was 
performed using an Applied Biosystems 7300 Real Time PCR System. Samples for 
each experimental condition were run in triplicate and were normalized to either Rplp0 
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(m36b4) or β-actin mRNA to determine relative expression levels. Primer sets used in 
this study are provided in supplemental Table 2-3. For expression analysis following a 
standard double thymidine block, cells were plated in triplicate at a density of 2x105 per 
well in six well dishes. After attachment, thymidine (2 mM in PBS) or an equal volume of 
PBS was added for 20 h. Cells were then washed and restored to their normal growth 
medium for 12 h prior to a second treatment with thymidine or PBS alone in serum-free 
medium in the presence or absence of rapamycin (20 nM) for 18 h. Cell counts were 
taken to confirm the proliferation arrest, and RNA was isolated and analyzed by qRT-
PCR, as above. 
 
Gene expression array and bioinformatic analyses 
Tsc1 and Tsc2 wild-type and null MEFs were grown to 70% confluence in 10 cm 
plates and were serum starved for 24 h in the presence of vehicle (DMSO) for 24 h or 
rapamycin (20 nM, Calbiochem) for 2, 6, 12, or 24 h. All vehicle-treated samples (0 h 
time points) were plated in triplicate and all rapamycin time course samples were plated 
in duplicate. For each replicate, RNA was isolated using an RNeasy Mini Kit (Qiagen), 
and 2.5 to 5 µg of RNA were used to synthesize double-stranded cDNA according to 
standard Affymetrix protocols (GeneChip One-Cycle Target Labelling). Linear 
amplification with T7-RNA polymerase and biotin labeling were performed by in vitro 
transcription, and the resulting biotin-labeled cRNA was fragmented and hybridized to 
the Affymetrix Mouse 430_2 oligonucleotide microarray chip for 16 h at 45°C. Following 
hybridization, the chip was washed, stained, and scanned on an Affymetrix GCS 3000 
GeneArray Scanner. Gene expression visualizations were done in Spotfire DecisionSite 
and Spotfire DXP (TIBCO). The data generated from the scan were then analyzed using 
the MicroArray Suite software (MAS 5.0, Affymetrix).  
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Table 2-3: RT-PCR Primers 
 
Primers for mouse transcripts 
Gene Forward Primer Reverse primer 
Acsl3 5’-ggggctggaacaattacaga-3’ 5’- atagccaccttcctcccagt-3’ 
Epas1 (Hif2a) 5’-cctgcagcctcagtgtatca-3’ 5’-gtgtggcttgaacagggatt-3’ 
G6pdx 5’-cctaccatctggtggctgtt-3’ 5’-tggctttaaagaagggctca-3’ 
Hif1a 5’-tccatgtgaccatgaggaaa-3’ 5’-cttccacgttgctgacttga-3’ 
Mvk 5’-gggacgatgtcttccttgaa-3’ 5’-gaacttggtcagcctgcttc-3’ 
Pdk1 5’-ggcggctttgtgatttgtat-3’ 5’-acctgaatcgggggataaac-3’ 
Pfkp 5’-aggagggcaaaggagtgttt-3’ 5’-ttggcagaaatcttggttcc-3’ 
Pgd 5’-agacaggcagccactgagtt-3’ 5’-aagttctgggtttcgctcaa-3’ 
Rpe 5’-gggcagaaattcatggaaga-3’ 5’-ctggggtcatcactcctca-3’ 
Rpia 5’-agtgctgggaattggaagtg-3’ 5’-ctctgggtgttgatccaggt-3’ 
Rplp0 (36b4) 5’-agatgcagcagatccgcat-3’ 5’-gttcttgcccatcagcacc-3’ 
Sc5d 5’-ccaaatggctggattcatct-3’ 5’-gtccacagggtgaaaagcat-3’ 
Scd1 5’-ctgacctgaaagccgagaag-3’ 5’-gcgttgagcaccagagtgta-3’ 
Slc2a1 (Glut1) 5’-gctgtgcttatgggcttctc-3’ 5’-agaggccacaagtctgcat-3’ 
Srebf1 (Srebp1) 5’-gatcaaagaggagccagtgc-3’ 5’-tagatggtggctgctgagtg-3’ 
Srebf2 (Srebp2) 5’-ggatcctcccaaagaaggag-3’ 5’-ttcctcagaacgccagactt-3’ 
 
Primers for human transcripts 
Gene Forward primer Reverse Primer 
ACSL3 5’-acacaagggcgcatatcttc-3’ 5’-gtggtgtgacacaggaccag-3’ 
EPAS1 5’- ttgatgtggaaacggatgaa-3’ 5’-ggaacctgctcttgctgttc-3’ 
G6PD 5’-aagaacgtgaagctccctga-3’ 5’-aatataggggatgggcttgg-3’ 
HIF1A 5’-ccagatctcggcgaagtaaa-3’ 5’-cctcacacgcaaatagctga-3’ 
MVK 5’-gctcaagttcccagagatcg-3’ 5’-atggtgctggttcatgtcaa-3’ 
PDK1 5’-gaagcagttcctggacttcg-3’ 5’-accaattgaacggatggtgt-3’ 
PFKP 5’-ctacaagcgacttgccatca-3’ 5’-atcatagatggcgagcatcc-3’ 
PGD 5’-ggtgcacaacgggatagagt-3’ 5’-ccatcggtgtcttggaactt-3’ 
RPE 5’-tggaaaggatctgggaagtg-3’ 5’-ccttggggtcaagatccata-3’ 
RPIA 5’-ctggatcgacacccagagat-3’ 5’-cgatcacgatgaagcgacta-3’ 
RPLP0 5’-agatgcagcagatccgcat-3’ 5’-gttcttgcccatcagcacc-3’ 
SC5DL 5’-tatctcttccgcccatgttc-3’ 5’-tggctcattcaccatttcaa-3’ 
SCD 5’-cccagctgtcaaagagaagg-3’ 5’-caagaaagtggcaacgaaca-3’ 
SLC2A1/GLUT1 5’-cttcactgtcgtgtcgctgt-3’ 5’-ccaggacccacttcaaagaa-3’ 
SREBF1  5’-tgcattttctgacacgcttc-3’ 5’- ccaagctgtacaggctctcc-3’ 
SREBF2 5’-tggcttctctccctactcca-3’ 5’-gagaggcacaggaaggtgag-3’ 
TSC2 5’-tgctcatcaacaggcagttc-3’ 5’-gccatcaccttctcgatgat-3’ 
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The raw data for microarray results were normalized using RMA from the 
R/Bioconductor package ‘affy’ [46-48]. The expression levels from rapamycin-treated (2,  
6, 12, and 24 h) Tsc1-/- and Tsc2-/- cells were compared to their 0 h controls (vehicle 
treated), and the vehicle-treated wild-type levels were compared to levels from both the 
0 h and 24 h rapamycin time points for Tsc1-/- and Tsc2-/- cells. Fold changes and p-
values for array comparisons were calculated using the R/Bioconductor package 
‘Limma’ [49]. Gene set enrichment analysis was performed on a set of 541 mTORC1-
regulated probes (representing 464 genes) that met the four criteria detailed in the 
results section accompanying Figure 1, at a p-value cutoff of < 0.05. Enrichment and 
pathway analysis was done using the MetaCore application (GeneGo). MotifAde 
analysis was performed, as described previously [19], on all genes sensitive to 
rapamycin at 24 h in both Tsc1-/- and Tsc2-/- cells.  
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SUMMARY 
Through unknown mechanisms, insulin activates the sterol regulatory element-
binding protein (SREBP1c) transcription factor to promote hepatic lipogenesis. We find 
that this induction is dependent on the mammalian target of rapamycin (mTOR) complex 
1 (mTORC1). To further define the role of mTORC1 in the regulation of SREBP1c in the 
liver, we generated mice with liver-specific deletion of TSC1 (LTsc1KO), which results in 
insulin-independent activation of mTORC1. Surprisingly, the LTsc1KO mice are 
protected from age- and diet-induced hepatic steatosis and display hepatocyte-intrinsic 
defects in SREBP1c activation and de novo lipogenesis. These phenotypes result from 
attenuation of Akt signaling driven by mTORC1-dependent insulin resistance. Therefore, 
mTORC1 activation is not sufficient to stimulate hepatic SREBP1c in the absence of Akt 
signaling, revealing the existence of an additional downstream pathway also required for 
this induction. We provide evidence that this mTORC1-independent pathway involves 
Akt-mediated suppression of Insig2a, a liver-specific transcript encoding the SREBP1c 
inhibitor INSIG2. 
 
BACKGROUND 
The liver is a key organ in the systemic response to insulin, controlling both 
glucose and lipid metabolism. Hepatocytes respond to insulin by halting 
gluconeogenesis and increasing de novo lipid synthesis. Genetic mouse models have 
demonstrated that both of these responses to insulin occur, at least in part, downstream 
of the protein kinase Akt2 [1-3]. Akt2 mediates these effects primarily through the 
regulation of two downstream transcription factors, FOXO1 and SREBP1c, which control 
the expression of the metabolic enzymes underlying these processes. FOXO1 
stimulates gluconeogenic gene expression in the liver and is directly phosphorylated and 
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inhibited by Akt [4]. While the mechanisms are less well characterized, Akt signaling 
appears to stimulate de novo lipid synthesis through the activation of SREBP isoforms 
(reviewed in [5]). SREBP1c is the dominant insulin-stimulated isoform in the liver 
responsible for inducing lipogenic gene expression and promoting fatty acid synthesis 
[6]. Akt activation appears to be both necessary and sufficient for the induction of hepatic 
SREBP1c and lipid accumulation [3, 7, 8]. An important feature of hepatic insulin 
signaling is that control of gluconeogenesis and lipogenesis is differentially affected 
under pathological conditions of insulin resistance associated with type 2 diabetes. 
Under such conditions, insulin fails to suppress glucose production by the liver, while the 
induction of hepatic lipogenesis is sustained, thereby contributing to both the 
hyperglycemic and hyperlipidemic states. Understanding this pathological phenomenon, 
referred to as selective insulin resistance [9], requires a deeper understanding of how 
insulin and Akt regulate hepatic lipid metabolism.    
Recent cell-based studies have implicated the activation of mTOR complex 1 
(mTORC1) downstream of Akt in the induction of SREBP isoforms (Chapter 2; [10, 11]). 
The primary mechanism by which Akt activates mTORC1 is through the phosphorylation 
and inhibition of the TSC2 protein within the TSC1-TSC2 complex (reviewed in [12]). 
This protein complex acts as a GTPase-activating protein (GAP) for a Ras-related small 
G protein called Rheb, thereby enhancing its conversion to the GDP-bound off state. 
GTP-bound Rheb stimulates mTORC1 kinase activity and downstream signaling. 
Therefore, Akt-mediated inhibition of the TSC1-TSC2 complex serves to activate Rheb 
and mTORC1. Importantly, increased activation of mTORC1, through the expression of 
an activated allele of Akt [10] or genetic disruption of the TSC1-TSC2 complex (Chapter 
2; [11]), has been found to activate SREBP isoforms and promote an SREBP-dependent 
increase in de novo lipid synthesis. Furthermore, a recent study has shown that the 
ability of insulin to stimulate SREBP1c in rat hepatocytes requires mTORC1 [13]. 
CHAPTER 3. mTORC1-Dependent and Independent Control of Hepatic SREBP1c 
	   83	  
SREBP1c regulation is quite complex [14, 15]. The protein is synthesized as an 
inactive precursor that resides in complex with SREBP cleavage-activating protein 
(SCAP) in the endoplasmic reticulum (ER) membrane, where it is sequestered through 
the interaction of SCAP with INSIG proteins. Through a poorly understood process, 
insulin stimulates trafficking of the SREBP1c-SCAP complex to the Golgi, where 
SREBP1c is proteolytically processed to generate the active transcription factor. The 
active form of SREBP1c is sensitive to proteasomal degradation but can enter the 
nucleus to engage its transcriptional targets, including its own gene promoter and those 
encoding the major enzymes of fatty acid synthesis [6]. A collection of previous studies 
has implicated insulin and Akt in controlling different aspects of SREBP1c activation [5].  
While the mechanisms remain to be determined, mTORC1 signaling downstream of Akt 
appears to regulate some aspect of the trafficking or processing of SREBP isoforms, 
without obvious effects on translation or stability (Chapter 2; [10, 11]). 
The role of mTORC1 activation in the metabolic response of the liver to insulin 
and nutrients is poorly understood [16]. Elevated levels of mTORC1 signaling have been 
associated with conditions of hepatic insulin resistance [17-19]. In vitro, mTORC1 
signaling can cause cell-intrinsic insulin resistance through negative feedback 
mechanisms affecting upstream regulators of Akt [20, 21]. In support of an in vivo role 
for these feedback mechanisms controlling insulin sensitivity, knockout of S6K1, a 
downstream target activated by mTORC1, leads to an increased response of Akt 
signaling to insulin in the mouse liver, as well as other metabolic tissues [22]. However, 
the phenotype of the S6K1 knockout mouse is confounded by a pronounced reduction in 
adiposity. Therefore, liver-specific genetic models are needed to better define the 
hepatocyte-intrinsic roles of mTORC1 in controlling insulin signaling and lipogenesis.  
Here, we seek to elucidate the role of mTORC1 signaling in the regulation of 
SREBP1c and lipid metabolism in the liver. We find that mTORC1 activation is required 
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for the induction of hepatic SREBP1c in response to insulin and feeding. To determine 
whether mTORC1 activation is sufficient to drive hepatic lipogenesis, we generate an 
mTORC1 gain of function mouse model lacking TSC1 in the liver. Contrary to our 
prediction, these mice are protected from both age- and diet-induced hepatic steatosis. 
In determining the mechanism of this protection, we find that there is a surprising defect 
in the induction of SREBP1c in the livers of these mice stemming from the attenuation of 
hepatic Akt signaling. These findings indicate that mTORC1 activity alone cannot 
stimulate lipogenesis in the liver and that a second Akt-driven pathway is also required. 
Finally, our data indicate that the mTORC1-independent pathway downstream of Akt 
involves the suppression of a liver-specific isoform of INSIG [23-25].  
 
RESULTS 
Insulin stimulates hepatic SREBP1c in an mTORC1-dependent manner. 
As the mechanism of hepatic SREBP1c induction by insulin and Akt is poorly 
understood, we sought to determine whether mTORC1 activity contributes to this 
induction in primary mouse hepatocytes. Insulin stimulates activating phosphorylation 
events on Akt leading to subsequent phosphorylation of the Akt targets FOXO1, 
FOXO3a, and TSC2, the latter target of which leads to mTORC1 activation and 
phosphorylation of S6K1 (Figure 3-1A and 3-2A). As described for other cell types, we 
find that inhibition of mTORC1 with rapamycin enhances the insulin-stimulated 
phosphorylation of Akt and its substrates in hepatocytes (Figure 3-1A), presumably 
through inhibition of negative feedback mechanisms (reviewed in [12, 21]). In response 
to insulin, SREBP1c induces its own expression, as well as genes encoding lipogenic 
enzymes, such as FASN [6, 15]. Importantly, despite enhancing Akt signaling, pre-
treatment with rapamycin suppressed the ability of insulin to stimulate Srebp1c and Fasn 
(Figure 3-1B). In contrast, mRNA expression of Igfbp1 and the gluconeogenic enzyme  
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Figure 3-1. mTORC1 activity is required for the insulin-stimulated induction of 
hepatic SREBP1c and de novo lipogenesis. (JLY) 
A) Primary hepatocytes were serum starved overnight, pretreated for 30 min with vehicle 
or rapamycin (Rap; 20 nM), and stimulated for 6 h with insulin (Ins; 10 nM), as indicated.  
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Figure 3-1 continued 
B) Hepatocytes were treated as in (A), and mRNA expression was measured by qRT-
PCR. Transcript levels are shown relative to untreated controls. *P<0.006 (Srebp1c) and 
P<4x10-7 (Fasn) compared to unstimulated; **P<0.03 (Srebp1c) and P<0.002 (Fasn) 
compared to insulin-stimulated, vehicle-treated.  
C) Hepatocytes treated as in (A) were labeled with 14C-acetate and the levels of 14C 
incorporation into the lipid fraction are shown relative to untreated controls. *P<5x10-5 
and **P<0.004 for the comparisons described in (B). Data are presented as the mean ± 
SEM from three (B) or four (C) independent experiments. 
(D,E) 8 week-old mice were fasted overnight (-) and then refed for 6 h (+) following a 30-
min pre-treatment with vehicle or rapamycin (10mg/kg). N=4 mice per condition. (D) 
Liver lysates were immunoblotted for markers of mTORC1 signaling and full length (fl) 
and processed (p) SREBP1. (E) Gene expression was measured by qRT-PCR. Data are 
shown as mean ± SEM relative to untreated controls. *P<0.003 (Srebp1c), P<0.002 
(Fasn) and P<0.0007 (Scd1) compared to fasted; **P<0.03 (Srebp1c), P<0.05 (Fasn), 
and P<0.0001 (Scd1) compared to fed, vehicle-treated. 
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Figure 3-2. mTORC1 activity is dispensable for insulin-mediated suppression of 
FOXO1 targets. (JLY) 
A) Model depicting the proposed pathways through which insulin suppresses 
gluconeogenesis and stimulates lipogenesis in the liver (see text for details). 
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Figure 3-2 continued 
B,C)  mTORC1 activity is not required for insulin-mediated suppression of FOXO1 
targets. (B) Primary hepatocytes were serum starved overnight, pretreated for 30 min 
with vehicle (DMSO) or rapamycin (Rap; 20 nM), and then stimulated for 6 h with insulin 
(Ins; 10 nM), as indicated. mRNA expression was measured by qRT-PCR. Transcript 
levels are shown relative to untreated controls and are presented as mean ± SEM from 
three independent experiments. *P<1x10-5 compared to unstimulated; **P<5x10-6 
compared to unstimulated for both targets. (C) 8 week-old mice were fasted overnight (-) 
and then refed for 6 hours (+) with or without 30 min pre-treatment with rapamycin 
(10mg/kg), where indicated (n=4 per group). RNA was isolated from livers and gene 
expression was measured by qRT-PCR. Data are shown as mean ± SEM relative to 
untreated controls. *P<0.001 (Pepck) and P<0.002 (Igfbp1) compared to fasted; 
**P<0.0005 (Pepck) and P<0.0003 (Igfbp1) compared to fasted. Note: There is no 
significant difference between the fold suppression by insulin in the presence or absence 
of rapamycin in hepatocytes (B) and livers (C). 
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Pepck, two canonical FOXO1 targets, was inhibited by insulin but not affected by 
rapamycin (Figure 3-2B). These findings are consistent with those described recently for 
rat hepatocytes [13] and demonstrate that mTORC1 is required for proper insulin 
stimulation of SREBP1c. Consistent with this effect on SREBP1c, rapamycin also 
significantly impairs the ability of insulin to stimulate de novo lipid synthesis in 
hepatocytes (Figure 3-1C). To determine the relevance of these findings in vivo, we 
subjected mice to an overnight fast followed by refeeding. Feeding activates hepatic Akt 
and mTORC1 signaling and promotes the expression and processing of SREBP1 and 
increased expression of its targets (Figure 3-1D,E; [26]). Importantly, SREBP1c 
activation was blocked by treatment with rapamycin just prior to feeding (Figure 3-1D,E), 
without effects on FOXO1 targets (Figure 3-2C). Taken together with studies in other 
settings [10, 11], these results indicate that mTORC1 is a critical effector downstream of 
insulin and Akt for the induction of SREBP1c in hepatocytes. 
 
Liver-specific deletion of Tsc1 results in insulin-independent activation of 
mTORC1. 
To further define the role of mTORC1 in the regulation of hepatic lipid 
metabolism, we employed a liver-specific gain of function model to disconnect mTORC1 
activation from its normal control by insulin. As insulin signals to mTORC1 through Akt-
mediated inhibition of the TSC1-TSC2 complex, loss of TSC1 or TSC2 leads to Akt-
independent activation of mTORC1 signaling. To delete Tsc1 specifically in hepatocytes, 
we used a previously described floxed allele of Tsc1 (Tsc1fl; Figure 3-3A; [27]), 
backcrossed onto a pure C57Bl/6J background. Following Cre-induced recombination, 
exons 17 and 18 of the Tsc1fl allele are deleted, and this has been demonstrated to 
generate a null allele [27]. Hepatocyte-specific deletion of this allele was achieved by 
crossing these mice to those expressing Cre from the albumin promoter (Alb-Cre; [28]).  
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Figure 3-3. Liver-specific Tsc1 deletion renders hepatic mTORC1 signaling 
constitutive and insulin independent.  
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Figure 3-3 continued 
A) Schematic of the Tsc1fl allele and resulting null allele following Cre-mediated excision. 
The position of the three PCR primers used for genotyping are shown with arrows.  
B) Representative PCR genotyping of liver tissue from the offspring of a cross between 
Tsc1fl/fl and Albumin (Alb)-Cre Tsc1fl/+ mice using the primers shown in (A). Genomic 
DNA from MEFs of the given genotype was used as controls for the three Tsc1 alleles.  
(AIL) 
C) Immunoblots of liver, muscle, and fat tissue extracts from ad libitum-fed mice of the 
given genotypes are shown. (JLY, HZ) 
D) Immunohistochemistry of phospho-S6 (S240/244) and staining with hematoxylin and 
eosin (H&E) were performed on adjacent liver sections from ad libitum-fed, 6 month-old 
mice of the given genotypes. (SM, HZ) 
E) 8 week-old Tsc1fl/fl and LTsc1KO mice were fasted overnight (-) and then re-fed for 6 
h (+), where indicated (N=3 mice per condition). Immunoblots of liver extracts from these 
mice are shown. (JLY) 
F) Primary hepatocytes from Tsc1fl/fl and LTsc1KO mice were serum-starved overnight 
and stimulated for 6 h with insulin (Ins; 10 nM) in the presence or absence of a 30-min 
pretreatment with rapamycin (Rap; 20 nM). (JLY) 
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Genomic appearance of the null allele and liver-specific loss of TSC1 protein 
were confirmed by PCR genotyping (Figure 3-3B) and immunoblotting (Figure 3-3C), 
respectively, of liver extracts from littermates of different genotypes. Mice with 
homozygous loss of Tsc1 in their livers (Alb-Cre Tsc1fl/fl; referred to as LTsc1KO) were 
born at Mendelian ratios and exhibited no loss of viability out to 9 months of age. As 
TSC1 stabilizes TSC2, LTsc1KO livers also exhibit a near complete loss of TSC2 protein 
(Figure 3-3C). Importantly, only LTsc1KO livers exhibited increased phosphorylation of 
S6 and 4EBP1, reflected by decreased electrophoretic mobility, which are common 
readouts of mTORC1 signaling (Figures 3-3C,D). Hepatic mTORC1 signaling was 
sustained even under fasting conditions in the LTsc1KO mice, and the level of activation 
was comparable to control Tsc1fl/fl mice just after feeding (Figure 3-3E). Likewise, 
primary hepatocytes isolated from LTsc1KO mice exhibited insulin-independent 
activation of mTORC1 signaling (Figure 3-3F). Therefore, the LTsc1KO mice provide a 
model of hepatic mTORC1 activation that occurs independent of the upstream insulin-
signaling pathway.  
 
LTsc1KO mice are protected from age- and diet-induced hepatic steatosis. 
To begin to understand the role of mTORC1 signaling in the control of hepatic 
lipid metabolism, we examined the histological features of livers from cohorts of Tsc1fl/fl 
and LTsc1KO mice. Contrary to our expectations, LTsc1KO mice were protected from 
age-induced hepatic steatosis at 9 months, exhibiting significantly lower levels of liver 
triglycerides (TGs; Figure 3-4A-C). A relative decrease in lipid accumulation in LTsc1KO 
livers was also evident in H&E-stained liver sections at 6 months (e.g., see Figure 3-3D). 
Given the surprising decrease in lipid accumulation in the livers of LTsc1KO mice fed a 
normal chow diet, we challenged the LTsc1KO mice with a lard-based high fat diet 
(HFD) to further examine this phenotype. As on a chow diet (data not shown), there was  
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Figure 3-4. Further characterization of lipid metabolism in LTsc1KO mice.  
A,B,C) LTsc1KO mice are protected from age-induced steatosis. Liver sections from 9 
month-old Tsc1fl/fl (n=9) and LTsc1KO (n=9) mice were stained with H&E. (A) 
Representative sections from these mice are shown with steatosis in Tsc1fl/fl livers but 
not in LTsc1KO livers (scale bars: 500 µM (40X), 100 µM (100X). (B) The results from 
blinded scoring of the H&E-stained liver sections for steatosis are provided.  
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Figure 3-4 continued 
(C) Liver triglycerides (TG) were measured in ad libitum-fed Tsc1fl/fl (n=2) and LTsc1KO 
(n=4) aged mice on chow diet, as in (A,B). TG levels are shown normalized to protein 
concentration and are presented as the mean ± SEM. *P<0.007 (HZ) 
D) LTsc1KO mice have normal serum levels of triglyceride (TG), non-esterified fatty acid 
(NEFA), and cholesterol. Blood collected from ad libitum-fed Tsc1fl/fl (n=5) and LTsc1KO 
(n=5) mice after HFD was assayed for levels of TGs, NEFAs, and cholesterol. Data and 
are presented as the mean ± SEM. (JLY) 
E) LTsc1KO mice do not have differences in hepatic triglyceride (TG) output. Hepatic TG 
production was measured in a cohort of chow-fed Tsc1fl/fl (n=5) and LTsc1KO (n=5) mice 
following a 4 h fast and injection with Tyloxapol (2 g/kg bodyweight) to inhibit lipolysis. 
Serum TG levels were measured and are plotted over time as mean ± SEM. (JLY) 
F) LTsc1KO livers do not display increased mitochondrial gene expression. RNA was 
isolated from livers of ad libitum-fed male Tsc1fl/fl (n=4) and LTsc1KO (n=4) mice after 
HFD and gene expression was measured by qRT-PCR. Data and are presented as the 
mean ± SEM relative to Tsc1fl/fl. (JLY) 
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no significant difference in weight gain between the Tsc1fl/fl and LTsc1KO mice on the 
HFD (Figure 3-5A). Dual-energy X-ray absorptiometry (DEXA) indicated that there was 
no difference in percentage body fat after 16 weeks of HFD (Figure 3-5B). However, the 
LTsc1KO mice exhibited protection from HFD-induced hepatic steatosis (Figure 3-5C). 
Blinded scoring of liver sections by a pathologist indicated that all Tsc1fl/fl mice had 
moderate to severe steatosis, while the majority of LTsc1KO mice exhibited negative to 
mild lipid accumulation (Figure 3-5D). Consistent with these histological findings, 
LTsc1KO livers had significantly reduced levels of TGs (Figure 3-5E). Therefore, 
constitutive mTORC1 signaling in the LTsc1KO livers is accompanied by a decrease, 
rather than the predicted increase, in hepatic lipid accumulation. 
 
LTsc1KO mice have defects in hepatic induction of SREBP1c and lipogenesis. 
To determine the mechanism of protection from hepatic steatosis in the LTsc1KO 
mice, we examined candidate pathways involved in lipid mobilization and metabolism. 
For instance, increased TG export could account for decreased accumulation in the liver. 
However, serum levels of TGs, non-esterified fatty acids (NEFAs), and cholesterol were 
not significantly different in mice fed a HFD, but TG and NEFA levels trended down in 
LTsc1KO compared to Tsc1fl/fl mice (Figure 3-4D). Furthermore, LTsc1KO mice did not 
display significant differences in hepatic TG output under fasting conditions, and again, 
these levels trended lower relative to controls (Figure 3-4E). Consistent with the lack of 
physiological evidence supporting a role for increased TG mobilization, transcript levels 
of proteins involved in these processes, such as Mttp, Dgat1, and Dgat2, were not 
significantly changed in LTsc1KO livers (Figure 3-5F). To address the possibility that 
LTsc1KO livers burn more lipid than controls, we measured expression of genes 
important for the β-oxidation of fatty acids. We found that transcript levels of Pparα, 
Mcad, and Cpt1a were not increased in the LTsc1KO livers, and in fact, Mcad  
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Figure 3-5. LTsc1KO mice are protected from diet-induced hepatic steatosis.  
A) A cohort of male Tsc1fl/fl (n=3) and LTsc1KO (n=4) mice were weighed between the 
ages of 5 and 25 weeks, while being fed a high-fat diet (HFD) for the final 16 weeks. 
(HZ) 
B) HFD-fed male Tsc1fl/fl (n=6) and LTsc1KO (n=6) mice were subjected to DEXA 
scanning. (CG, HZ) 
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Figure 3-5 continued 
C,D) Liver sections from 6-month old Tsc1fl/fl (n=7) and LTsc1KO (n=7) mice fed a HFD, 
as in (A), were stained with H&E. (C) Representative sections from these mice are 
shown (scale bars: 500 µM (40X), 50 µM (200X). D) The results from blinded scoring of 
the H&E-stained liver sections for negative/mild, moderate, or severe steatosis are 
provided. (RB, HZ) 
E) Liver triglycerides (TG) were measured in ad libitum-fed Tsc1fl/fl (n=5) and LTsc1KO 
(n=5) mice on a HFD, as in (A). TG levels are shown normalized to protein concentration 
and are presented as the mean ± SEM. *P<0.05 (HZ) 
F,G) Expression of mRNA in the livers of ad libitum-fed Tsc1fl/fl (n=4) and LTsc1KO (n=4) 
mice on a HFD, as in (A), was measured by qRT-PCR for the given genes, and levels 
are presented as mean ± SEM relative to Tsc1fl/fl. *P<0.05 (Mcad). (JLY) 
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expression was significantly reduced in these livers relative to controls (Figure 3-5G). 
This is consistent with recent findings that mTORC1 signaling decreases the expression 
of β-oxidation genes in the liver [29]. As mitochondria are the major site of β-oxidation 
and mTORC1 signaling has been proposed to promote mitochondrial biogenesis [30], 
we also measured levels of mitochondrial markers. However, transcripts encoding the 
major mitochondrial transcription factor TFAM and the mitochondrial enzymes COX-IV 
and citrate synthase were not different (Figure 3-4F). Collectively, these results suggest 
that neither an increase in hepatic lipid output nor consumption underlie the protection 
from steatosis exhibited by the LTsc1KO mice. 
Previous studies have demonstrated that mTORC1 signaling can drive 
lipogenesis through activation of SREBP isoforms (Chapter 2; [10, 11]), and a similar 
role in the liver is supported by our findings above (Figure 3-1). However, like LTsc1KO 
mice, Srebp1 knockout mice are protected from hepatic steatosis despite normal 
increases in adiposity [31]. Therefore, we considered the possibility that LTsc1KO livers 
might have a defect in SREBP1c induction that could account for their decreased TG 
levels. Indeed, we found that the expression of Srebp1c and its lipogenic targets, Fasn 
and Scd1, were significantly reduced in the livers of LTsc1KO mice (Figure 3-6A). 
Consistent with a defect in SREBP1c activation, a more pronounced decrease in the 
levels of processed, active SREBP1 relative to full-length, inactive SREBP1 was 
detected in the LTsc1KO livers (Figure 3-6B). Reduced levels of FASN and SCD1 
protein were also evident in these livers. The differences in lipogenic gene expression 
were not restricted to the HFD-fed group, but were also detected in young mice (9 
weeks) fed a normal chow diet (Figure 3-7A). Furthermore, young LTsc1KO mice 
displayed defects in the hepatic induction of processed SREBP1 in response to feeding 
(Figure 3-6C). The decreased ratio of processed to full length SREBP1 in the LTsc1KO 
livers is also reflected in decreased induction of its lipogenic targets at the protein and  
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Figure 3-6. LTsc1KO livers and hepatocytes have defects in the induction of 
SREBP1c expression and de novo lipogenesis.  
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Figure 3-6 continued 
A) Expression of mRNA in the livers of male ad libitum-fed Tsc1fl/fl (n=4) and LTsc1KO 
(n=4) mice on a HFD was measured by qRT-PCR for the given genes, and levels are 
presented as mean ± SEM relative to Tsc1fl/fl. *P<0.005 (Srebp1c), P<0.05 (Fasn), and 
P<0.004 (Scd1).  (JLY) 
B) Immunoblots of full-length (fl) and processed (p) SREBP1, FASN, and SCD1 are 
shown in liver lysates from mice described in (A). (JLY) 
(C, D) 8 week-old Tsc1fl/fl and LTsc1KO mice were fasted overnight (-) with or without 
refeeding for 6 h (+), as indicated (N=4 per condition). (C) Liver lysates from Tsc1fl/fl and 
LTsc1KO mice were immunoblotted for full length (fl) and processed (p) SREBP1 and its 
targets. The ratio of SREBP1(p) to SREBP1(fl) in the fasted and refed state was 
quantified for both genotypes and is presented as mean ± SEM relative to fasted wild-
type samples. *P<0.01 for the fold induction by feeding compared to Tsc1fl/fl livers. (D) 
RNA was isolated from the livers of these mice and gene expression was measured by 
qRT-PCR and is shown as mean ± SEM relative to fasted samples for each genotype. 
*P<0.0005 (Scd1) and P<0.003 (Fasn) for the fold induction by feeding compared to 
Tsc1fl/fl livers. Note: There are no significant differences in fasted expression levels 
between Tsc1fl/fl and LTsc1KO livers. (JLY) 
E) Primary hepatocytes from Tsc1fl/fl and LTsc1KO mice were serum starved overnight 
followed by insulin stimulation (Ins; 10 nM) for 6 h. Cells were labeled with 14C-acetate 
for the final 4 h, and its incorporation into the lipid fraction was measured. Data are 
presented as mean ± SEM relative to unstimulated wild-type samples. *P<0.01 for the 
fold induction by insulin compared to Tsc1fl/fl hepatocytes. (JLY) 
F) Expression of mRNA from primary hepatocytes treated as described in (E) was 
analyzed by qRT-PCR for the given genes, and levels are presented as mean ± SEM  
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Figure 3-6 continued 
relative to the unstimulated samples for each genotype. *P<0.013 (Srebp1c) and 
P<0.023 (Fasn) for the fold induction by insulin compared to Tsc1fl/fl hepatocytes. Data in 
(E) and (F) are representative of three independent experiments. (JLY) 
 
CHAPTER 3. mTORC1-Dependent and Independent Control of Hepatic SREBP1c 
	   102	  
       
Figure 3-7. LTsc1KO livers from young, chow-fed mice display decreased 
lipogenic gene expression and defects in the induction of SREBP2 targets by 
feeding. (JLY) 
A) Livers from fasted 8 week-old male Tsc1fl/fl (n=4) and LTsc1KO (n=4) mice, fed a 
normal chow diet, were analyzed for mRNA expression by qRT-PCR. Data and are 
presented as the mean ± SEM relative to Tsc1fl/fl. *P<0.004 (Srebp1c) and P<0.01 
(Fasn) comparing Tsc1fl/fl and LTsc1KO.  
B) 8 week-old Tsc1fl/fl (n=4) and LTsc1KO (n=4) mice were fasted overnight (-) with or 
without refeeding for 6 hours (+), as indicated. RNA was isolated from livers and gene 
expression was measured by qRT-PCR. Expression levels of transcripts are shown as 
mean ± SEM relative to fasted samples for each genotype. *P<0.026 (Ldlr) and 
*P<0.044 (Hmgcr) compared to the fold induction in Tsc1fl/fl livers.   
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transcript levels (Figure 3-6C,D). LTsc1KO mice also exhibit defects in the feeding-
induced expression of canonical SREBP2 target genes, including Ldlr and Hmgcr 
(Figure 3-7B; [6]). Importantly, a hepatocyte-intrinsic defect in the induction of de novo 
lipid synthesis is detected in primary hepatocytes from LTsc1KO livers (Figure 3-6E), 
and there was a corresponding defect in the insulin-stimulated expression of Srebp1c 
and its target Fasn (Figure 3-6F). Taken together with our previous findings, these data 
indicate that mTORC1 activation is required but not sufficient to induce SREBP1c and 
lipogenesis in hepatocytes and suggest that defects in the induction of SREBP1c might 
underlie the protection of LTsc1KO mice from hepatic steatosis. 	  
Elevated hepatic mTORC1 signaling attenuates insulin signaling to Akt. 
Decreases in hepatic lipid accumulation and steatosis accompanied by 
decreases in SREBP1c and de novo lipogenesis are phenotypes described for the liver-
specific knockout of Akt2 [3]. It has been well established in cell culture models that 
mTORC1 activation stimulates negative feedback mechanisms that can dampen the 
response of cells to insulin, resulting in decreased Akt signaling (reviewed in [12, 21]). 
However, it is unknown whether mTORC1 activation in the liver can cause hepatic 
insulin resistance. Indeed, LTsc1KO mice display decreased phosphorylation of Akt and 
its downstream target FOXO1 in their livers (Figure 3-8A). In contrast, phosphorylation of 
GSK3α and β was not substantially different in Tsc1fl/fl and LTsc1KO livers, consistent 
with the fact that additional protein kinases can phosphorylate these Akt substrates [32-
35]. Atypical PKCs have also been implicated in the promotion of hepatic lipogenesis 
downstream of the insulin receptor [36, 37]. However, the activating phosphorylation of 
PKCζ/λ was increased, rather than decreased, in the LTsc1KO livers (Figure 3-9A), 
perhaps suggesting a compensatory mechanism. As the AMP-dependent protein kinase 
(AMPK) has recently been found to block the processing of SREBP isoforms [38], we  
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Figure 3-8. Attenuation of Akt signaling in LTsc1KO livers and hepatocytes is 
responsible for the defect in SREBP1c induction. (JLY) 
A) Immunoblots of liver lysates from ad libitum-fed male Tsc1fl/fl and LTsc1KO mice 
following a 16-week HFD are shown for the indicated phospho-(P) and total proteins. 
(B) 8 week-old Tsc1fl/fl and LTsc1KO mice were fasted overnight (-) with or without 
refeeding for 6 h (+), as indicated, prior to immunoblot analysis of liver lysates.  
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Figure 3-8 continued 
C) Primary hepatocytes from Tsc1fl/fl (+) and LTsc1KO (-) mice were serum starved 
overnight and then stimulated with insulin (Ins; 10 nM) for 1 h, where indicated. 
D) Following overnight serum starvation, LTsc1KO hepatocytes were treated with 
rapamycin (Rap; 20 nM) for 30 min, where indicated, prior to insulin stimulation (10 nM) 
for 6 h.  
E) Primary hepatocytes from Tsc1fl/fl and LTsc1KO mice were infected with adenovirus 
expressing either empty vector (Vec) or myr-Akt2 (Akt2), and 6 h post-infection, cells 
were serum starved overnight before lysis and immunoblotting.  
F) Following overnight serum starvation, uninfected cells were stimulated with insulin (10 
nM) for 6 h, whereas cells infected as in (E) were left unstimulated. Cells were labeled 
with 14C-acetate for the final 4 h, and its incorporation into the lipid fraction was 
measured. Data are presented as mean ± SEM relative to unstimulated Tsc1fl/fl samples 
for the uninfected group or to the vector-expressing Tsc1fl/fl samples for the infected 
group for at least two independent experiments. *P<0.05 for the difference in fold 
induction by insulin compared to Tsc1fl/fl hepatocytes.  
G) Primary hepatocytes were infected as described in (E), with vector-expressing cells 
being treated with insulin (10 nM) for 6 h, where indicated. Expression of mRNA was 
measured by qRT-PCR for the given genes, and levels are presented as mean ± SEM 
relative to the unstimulated vector-expressing group for each genotype. *P<0.027 
(Srebp1c) and P<0.024 (Fasn) for the fold induction by insulin compared to Tsc1fl/fl 
hepatocytes.  
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Figure 3-9.	  Further characterization of signaling and metabolic phenotypes of 
LTsc1KO mice. 
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Figure 3-9 continued  
A) Atypical PKC phosphorylation is not attenuated in LTsc1KO livers. Liver lysates from 
ad libitum-fed male Tsc1fl/fl and LTsc1KO mice after a 16-week HFD were 
immunoblotted for the indicated phospho- (P) and total proteins. (JLY) 
B) LTsc1KO livers do not display increased activation of AMPK. Immunoblots of liver 
lysates from ad libitum-fed male Tsc1fl/fl and LTsc1KO mice following a 16-week HFD 
are shown for the indicated phospho- (P) and total proteins. (JLY) 
C) Expression of FOXO1 targets is elevated in LTsc1KO livers. Expression of mRNA in 
the livers of Tsc1fl/fl (n=4) and LTsc1KO (n=4) mice, described in (A), was measured by 
qRT-PCR for the given genes, and levels are presented as mean ± SEM relative to 
Tsc1fl/fl. *P<0.032 (Pepck) and P<0.005 (Igfbp1) comparing Tsc1fl/fl and LTsc1KO levels. 
(JLY) 
D,E) Relative to controls, LTsc1KO mice exhibit more severe glucose intolerance, but 
the same insulin tolerance, on a HFD. Glucose (D) and insulin (E) tolerance tests were 
performed at 25 and 26 weeks of age, respectively, following a 16-week HFD on the 
same cohort of fasted Tsc1fl/fl (n=12) and LTsc1KO (n=7) mice. (D) P<0.007 for area 
under the curve analysis comparing Tsc1fl/fl to LTsc1KO. *Significance for individual time 
points: P<0.004 (40 min), P<0.024 (60 min), P<0.04 (90 min), and P<0.003 (120 min). 
(HZ) 
F) LTsc1KO mice do not exhibit differences in serum insulin levels on chow or high-fat 
diet. Serum insulin was measured from overnight fasted Tsc1fl/fl and LTsc1KO mice (n ≥ 
6 per genotype) before and after HFD. NOTE: There is no difference between genotypes 
on either diet, but HFD increased serum insulin significantly in both genotypes P<2x10-5 
(Tsc1fl /fl) and P<0.0003 (LTsc1KO). (HZ) 
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also examined AMPK activation but found no difference between the control and 
LTsc1KO livers (Figure 3-9B). One feedback mechanism by which mTORC1 activation 
is thought to inhibit insulin signaling is through the downregulation of IRS1 protein levels 
(reviewed in [21]), and indeed, IRS1 levels were reduced in LTsc1KO livers (Figure 3-
8A). As would be expected from the defect in Akt-mediated phosphorylation of FOXO1, 
LTsc1KO mice exhibit a significant increase in hepatic expression of the FOXO1 targets 
Pepck and Igfbp1 (Figure 3-9C) and a decrease in glucose tolerance (Figure S4D) 
relative to controls. However, LTsc1KO mice do not display differences in insulin 
tolerance (Figure 3-9E). Young LTsc1KO mice on a normal chow diet also exhibit 
attenuation of Akt activation in response to feeding (Figure 3-8B). Finally, a cell-intrinsic 
reduction in the ability of insulin to stimulate Akt was confirmed in primary hepatocytes 
from LTsc1KO livers (Figure 3-8C), and this was rescued by pretreatment with 
rapamycin (Figure 3-8D). The hepatocyte-intrinsic defect in insulin sensitivity in 
LTsc1KO mice is further supported by the fact that there are no significant differences in 
circulating insulin levels on either a normal chow or high fat diet (Figure 3-9F). 
Therefore, uncontrolled mTORC1 activity in the liver causes defects in insulin signaling 
to Akt. 
 
Restoration of Akt signaling to LTsc1KO hepatocytes rescues SREBP1c 
induction.  
To determine whether the mTORC1-dependent attenuation of Akt signaling 
underlies the defect in the ability of insulin to stimulate lipogenesis in LTsc1KO 
hepatocytes, we employed a membrane-targeted constitutively active allele of Akt2 (myr-
Akt2), which bypasses negative-feedback mechanisms acting on upstream components 
in the pathway. Unlike endogenous Akt (Figure 3-8C), adenovirally delivered myr-Akt2 is 
phosphorylated to a similar extent in both Tsc1fl/fl and LTsc1KO hepatocytes (Figure 3-
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8E). Interestingly, restoring Akt2 signaling to LTsc1KO hepatocytes ameliorated their 
defect in lipogenesis. Unlike insulin, myr-Akt2 stimulated similar levels of de novo lipid 
synthesis in both Tsc1fl/fl and LTsc1KO hepatocytes (Figure 3-8F). As expected from this 
rescue of lipogenesis, and in contrast to insulin, myr-Akt2 also induced expression of 
Srebp1c and Fasn to a similar extent in Tsc1fl/fl and LTsc1KO hepatocytes (Figure 3-8G). 
These findings support a model in which Akt2 signaling is essential for the induction of 
hepatic SREBP1c and lipogenesis and that, in addition to a requirement for mTORC1 
activity, at least one additional parallel pathway downstream of Akt2 is essential for this 
induction. 
  
INSIG2a suppression is an mTORC1-independent mechanism regulating SREBP1c 
downstream of Akt.  
To gain insight into the mTORC1-independent mechanism of SREBP1c induction 
downstream of Akt2, we examined the regulation of candidate pathways. Akt and other 
kinases phosphorylate and inhibit GSK3α and β, which have been found to regulate the 
stability of processed, active SREBP isoforms in cell culture models [39]. However, 
unlike Akt and FOXO1, we did not observe substantial differences in the inhibitory 
phosphorylation of GSK3 in the livers or hepatocytes of LTsc1KO mice (Figure 3-8A and 
3-10A). Another potential candidate for SREBP1c regulation downstream of Akt is the 
LXR family of nuclear receptors, which can transcriptionally activate Srebp1c in 
response to insulin [40]. However, no significant differences in the expression of Lxra or 
Lxrb or their canonical transcriptional target Abca1 were detected in the LTsc1KO livers 
(Figure 3-10B). 
Unlike hepatocytes, mTORC1 signaling is both necessary and sufficient to 
activate SREBP isoforms in other cell types (Chapter 2; [10, 11]). Therefore, we decided 
to investigate a mechanism of SREBP1c regulation that is believed to be specific to the  
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Figure 3-10. Additional analysis of the mechanism underlying the defects in 
SREBP1c induction downstream of Akt in LTsc1KO hepatocytes and livers. (JLY) 
A) LTsc1KO hepatocytes do not have defects in insulin-stimulated GSK3 
phosphorylation. Primary hepatocytes from Tsc1fl/fl (+) and LTsc1KO (-) mice were  
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Figure 3-10 continued 
infected with adenovirus expressing either empty vector (Vec) or myr-Akt2 (Akt2). After 6 
hours of infection, cells were serum starved overnight, then stimulated with insulin (Ins; 
10nM) for 1 hour, where indicated, prior to immunoblot analyses.  
B) LTsc1KO livers express normal levels of Lxra, Lxrb, and Abca1. RNA was isolated 
from livers of ad libitum-fed Tsc1fl/fl (n=4) and LTsc1KO (n=4) mice after HFD and gene 
expression was measured by qRT-PCR. Data are presented as mean ± SEM relative to 
Tsc1fl/fl mice.  
C) Protein levels of INSIG1 and INSIG2 are respectively decreased and increased in 
LTsc1KO livers. Liver lysates of mice described in (B) were immunoblotted for the 
indicated proteins. 
D) LTsc1KO livers express reduced levels of Insig1. Expression of RNA from livers of 
mice described in (B) was analyzed by qRT-PCR. Data are presented as mean ± SEM 
relative to Tsc1fl/fl mice. *P <0.02. 
E) Suppression of INSIG2 protein by refeeding is blocked by inhibition of Akt in a dose-
dependent manner. 8 week-old mice were fasted overnight (-) and then refed for 6 hours 
(+) with or without 30 min pre-treatment with vehicle or three different doses of Aktviii 
(Akti; 10, 25 and 50mg/kg), where indicated. Liver lysates were immunoblotted for the 
indicated phospho- (P) and total proteins. 
F) Akt inhibition blocks refeeding induced activation of SREBP1 processing. 8 week-old 
mice were fasted overnight (-) and then refed for 6 hours (+) with or without 30 min pre-
treatment with rapamycin (Rap; 10mg/kg) or Aktviii (Akti; 50mg/kg), where indicated. 
Liver lysates were immunoblotted for processed (p) SREBP1 and phospho- (P) and total 
Akt. 
G) INSIG2 overexpression blocks Srebp1c induction by Myr-Akt. Wild-type hepatocytes 
were transiently transfected with Myr-Akt and either vector or INSIG2. 24 h post- 
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Figure 3-10 continued 
transfection, cells were serum starved over night, followed by RNA isolation. Expression 
was measured by qRT-PCR. Data are presented as mean of technical duplicates ± SEM 
relative to vector. *P<0.002 (Srebp1c) and P<0.03 (Igbfp1) for Myr-Akt compared to 
vector and P<0.04 (Igfbp1) for Myr-Akt and INSIG2 co-expression compared to vector; 
**P<0.03 (Srebp1c) for Myr-Akt co-expressed with INSIG2 compared to vector. 
H) Inhibition of Insig2a does not rescue the defect in insulin-stimulated suppression of 
Pepck in LTsc1KO hepatocytes. Tsc1fl/fl and LTsc1KO primary hepatocytes were 
transiently transfected with control and Insig2 siRNA, as indicated. 24 h post-
transfection, cells were serum starved overnight followed by a 6 h stimulation with insulin 
(Ins; 10nM) and RNA isolation. Pepck expression was measured by qRT-PCR and the 
mean ± SEM is graphed as fold-suppression by insulin relative to unstimulated for each 
genotype. *P<0.02 and P<0.04 for fold-change between insulin stimulation of Tsc1fl/fl and 
LTsc1KO hepatocytes with control and Insig2 siRNA, respectively. 
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liver. Insulin signaling has been found to suppress a liver-specific transcript encoding the 
SREBP-inhibitory protein INSIG2, called Insig2a [23-25]. As INSIG proteins can block 
the induction of hepatic SREBP1c and lipogenesis [41-43], the suppression of Insig2a is 
likely to contribute to the activation of SREBP1c in response to insulin [23] . Interestingly, 
we found that LTsc1KO livers express elevated levels of Insig2a transcripts and INSIG2 
protein (Figure 3-11A and 3-10C). This is in contrast to Insig1, which is a known 
transcriptional target of SREBP and, like other targets, is reduced in the LTsc1KO livers 
(Figure 3-10C,D). Consistent with the insulin-stimulated suppression of Insig2a 
functioning in a parallel pathway to mTORC1, we found that rapamycin does not effect 
Insig2a suppression in intact livers or isolated hepatocytes from wild-type mice (Figure 
3-11B,C). However, an Akt-specific inhibitor (Aktviii) completely reversed the 
suppression of Insig2a in response to feeding or insulin, indicating that this mechanism 
occurs downstream of Akt. The feeding-induced suppression of INSIG2 protein levels 
was blocked in a dose-dependent manner by the Akt inhibitor (Figure 3-10E). In contrast 
to the differential effects on Insig2a expression, the Akt inhibitor and rapamycin have 
similar inhibitory effects on the induction of SREBP1c processing and expression (Figure 
3-10F and 3-11B,C). Consistent with the elevated expression of Insig2a in LTsc1KO 
livers (Figure 3-11A), LTsc1KO hepatocytes are defective in the suppression of Insig2a 
in response to insulin (Figure 3-11D).  Importantly, the restoration of Akt signaling to 
LTsc1KO hepatocytes completely rescues the suppression of Insig2a (Figure 3-11D).  
Consistent with Akt-mediated downregulation of Insig2a being required for proper 
Srebp1c induction, forced expression of Insig2 significantly decreased the ability of 
activated Akt to stimulate Srebp1c, while having no effect on its suppression of the 
FOXO1 target Igfbp1 (Figure 3-10G). Finally, siRNA-mediated suppression of Insig2a in 
LTsc1KO hepatocytes restores the insulin-stimulated induction of Srebp1c (Figure 3-
11E), while maintaining the defect in insulin-mediated suppression of Pepck (Figure 3- 
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Figure 3-11. The mTORC1-independent pathway to SREBP1c involves Akt-
mediated suppression of Insig2a. (JLY) 
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Figure 3-11 continued 
A) Expression of Insig2a in the livers of ad libitum-fed male Tsc1fl/fl (n=4) and LTsc1KO 
(n=4) mice on a HFD was measured by qRT-PCR and levels are presented as mean ± 
SEM relative to Tsc1fl/fl. *P<0.0002. 
B) 8 week-old mice were fasted overnight (-) and then refed for 6 h (+) following a 30-
min pre-treatment with vehicle, rapamycin (Rap; 10mg/kg) or Aktviii (Akti; 50mg/kg) (N=4 
per condition). Hepatic RNA was isolated and gene expression was measured by qRT-
PCR. Data are shown as mean ± SEM relative to fasted controls. *P<3x10-6 (Insig2a) 
and P<0.0002 (Srebp1c) compared to fasted; **P<0.01 and ***P<0.0008 compared to 
vehicle-treated fed mice. Note: There is no significant difference between the fold 
suppression of Insig2a by refeeding in the presence or absence of rapamycin or 
between Insig2a levels in fasted mice versus those fed in the presence of Aktviii. 
C) Tsc1fl/fl primary hepatocytes were serum starved overnight and pretreated for 30 min 
with vehicle, rapamycin (20 nM), or Aktviii (10 µM) prior to 6 h stimulation with insulin 
(Ins; 10 nM), gene expression was measured by qRT-PCR. Data are presented as the 
mean ± SEM relative to unstimulated cells and are representative of two-independent 
experiments. Insig2a: *P<0.003 for insulin-stimulated suppression and P<0.01 for 
insulin-stimulated suppression in the presence of rapamycin. Note: There is no 
significant difference between the fold suppression of Insig2a by insulin in the presence 
or absence of rapamycin. Srebp1c: *P<0.0003 compared to unstimulated; **P<0.003 
and ***P< 0.03 compared to vehicle-treated, insulin-stimulated samples.  
D) Primary hepatocytes from Tsc1fl/fl and LTsc1KO mice were left uninfected or were 
infected with adenovirus expressing either empty vector (Vec) or myr-Akt2 (Akt2), and 6 
h post-infection, cells were serum starved overnight. Uninfected cells were stimulated 
with insulin (10 nM) for 6 h, whereas infected cells were left unstimulated. Insig2a  
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Figure 3-11 continued 
expression was measured by qRT-PCR. Data are presented as mean ± SEM relative to 
the unstimulated samples for the uninfected group or the vector-expressing samples for 
the infected group for each genotype and are representative of at least two independent 
experiments. *P<0.05 compared to the fold suppression by insulin in Tsc1fl/fl cells. The 
fold suppression of Insig2a induced by Myr-Akt2 in Tsc1fl/fl and LTsc1KO hepatocytes is 
not significantly different (NS).  
E) Tsc1fl/fl (Tsc1 +) and LTsc1KO (Tsc1 -) primary hepatocytes were transiently 
transfected with control or Insig2 siRNA. 24-h post-transfection, cells were serum 
starved overnight followed by a 6 h stimulation with insulin (10nM). Gene expression 
was measured by qRT-PCR and levels are presented as mean ± SEM relative to 
unstimulated controls for each genotype. *P<0.04 (Insig2a) and *P<0.01 (Srebp1c) 
compared to the fold-change in response to insulin in Tsc1fl/fl hepatocytes treated with 
control siRNAs. The insulin-stimulated induction of Srebp1c in control siRNA-treated 
Tsc1fl/fl and Insig2 siRNA-treated LTsc1KO hepatocytes is not significantly different (NS). 
F) Model of two parallel pathways downstream of insulin and Akt2 required for the 
induction of hepatic SREBP1c and lipogenesis. 
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10H). Collectively, these data are consistent with two parallel pathways downstream of 
Akt2, one involving the suppression of Insig2a expression and the other requiring 
mTORC1 activation, both being essential for insulin-stimulated induction of hepatic 
SREBP1c (Figure 3-11F). 
 
DISCUSSION 
Recent genetic evidence suggests that Akt is a major effector of insulin signaling 
for the induction of hepatic lipogenesis [3, 7, 8]. Whole-body and liver-specific knockouts 
of Akt2 are protected from hepatic steatosis under conditions of obesity caused by leptin 
deficiency (ob/ob) or a lard-based HFD [3]. This phenotype is similar to that described 
for Srebp1 knockout mice, which are also protected from steatosis in the background of 
obesity [31]. Importantly, the protection from hepatic lipid accumulation in the Akt2 
knockout models is accompanied by reduced expression of Srebp1c and decreased de 
novo lipogenesis, suggesting that a defect in SREBP1c induction underlies this 
phenotype. However, on a coconut oil-based HFD with sucrose (Surwit), the liver-
specific Akt2 knockout mice do not exhibit defects in the expression of Srebp1c or its 
lipogenic targets but maintain their reduced levels of hepatic TGs. This suggests that 
SREBP1c-independent pathways downstream of Akt might also contribute to hepatic 
lipid content. Interestingly, mice with liver-specific deletion of Pten, which exhibit 
constitutive activation of Akt signaling, develop severe hepatic steatosis on a normal 
chow diet [44, 45], and this phenotype is dependent on Akt2 and its regulation of 
lipogenic gene expression downstream of SREBP1c [45]. Likewise, hepatic expression 
of constitutively active Akt also induces SREBP1c and causes fatty liver disease and 
hypertriglyceridemia [8], much like transgenic overexpression of SREBP1c itself [46]. 
While studies have indicated that atypical PKCs might play a parallel role [36, 37], these 
collective findings demonstrate that Akt is a major insulin-responsive effector in the 
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induction of hepatic SREBP1c. While this regulation appears to contribute to both 
physiological and pathological hepatic lipid accumulation, the critical mechanisms 
downstream of Akt are not well defined.  
Together with a recent study in rats [13], our current findings indicate that 
mTORC1 is an essential downstream target of insulin and Akt signaling for the proper 
induction of SREBP1c and lipogenesis in the liver. However, the LTsc1KO mouse model 
demonstrates that mTORC1 activation alone is not sufficient to induce SREBP1c. We 
were particularly surprised to find that chronic mTORC1 signaling, instead, leads to a 
decrease in the induction of SREBP1c and lipogenesis and protection from both age- 
and diet-induced hepatic steatosis. The decreased activation of SREBP1c in LTsc1KO 
hepatocytes is the result of mTORC1-driven inhibitory feedback mechanisms causing 
insulin resistance and attenuation of Akt signaling to its other downstream pathways. 
Due to the disconnect between Akt and mTORC1 signaling in these mice, the LTsc1KO 
model affords a unique experimental system in which to identify mTORC1-independent 
pathways and processes downstream of Akt in the liver. Analyses of the LTsc1KO mice 
revealed that Akt stimulates hepatic SREBP1c and lipogenesis through parallel 
mTORC1-dependent and independent pathways and that the latter pathway involves 
suppression of a liver-specific inhibitor of SREBP1c.   
Although functionally similar, distinct mechanisms regulate the expression and 
stability of INSIG1 and INSIG2 [14, 15]. SREBP induces the expression of Insig1, and 
the INSIG1 protein is stabilized under sterol-rich conditions, creating an autoinhibitory 
feedback mechanism [47-49]. In contrast to INSIG1, the Insig2 gene is not 
transcriptionally regulated by SREBP, and the INSIG2 protein is much more stable and 
unaffected by sterols.  Importantly, the predominant liver-specific transcript encoding 
INSIG2, referred to as Insig2a, is strongly downregulated at the message level by insulin 
signaling [23], perhaps facilitating SREBP1c release from the ER and its subsequent 
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processing and activation. In this study, we find that Akt is responsible for Insig2a 
suppression by insulin and that this occurs independent of mTORC1 signaling. While the 
pathway by which Akt suppresses Insig2a is currently unknown, our data indicate that 
this is a major mTORC1-independent pathway downstream of Akt in the liver regulating 
SREBP1c activation. We hypothesize that the failure to suppress Insig2a in LTsc1KO 
hepatocytes blocks the pathway to SREBP1c activation at a step prior to that dependent 
on mTORC1 signaling. Therefore, insulin induces SREBP1c processing and activation 
through Akt-mediated suppression of Insig2a and stimulation of mTORC1 signaling, 
which both regulate essential but distinct steps in the pathway to full activation of 
SREBP1c. Future mechanistic studies are needed to define both the signaling pathway 
by which Akt suppresses Insig2a expression and the molecular target of mTORC1 
signaling involved in promoting SREBP1c activation. 
 
MATERIALS AND METHODS 
Primary hepatocyte cultures.  
Primary hepatocytes were isolated from 7 to 9 week-old male mice following 
portal vein collagenase perfusion (Blenzyme 3; Roche) and percoll gradient purification. 
For insulin stimulation experiments, hepatocyte cultures were treated as described 
elsewhere [13]. Infection with adenovirus (Vector Biolabs) was performed 2 h after 
plating at an moi of 10. After 6 h infection, cells were washed once with PBS before 
serum starving overnight prior to insulin stimulation. Non-targeting control and Insig2 
siRNAs (ON-TARGETplus, Dharmacon) were transiently transfected into primary 
hepatocytes 6 h after plating using Lipofectamine 2000 (Invitrogen). 24 h post-
transfection, cells were serum starved overnight prior to insulin stimulation. 
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Measurement of de novo lipogenesis.  
For the measurement of lipogenesis, primary hepatocytes were cultured and 
treated as described above. For the final 4 h of a 6-h insulin stimulation, cells were 
labeled with 1-14C acetic acid (Perkin Elmer). Cells were washed twice with PBS before 
lysis in 0.5% Triton X-100. The lipid fraction was extracted by the addition of chloroform 
and methanol (2:1 v/v) with vortexing, followed by the addition of water with vortexing. 
Samples were centrifuged (1000 rpm, 15 min), and 14C incorporation was measured in 
the bottom, lipid-containing phase using a Beckman LS6500 scintillation counter. Each 
condition was assayed in duplicate and normalized to protein concentrations in the 
original lysates.  
 
Gene expression analysis.  
For gene expression analyses, RNA was isolated from mouse tissue using 
TRIzol (Invitrogen) and from primary hepatocytes using the RNeasy Mini Kit (Qiagen) 
and was reverse transcribed into cDNA using the Superscript III First Strand Synthesis 
System for RT-PCR kit (Invitrogen). SYBR green-based quantitative RT-PCR was 
performed using an Applied Biosystems 7300 Real Time PCR System. Duplicate or 
triplicate samples were collected for each experimental condition, and triplicate runs of 
each sample were normalized to Rplp0 (m36b4) mRNA to determine relative expression 
levels. The sequences for the primer pairs used in this study are listed in Table 3-1.  
 
Immunoblotting and immunohistochemistry.  
Lysates from cultured primary hepatocytes were prepared as previously 
described [50]. Tissue lysates were prepared from tissue that was frozen in liquid 
nitrogen immediately following resection. Frozen tissue samples were homogenized in 
NP-40 lysis buffer, and remaining debris was cleared from lysates by subsequent 10 and  
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Table 3-1 – RT-PCR and PCR primers used in this study.  
RT-PCR:  Forward (5’-3’)      Reverse (5’-3’) 
Abca1  GGCAGTGTCCAACATCTGAAAA CAGGGTTGGAGCCTGCTATTC 
Dgat1   CATGCGTGATTATTGCATCC ACAGGTTGACATCCCGGTAG 
Dgat2  GCGCTACTTCCGAGACTACTT GGGCCTTATGCCAGGAAACT        
Cox4i1  TGAATGGAAGACAGTTGTGGG GATCGAAAGTATGAGGGATGGG 
Cpt1a   GGAGAGAATTTCATCCACTTCCA CTTCCCAAAGCGGTGTGAGT  
Cs  GGGACTTGTGTATGAGACTTCG  AGCCAAAATAAGCCCTCAGG 
Fasn   AAGGCTGGGCTCTATGGATT GGAGTGAGGCTGGGTTGATA 
Hmgcr  TGTTCACCGGCAACAACAAGA CCGCGTTATCGTCAGGATGA 
Igfbp1  GGAGCCTGTGTACCAGAACC CCTTTGCCTCTTCATGCTG 
Insig1  CACGACCACGTCTGGAACTAT TGAGAAGAGCACTAGGCTCCG 
Insig2a  CCCTCAATGAATGTACTGAAGGATT TGTGAAGTGAAGCAGACCAATGT 
Ldlr  TGACTCAGACGAACAAGGCTG ATCTAGGCAATCTCGGTCTCC 
Lxra  GCCCTGCACGCCTACGT  TAGCATCCGTGGGAACATCA 
Lxrb  GCTGATGATCCAGCAGTTAG CGGAGAAAGATCGTTTGTTG 
Mcad  TTTCGAAGACGTCAGAGTGC TGCGACTGTAGGTCTGGTTC 
Mttp  CGTCCACATACAGCCTTGAC CCACCTGACTACCATGAAGC 
Pepck  CCACAGCTGCTGCAGAACA GAAGGGTCGCATGGCAAA 
Ppara  TGTTTGTGGCTGCTATAATTTGC GCAACTTCTCAATGTAGCCTATGTTT 
Scd1   CTGACCTGAAAGCCGAGAAG  GCGTTGAGCACCAGAGTGTA 
Srebp1c GGAGCCATGGATTGCACATT GCTTCCAGAGAGGAGGCCAG 
Tfam  CACCCAGATGCAAAACTTTCAG CTGCTCTTTATACTTGCTCACAG 
 
Genotyping: 
Tsc1  AGGAGGCCTCTTCTGCTACC (1) CAGCTCCGACCATGAAGTG (2) 
       TGGGTCCTGACCTATCTCCTA (3) 
Cre  GCGGTCTGGCAGTAAAAACTATC GTGAAACAGCATTGCTGTCACTT
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30 minute spins at 16,000 x g. All primary antibodies were obtained from Cell Signaling 
Technology, except those to tubulin and actin (Sigma) and histone H1, SREBP1, 
INSIG1, and INSIG2 (Santa Cruz). For immunohistochemistry, paraffin-embedded 
sections were stained with phospho-S6 (S240/244) using a tissue staining kit (R&D 
Biosystems). 
 
Mouse studies.  
Mice harboring the Tsc1fl allele on an FVB background were described 
previously [27]. For the current study, these mice were crossed onto a C57Bl/6J 
background through 7 backcrosses. Alb-Cre transgenic mice on this same background 
were described previously [28]. Study cohorts were generated by crossing Tsc1fl/fl mice 
with Alb-Cre Tsc1fl/+ mice. PCR genotyping for Tsc1 and Cre was performed as 
described [27]. Mice were fed either a normal chow diet (9% kcal from fat) or a HFD 
(60% kcal from fat; F3282, Bio-serv). For fasting-refeeding studies, mice were fasted 
overnight and either euthanized or refed normal chow for 6 h. Vehicle (5% Tween-80, 
5% PEG-400 in 1X PBS), rapamycin (10mg/kg), or Aktviii (50mg/kg; EMD) were 
administered via i.p. injection 30 min prior to refeeding. Histological preparation and 
analyses was performed in the Dana-Farber/Harvard Cancer Center Rodent 
Histopathology Core by Dr. R.T. Bronson, an expert rodent pathologist. Liver TGs were 
measured by enzymatic assay using a kit and were normalized to protein content. Body 
fat percentage was measured by dual-energy X-ray absorptiometry (DEXA; PIXImus). 
 
Metabolic studies.  
For the glucose (GTT) and insulin (ITT) tolerance tests, animals were injected 
with 1 g glucose/kg body weight after an overnight fast (GTT) or 1.5 units of insulin/kg 
(ITT) after a 5 h fast, followed by blood glucose measurements from a tail nick using the 
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OneTouch (Lifescan, Milpitas, CA) glucometer system at the indicated time points. All 
mouse studies were approved by the Harvard Medical Area Standing Committee on 
Animals.  
 
Triglyceride production.  
Blood was collected via tail bleeding at baseline before injection with Tyloxapol (2 
g/kg in PBS; Sigma) followed by subsequent tail nick bleeding every hour for 4 h. Serum 
triglyceride levels were measured using a colorimetric assay (Infinity Triglycerides, 
Thermo).  
 
Measurement of serum parameters.  
Serum levels of non-esterified fatty acids and total cholesterol were measured 
using kits (Wako Chemicals and ThermoDMA). Serum insulin levels were measured by 
ELISA (Linco). 
 
Statistical analyses.  
Statistical significance was measured using a Student’s two-tailed t-test and a 
statistical cutoff of P<0.05. Data are presented as mean ± SEM. Immunoblot 
quantification was performed using ImageJ software. 
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SREBP as a key effector of mTORC1 signaling 
The data from our studies and other recent studies have demonstrated that the 
SREBPs are major downstream effectors of mTORC1 (Chapters 2 and 3; [1, 2, 3]). 
SREBPs play an important role in both the physiological and pathological regulation of 
lipid metabolism. Because aberrant lipid and cholesterol production can be detrimental 
to cells and tissues, activation of SREBP is a complex, highly regulated process. 
SREBPs are synthesized as inactive precursors that reside in the endoplasmic reticulum 
(ER). Signals that indicate the need to produce lipids and sterols, such as insulin or 
decreased intracellular levels of cholesterol, induce SREBP to traffic to the Golgi where 
it is proteolytically processed, releasing the active transcription factor form, which then 
translocates to the nucleus to turn on target genes [4]. Previous studies suggest that 
SREBP activation is controlled by growth factors through the PI3K-Akt pathway [5, 6]. 
Akt has been proposed to regulate SREBP, in part, by promoting the stability of its 
processed form through inhibition of glycogen synthase kinase 3 (GSK3), which has 
been shown to phosphorylate the processed active form of SREBP1 and target it for 
proteasomal degradation [7]. However, consistent with our findings, Akt has also been 
demonstrated to activate SREBP in a manner dependent on mTORC1 [1]. We and 
others have also found that the physiological induction of SREBP1c by insulin in 
hepatocytes is sensitive to rapamycin (Chapter 3; [3, 8]). We find that mTORC1 
signaling also increases the transcript levels of both Srebp1 and Srebp2 [2]. However, 
SREBP1 is known to strongly induce its own transcription [9], and this is further 
demonstrated in our study (Chapter 2; [2]). Importantly, a specific increase in the levels 
of processed active SREBP1 is detected in cells lacking the TSC1-TSC2 complex, and 
this increase is sensitive to rapamycin [2]. The mTORC1-stimulated increase in 
processed SREBP1 occurs independent of GSK3 or effects on SREBP1 protein stability. 
Knockdown experiments demonstrated that S6K1 is required downstream of mTORC1 
CHAPTER 4. Discussions and Future Directions 
	   131	  
for accumulation of processed SREBP1 and expression of its target genes in this setting. 
In hepatocytes, the small molecule inhibitor PF-4708671, which is an S6K1-specific 
inhibitor [10], blocks the insulin-stimulated activation of Srebp1c expression (Figure 4-1). 
A role for S6K1 in the activation of SREBP is consistent with genetic studies in 
Drosophila, where the orthologs of both S6K1 and SREBP have been found to be critical 
for the ability of TORC1 to promote an increase in cell and organ size [1, 11]. 
While the mechanism is currently unknown, our data are consistent with S6K1 
regulating a step in the complex processing of the SREBPs. A previous study has 
suggested that a pathway downstream of PI3K and Akt stimulates the trafficking of full-
length SREBP2 to the golgi, where it is processed and activated [12]. It has also been 
reported that ER stress can promote SREBP trafficking and activation in an adaptive 
mechanism to expand the ER [13-15]. However, despite elevated basal levels of ER 
stress in cells and tumors lacking the TSC1-TSC2 complex due to uncontrolled 
mTORC1 signaling [16], this mechanism does not appear to contribute to the activation 
of SREBP, as knockdown of S6K1 blocks SREBP1 activation without relieving ER stress 
in these cells (J.L.Y. and B.D.M, unpublished). We hypothesize that S6K1 plays a more 
direct role, phosphorylating and regulating one of the many proteins involved in ER 
retention, trafficking, or proteolytic processing of SREBP. However, at this stage, 
additional S6K-independent mechanisms regulating SREBP activation downstream of 
mTORC1 cannot be ruled out. For example, a recent study demonstrated that mTORC1, 
through direct phosphorylation, regulates the localization of a phosphatidic acid 
phosphatase called lipin to modulate SREBP promoter activity and nuclear protein 
accumulation [17]. Future studies will undoubtedly reveal potential additional molecular 
mechanism(s). Ultimately, the existence of several mTORC1-dependent mechanisms of 
SREBP regulation further illustrates the importance of this target as a major 
transcriptional effector of mTORC1 signaling. 
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Figure 4-1. S6K1 is required for induction of hepatic Srebp1c expression by 
insulin. Primary hepatocytes were serum starved overnight, pretreated for 30 min with 
vehicle, PF-4708671 (S6K1i; 20 µM), rapamycin (Rap; 20 nM), PP242 (2.5 µM), or 
Aktviii (10 µM) and stimulated for 6 h with insulin (Ins; 10 nM), as indicated. mRNA 
expression was measured by qRT-PCR. Transcript levels are shown relative to 
untreated controls.  
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mTORC1-dependent regulation of SREBP in hepatic lipid metabolism 
Selective insulin resistance has been proposed to explain the paradox of type 2 
diabetes mellitus (T2DM), in which patients exhibit insulin resistance with respect to 
hepatic production of glucose, but not lipid. The induction of hepatic lipogenesis is 
selectively maintained in T2DM, leading to pathological production of triglycerides and 
the development of nonalcoholic fatty liver disease and hypertriglyceridemia. In contrast 
to individuals with T2DM, patients and mice exhibiting hepatic loss of insulin receptor 
function are completely resistant to all functions of insulin on the liver. Therefore, while 
they similarly fail to suppress hepatic glucose production and become hyperglycemic, 
they also fail to stimulate lipogenesis and are protected from hepatic lipid accumulation 
[18, 19]. Brown and Goldstein have proposed that there must exist a branch point 
downstream of the insulin receptor that regulates hepatic glucose and lipid production 
independently to account for this selectivity [20].  
Recent genetic evidence suggests that this bifurcation in insulin signaling occurs 
somewhere downstream of Akt but upstream of the key lipogenic transcription factor 
SREBP1c. Whole-body and liver-specific knockouts of Akt2 are protected from hepatic 
steatosis under conditions of obesity caused by leptin deficiency (ob/ob) or a lard-based 
HFD, which is accompanied by reduced expression of Srebp1c and decreased de novo 
lipogenesis [21]. However, on a coconut oil-based HFD with sucrose (Surwit), the liver-
specific Akt2 knockout mice do not exhibit defects in the expression of Srebp1c or its 
lipogenic targets but maintain their reduced levels of hepatic TGs [21]. In a model of 
acute refeeding with a high carbohydrate diet (HCD), Wan et al. found that liver-specific 
loss of Akt led to lower levels of lipid synthesis without defects in mTORC1 or SREBP1c 
activation or suppression of INSIG2a [22]. This suggests that SREBP1c-independent 
pathways downstream of Akt might also contribute to hepatic lipid content.	  Overall, these 
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findings support Akt as the main insulin-responsive effector driving induction of hepatic 
SREBP1c resulting in both physiological and pathological lipogenesis. However, the 
critical pathway(s) downstream of Akt responsible is not well defined.  
Recently, mTORC1 has been proposed to be this bifurcation point downstream 
of Akt [3]. Our findings in primary mouse hepatocytes are consistent with this model, as 
the insulin-stimulated induction of lipogenic gene expression and lipogenesis were 
sensitive to rapamycin, whereas the suppression of gluconeogenic genes was not 
affected by rapamycin. This result is also consistent with previous studies showing that 
mTORC1 activation is sufficient to stimulate an SREBP-dependent increase in lipid 
synthesis (Chapter 2; [2]) and that raptor-deficient livers have decreased de novo 
lipogenesis [22]. However, the LTsc1KO mouse model, which results in the insulin and 
Akt-independent activation of hepatic mTORC1 signaling, demonstrates that constitutive 
mTORC1 activation is not sufficient to induce SREBP1c and drive hepatic lipid 
accumulation and it actually leads to a decrease in lipid production and protection from 
both age and diet-induced hepatic steatosis (Chapter 3; [8]). We find that the decreased 
induction of SREBP1c is the result of mTORC1-driven feedback mechanisms causing 
hepatic insulin resistance and attenuation of Akt signaling to its other downstream 
pathways.  
As disruption of the TSC1-TSC2 complex completely disconnects mTORC1 
activation from its regulation by insulin and Akt and results in attenuation of normal Akt 
signaling, the LTsc1KO model provides a unique experimental system in which to 
identify mTORC1-independent pathways downstream of Akt in the liver. After examining 
some obvious candidates for SREBP1c regulation downstream of Akt, such as GSK3 
and LXR, we focused on the INSIG proteins, as key negative regulators of SREBP1c. 
Although functionally similar, distinct mechanisms regulate the expression of different 
INSIG isoforms [23, 24]. Insig1 is a transcriptional target of the SREBPs, creating in an 
CHAPTER 4. Discussions and Future Directions 
	   135	  
autoinhibitory feedback mechanism [25-27]. However, a liver-specific transcript encoding 
INSIG2, referred to as Insig-2a, is strongly downregulated at the message level by 
insulin signaling [28], thereby facilitating SREBP1c release from the ER and its 
subsequent processing and activation. Importantly, we found that Akt is responsible for 
Insig2a suppression by insulin and that this occurs independent of mTORC1 signaling 
(Chapter 3; [8]). While the pathway by which Akt suppresses Insig2a is currently 
unknown, we predict that this is the major mTORC1-independent pathway downstream 
of Akt in the liver regulating SREBP1c activation. We hypothesize that the failure to 
suppress Insig2a in LTsc1KO hepatocytes blocks the pathway to SREBP1c activation at 
a step prior to that dependent on mTORC1 signaling. Therefore, insulin induces 
SREBP1c processing and activation through Akt-mediated suppression of Insig2a and 
stimulation of mTORC1 signaling, which both regulate essential, but distinct, steps in the 
pathway to full activation of SREBP1c.  
It is interesting to note that the LTsc1KO mice described in this study phenocopy 
liver-specific knockouts of the insulin receptor and Akt2 [18, 21]. While the overall 
phenotype is milder than these other models, disruption of the TSC1-TSC2 complex and 
constitutive activation of mTORC1 results in a phenotype resembling total hepatic insulin 
resistance, with loss of control over both gluconeogenesis and lipogenesis. This finding 
lends strong in vivo support to cell culture studies demonstrating that mTORC1 
activation can cause cell-intrinsic insulin resistance (Reviewed in [29, 30]) and is 
consistent with the enhanced peripheral insulin sensitivity described for whole-body 
knockouts of the mTORC1 target S6K1 [31]. The LTsc1KO phenotype also suggests 
that the phenomenon of selective insulin resistance is unlikely to be due soley to 
sustained activation of hepatic mTORC1 signaling. Our studies on SREBP1c regulation 
downstream of insulin and Akt suggest that mechanisms leading to the suppression of 
Insig2a might also be intact under conditions of insulin resistance, thereby allowing 
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sustained activation of hepatic SREBP1c and lipogenesis. It is clear that genetic mouse 
models, such as the LTsc1KO mice, which provide in vivo tools to manipulate the insulin 
signaling network in distinct ways, will continue to reveal tissue-specific mechanisms 
affecting systemic metabolic homeostasis under both physiological and pathological 
states. 
 
Transcriptional Control of Cellular Metabolism by mTOR Signaling: Implications 
for mTORC1-driven cancer 
Tumor cells are characterized by adaptations in cellular metabolism that afford 
growth and proliferative advantages over normal cells and thus contribute to cancer 
pathophysiology. There is an increasing appreciation that oncogenic signaling controls 
the metabolic reprogramming of cancer cells, however, the mechanisms and critical 
players are only beginning to be elucidated. Recent studies have revealed that the 
mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth 
and proliferation downstream of oncogenic signaling pathways, controls specific aspects 
of cellular metabolism through the induction of metabolic gene expression. mTORC1 
activation is sufficient to promote flux through glycolysis and the oxidative branch of the 
pentose phosphate pathway, as well as to stimulate de novo lipogenesis, all processes 
that are important in tumor biology. As mTORC1 signaling is aberrantly elevated in the 
majority of genetic tumor syndromes and sporadic cancers, this pathway is poised to be 
a major driver of the metabolic conversion of tumor cells.  
 
Transcriptional control of tumor cell metabolism 
Cancer researchers have known for over 80 years that the metabolic processes 
at work within tumors are vastly different from those of their tissue of origin [32]. This 
metabolic shift promotes bioenergetic and anabolic changes that provide a growth and 
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proliferation advantage to tumor cells under the suboptimal growth conditions of the 
tumor microenvironment. This distinction between the behavior of normal and tumor 
cells, by definition, represents a therapeutic opportunity to selectively target tumor cells. 
However, there is a substantial void in our knowledge of how oncogenic events alter the 
metabolic program of cancer cells and how best to take advantage of these differences 
for the development of specific anti-tumor therapies. Our laboratory has recently found 
that the mammalian target of rapamycin (mTOR) signaling pathway, which is frequently 
activated in genetic tumor syndromes and cancers, induces the expression of a 
metabolic gene regulatory network (Chapter 2; [2]). The potential implications of these 
finding for tumor cell metabolism, growth, and viability are discussed below. 
 
Toward understanding the consequences of aberrant mTORC1 signaling 
The ser/thr kinase mTOR exists within two distinct protein complexes, and we 
focus here on mTOR complex 1 (mTORC1), which senses the availability of growth 
factors, nutrients, and cellular stress to coordinate anabolic processes promoting cell 
growth and proliferation [33]. Most of the signals that regulate mTORC1 are transmitted 
through upstream signaling pathways that converge upon a small G protein switch. Rheb 
is a Ras-related small G protein that, when in its GTP-bound state, is a potent and 
essential activator of mTORC1. In general, signals impinging on mTORC1 regulation 
generally alter the GDP/GTP-bound status of Rheb by regulating the TSC1-TSC2 
complex, which has GTPase activating protein (GAP) activity towards Rheb. Therefore, 
when the TSC1-TSC2 complex is active, it stimulates the intrinsic GTPase activity of 
Rheb, effectively converting Rheb to its GDP-bound state and shutting down mTORC1 
activity [30]. Growth promoting conditions inhibit the TSC1-TSC2 complex to stimulate 
mTORC1, while poor growth conditions activate the TSC1-TSC2 complex to suppress 
mTORC1 signaling. The TSC1-TSC2 complex is encoded by the two tumor suppressor 
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genes mutated in the genetic tumor syndrome tuberous sclerosis complex (TSC). 
Importantly, within the network of signaling pathways that regulate mTORC1 activity 
upstream of the TSC1-TSC2 complex are numerous oncogenes and tumors 
suppressors, including those most commonly affected in human malignancies (Figure 4-
2). In fact, aberrant activation of mTORC1 signaling is a frequent occurrence in the most 
common types of human cancer and a variety of genetic tumor syndromes [34]. 
While we have made enormous progress in understanding the upstream 
signaling pathways that regulate mTORC1, relatively little is known about the 
downstream consequences of mTORC1 activation. The two best-characterized, direct 
targets of mTORC1 are the ribosomal S6 kinases (S6K1 and S6K2) and eukaryotic 
initiation factor 4E (eIF4E)-binding proteins (4EBP1 and 4EBP2), which are respectively 
activated and inhibited by mTORC1. Through these targets, and likely others, mTORC1 
regulates specific aspects of cap-dependent translation initiation. In addition, through 
poorly understood mechanisms, mTORC1 activation promotes ribosome biogenesis, 
thereby enhancing the protein synthetic capacity of the cell. Through mechanisms that 
are emerging, but incompletely elucidated, mTORC1 is also a key inhibitor of the 
catabolic process of autophagy. For more information on these broad subject areas 
related to mTOR, see reviews from Ma and Blenis [35], Mayer and Grummt [36], and 
Neufeld [37]. Given its common activation in human cancers, there is much interest in 
elucidating other downstream processes controlled by mTORC1 to better understand its 
contributions to cancer pathogenesis and to identify novel therapeutic avenues. 
To elucidate the cell intrinsic effects of mTORC1 activation, we recently used a 
reductionist approach to isolate mTORC1 signaling from the many branching pathways 
lying upstream (Chapter 2 [2]). We took advantage of the fact that loss of TSC1 or TSC2 
results in constitutive Rheb-GTP loading and mTORC1 activation, even in the absence 
of growth factors. Therefore, cell lines lacking TSC1 or TSC2 represent a genetic gain of  
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Figure 4-2. Model of the small G protein switch controlling mTORC1 activation 
downstream of common oncogenes and tumors suppressors and the effects on 
cell physiology.  A network of upstream signaling pathways comprised of the 
oncogenes and tumor suppressors listed control the activation status of mTORC1 by 
regulating the TSC1-TSC2 complex.  Oncogenic signaling events inhibit the TSC1-TSC2 
complex to promote the accumulation of Rheb-GTP and subsequent activation of 
mTORC1.  Reciprocally, through their inhibitory effects on oncogenic signaling, tumor 
suppressors in effect stimulate the TSC1-TSC2 complex to inhibit the activation of 
mTORC1 by Rheb.  In addition to its previously defined roles in promoting protein 
synthesis and blocking autophagy, mTORC1 activation can drive specific metabolic 
processes through regulation of metabolic gene expression.  These include glucose 
uptake and glycolysis through HIF1α and the pentose phosphate pathway and lipid 
biosynthesis through SREBP (see text for details). 
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function model, where mTORC1 activation is uncoupled from regulation by upstream 
pathways that normally converge upon the TSC1-TSC2 complex. Combining the 
analysis of these cells with the use of rapamycin, a highly specific pharmacological 
inhibitor of mTORC1, provides an approach to identify cellular processes that mTORC1 
activation alone is sufficient to regulate.  
 
Transcriptional control of metabolic pathways downstream of mTORC1 
We employed unbiased genomic and metabolomic analyses to identify 
mTORC1-regulated transcripts and metabolites (Chapter 2; [2]). Gene expression arrays 
were used to compare Tsc1- and Tsc2-deficient mouse embryo fibroblasts (MEFs) to 
their littermate-derived wild-type counterparts under serum-free growth conditions, 
where mTORC1 is inactive in wild-type cells and fully stimulated in both Tsc1 and Tsc2 
null cells. A time course of rapamycin treatment was included to establish a role for 
mTORC1 in any changes detected. Transcripts were classified as being induced by 
mTORC1 signaling only if they were significantly elevated in both Tsc1 and Tsc2 null 
cells relative to wild-type and reduced toward wild-type levels by rapamycin treatment. 
Only 130 genes met these highly stringent criteria. Gene set enrichment analysis 
revealed significant over-representation of genes from three specific metabolic pathways 
amongst those induced by mTORC1 signaling: glycolysis, the pentose phosphate 
pathway, and lipid and sterol biosynthesis. To determine whether the stimulation of 
these metabolic genes downstream of mTORC1 altered cellular metabolism, we used 
both focused metabolic assays and metabolomic approaches. Steady state and 
metabolic flux analyses revealed that mTORC1 activity promotes flux through glycolysis 
and, specifically, the NADPH-producing oxidative arm of the pentose phosphate 
pathway. Finally, we found that Tsc2-deficient cells demonstrate an mTORC1-
dependent increase in de novo lipogenesis. Therefore, the robust pathway-specific 
CHAPTER 4. Discussions and Future Directions 
	   141	  
induction of metabolic genes by mTORC1 signaling drives corresponding metabolic 
changes in cells.    
To gain insight into how mTORC1 controls metabolic gene expression and 
thereby affects cellular metabolism, we used a bioinformatic apporach to identify 
overrepresented transcription factor binding motifs in the promoters of mTORC1-
regulated genes (Chapter 2; [2]). Interestingly, the two most significantly enriched cis-
regulatory elements amongst rapamycin-sensitive genes in this study were for sterol 
regulatory element binding protein (SREBP) and Myc, both of which are global 
regulators of cellular metabolism. Importantly, c-Myc and hypoxia-inducible factor 1 
(HIF1) recognize an overlapping motif and are both known to promote the transcription 
of glycolytic genes [38]. We found that, in the setting of TSC gene disruption, mTORC1 
signaling drives glucose uptake and glycolysis through up-regulation of HIF1α. On the 
other hand, the SREBPs (SREBP1a, 1c, and 2) are known to stimulate the expression of 
a large number of lipid and sterol biosynthesis genes [4]. We demonstrated that these 
transcription factors are, indeed, essential for the mTORC1-induced expression of these 
genes and for the promotion of de novo lipogenesis by mTORC1 signaling (Chapter 2; 
[2]). Interestingly, SREBP1 was also found to be required for the mTORC1-dependent 
increase in the expression of glucose-6-phosphate dehydrogenase (G6pd), the rate-
limiting enzyme of the oxidative branch of the pentose phosphate pathway. This 
suggests that mTORC1 can coordinate de novo lipogenesis and the generation of 
reducing equivalents required to fuel this anabolic process through regulation of this 
transcription factor. Importantly, two previous studies demonstrated that activated alleles 
of Akt, which potently activate mTORC1, can stimulate HIF1α and the SREBPs to 
respectively induce expression of glycolytic and lipogenic gene sets similar to those 
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identified in our study [39, 40]. This suggests that activation of mTORC1 through 
upstream oncogenic pathways, will also promote these metabolic changes. 
 
Normoxic induction of HIF1α  by mTORC1 
HIF1α protein levels are elevated in many human cancers through genetic 
events or intratumoral hypoxia that promote its stability, and increased HIF1α levels 
correlate poorly with patient survival [41]. We find that mTORC1 activation alone is 
sufficient to drive increases in HIF1α levels under normoxic conditions (Chapter 2; [2]), 
without effects on its stability (S. Menon and B.D.M., unpublished). Consistent with 
previous findings [42, 43], we show that, through phosphorylation and inhibition of 
4EBP1, mTORC1 can stimulate cap-dependent translation from the 5’-untranslated 
region of the HIF1α mRNA. However, we also found increases in both HIF1α and HIF2α 
transcripts, suggesting either additional mechanisms of regulation or auto-regulation of 
their expression. The ability of mTORC1 to promote elevated normoxic levels of HIF1α 
suggests that even oxygenated regions of tumors characterized by high mTORC1 
activity could display HIF1α-dependent metabolic changes, resulting in aerobic 
glycolysis (more commonly referred to as the “Warburg effect”). The ability of mTORC1 
to promote glucose uptake and gylcolytic flux through HIF1α also suggests that FDG-
PET positivity may be a useful indicator for monitoring mTOR-driven tumors, a notion 
supported by genetic tumor models in mice [39, 44]. Like HIF1α, c-Myc can also induce 
the expression of genes involved in glucose uptake and glycolysis [38] and can be 
translated in an mTORC1-dependent manner in some settings [45]. Therefore, it is 
possible that in such settings, mTORC1 might enhance glycolytic gene expression 
through c-Myc rather than HIF1α. 
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Implications for tumor development, progression, and treatment 
Increased aerobic glycolysis (the Warburg effect) and de novo lipogenesis are 
the two most commonly detected metabolic changes in tumors and can be considered 
the metabolic hallmarks of cancer. Our study to uncover the downstream consequences 
of mTORC1 activation, a common event in human cancer [34], demonstrates that 
mTORC1 signaling is sufficient to drive these metabolic processes (Chapter 2; [2]). 
mTORC1 promotes these metabolic changes through induction of a transcriptional 
program affecting metabolic gene targets of HIF1α and SREBP1 and 2. While the 
glucose transporters and glycolytic enzymes encoded by HIF1α are well known to be 
upregulated in tumors [41], less is known regarding the expression status of the diverse 
array of SREBP targets. One notable exception is fatty acid synthase (FASN), which 
encodes a multifunctional enzyme complex that converts acetyl-CoA to the 16-carbon 
saturated fatty acid palmitate. Since most normal tissues do not undergo substantial 
levels of de novo lipid biosynthesis, obtaining lipids from dietary sources instead, FASN 
levels are low in most tissues. However, FASN is transcriptionally upregulated in most 
types of human cancer [46]. Oncogenic activation of the PI3K-Akt pathway has been 
implicated in the increased expression of FASN in ovarian and prostate cancer [47]. Our 
findings that mTORC1 signaling can stimulate FASN expression through SREBP 
suggest that mTORC1 might play a critical role in FASN expression and lipogenesis in 
human cancers characterized by activation of the PI3K-Akt pathway. Interestingly, we 
found that the SREBPs are essential for mTORC1-driven cell proliferation (Chapter 2; 
[2]), suggesting that specific enzymes encoded by gene targets of these transcription 
factors could represent novel targets for cancer therapeutics. To this end, there have 
been many studies suggesting efficacy of FASN inhibitors in pre-clinical tumor models 
[48]. Inhibiting lipid biosynthesis may be particularly effective in settings of aberrantly 
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high mTOR activity, which drives uncontrolled protein synthesis, as lipids are required 
for biogenesis of not only plasma membrane but also endoplasmic reticulum. Indeed, 
knockdown of SREBP1 and SREBP2 in TSC2-deficient cells further exacerbates mTOR-
driven ER stress (J.L.Y. and B.D.M. unpublished). 
In addition to lipogenesis, there are a number of other processes induced by 
SREBP that could contribute to the tumor-promoting activities of mTORC1. SREBP 
stimulates the expression of genes involved in the synthesis of isoprenoids, which 
modify many signaling proteins, including members of the Ras superfamily, and could 
contribute to cancer pathogenesis. The observation that acetyl-CoA derived from the 
reaction catalyzed by the SREBP target ATP-citrate lyase (ACLY) is required for histone 
acetylation [49] suggests a potential role for global regulation of chromatin downstream 
of mTORC1. Perhaps most notable is our finding that mTORC1 increases flux through 
the oxidative arm of the pentose phosphate pathway and regulates expression of the 
rate-limiting enzyme in this pathway (G6PD) through SREBP1. Relative to glycolysis and 
lipogenesis, dysregulation of the pentose phosphate pathway in cancer has received 
much less attention in the field of tumor cell metabolism, despite mounting evidence for 
the importance of this pathway in tumor development and progression. A causal role for 
G6PD in tumorigenesis was demonstrated by its ability to transform NIH-3T3 cells [50], 
and G6PD has been found to be elevated in animal tumor models [51, 52] and human 
neoplasms of the breast, endometrium, cervix, lung and prostate [53-57]. Through the 
production of NADPH, upregulation of the oxidative pentose phosphate pathway is likely 
to represent an important mechanism by which some tumor cells meet the unique 
metabolic demands of rapid anabolic growth and proliferation. In addition, G6PD-
produced NADPH is important for regenerating reduced glutathione oxidized in the 
protection against reactive oxygen species (ROS). Tumor cells may benefit from 
upregulation of this pathway to control elevated ROS levels resulting from the fluctuating 
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availability of oxygen and nutrients in the tumor microenvironment. It will be important for 
future studies to determine whether there are also SREBP-independent inputs into the 
regulation of the pentose phosphate pathway downstream of mTORC1 and whether 
mTORC1 signaling promotes resistance to oxidative stress.  
Given the shear number of oncogenes and tumor suppressors lying upstream of 
mTORC1, it will be important to identify the oncogenic settings in which mTORC1 
signaling is the major driver of these common metabolic changes. It seems likely that 
parallel pathways downstream of oncogenes such as PI3K and RAS will also contribute 
to the control over these metabolic parameters within different tumors. It is this 
complexity that we must understand in order to develop therapeutic strategies aimed at 
tumor-specific cell metabolism.  
 
Studies toward defining the role of the mTOR-SREBP connection in tumor cell 
metabolism 
We explored whether mTORC1 regulates SREBP in cancers and tumor 
syndromes driven by aberrant activation of mTORC1. In cells, mTORC1 activation upon 
loss of TSC1-TSC2 complex function is sufficient to drive activation of SREBP, its target 
genes, and lipogenesis. Similar activation of mTORC1 results when Tsc2+/- mice lose the 
wild-type allele of Tsc2 in renal epithelial cells, leading to the development of renal 
cystadenomas [58]. These tumors are characterized by elevated mTORC1 signaling and 
are sensitive to treatment with rapamycin [59]. Loss of heterozygosity events also cause 
TSC patients to develop a kidney lesion known as angiomyolipoma (AML), which 
contains fat, smooth muscle, and vascular components, and these tumors are also 
partially sensitive to rapamycin [60]. While TSC-associated AMLs are distinct from the 
epithelium-derived tumors in the Tsc2+/- mice, the mouse model affords a system to 
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study tumors driven by mTORC1 activation and caused by genetic lesions similar to the 
human TSC disease.  
In an analysis of kidney tumors from Tsc2+/- mice, aged 12 months, treated for 36 
hours with either rapamycin or vehicle (n=2 per treatment), we found that SREBP 
targets, including fatty acid synthase (FASN), glucose 6-phosphate dehydrogenase 
(G6PD), and acetyl-CoA carboxylase (ACC), are elevated relative to adjacent normal 
tissue (Figure 4-3A). The increased immuno-staining of FASN and ACC in the tumor 
relative to the surrounding normal tissue was eliminated upon treatment with rapamycin 
(Figure 4-3B). AMLs from four TSC patients diplayed increased FASN staining in the 
adipocytes from these lesions compared to normal adipose, and the smooth muscle 
component also showed elevated expression of FASN (Figure 4-3C). This suggests that 
mTORC1 dependent activation of lipogenic genes may be relevant to the pathogenesis 
of TSC and that inhibiting lipogenic pathways could be therapeutically effective. 
To extend these observations in other settings relevant to common forms of 
human cancer, we explored SREBP activation in lung tumor models, driven by activating 
mutations in PIK3CA (H10474, PIK3CAH1047R) and Kras (G12D, KrasG12D) (n=2-4 per 
condition, courtesy of Drs. Jeffrey Engleman and Kwok-Kin Wong, Massachusetts 
General Hospital and Harvard Medical School). Interestingly, IHC demonstrated that 
SREBP targets, including Fasn and G6PD, are elevated in the tumors from both of these 
models relative to surrounding normal tissue (Figure 4-4A). It will be import to determine 
whether rapamycin reduces the increased expression of lipogenic genes in these lung 
tumors. Interestingly, unlike the TSC-deficient cystadenomas, the PIK3CA and Kras 
tumors are not sensitive to rapamycin [61], although loss of Tsc1 sensitizes the Kras-
driven tumors [62]. It will be interesting to determine whether rapamycin-sensitive 
changes in SREBP activity correlate with drug sensitivity. If so, this would suggest that 
SREBP targets could be used as biomarkers for treatment efficacy.  
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Figure 4-3. TSC-deficiency activates SREBP through mTORC1. 
A) Kidney sections from Tsc2+/- mice were stained for phospho-S6, as a marker of 
mTORC1 activation, and SREBP targets FASN, ACC, and G6PD.  
B) Tsc2+/- mice were treated with either vehicle or rapamycin (10mg/kg) for 36 hours. 
Kidney sections were stained for FASN and ACC. 
C) Human angiomyolipomas and normal adipose tissue were stained for FASN. 
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Figure 4-4. Oncogenic PIK3CA and KRas induce SREBP and lipogenesis through 
mTORC1. 
A) PIK3CAH1047R and K-RasG12D lung tumors treated with vehicle for 2 weeks were 
stained for G6pd and Fasn.   
B,C) MCF-10A lines transformed with PIK3CAH1047R and K-RasG12D were serum starved 
in the presence of vehicle, rapamycin (20nM), Aktviii (20uM), and UO126 () for 16 hours. 
Western blots for the indicated proteins. NOTE: Images shown are from the same 
western blot, but conditions that are not relevant were excised. 
D) Cells treated as in (B,C; top) or transfected with either control  or SREBP1 and 
SREBP2 for 48h (bottom) were labeled with 14C-acetate and the levels of 14C 
incorporation into the lipid fraction are shown relative to untreated controls.  
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To follow up these in vivo findings in an isogenic, cell-based system that enables 
one to study transforming events that lead to mTORC1 activation, I have used MCF10A 
cells, a non-transformed breast epithelial cell line, that have been transformed by 
expression of either PIK3CAH1047R or KrasG12D. We confirmed that mTORC1 signaling is 
activated as expected upon transformation and is appropriately reduced in response to 
the inhibitors (Figure 4-4B). Levels of processed active SREBP1 are elevated in 
transformed lines and strongly reduced toward parental levels by treatment with 
rapamycin (Figure 4-4C). Importantly, this mTORC1-dependent activation of SREBP1 
correlates with oncogene-induced, mTORC1-dependent changes in de novo 
lipogenesis, a process that depends on SREBPs (Figure 4D). Currently, these 
experiments are being repeated and followed up by another graduate student in the lab. 
In a recent collaboration with the laboratory of Dr. Karen Cichowski (Brigham and 
Women’s Hospital, Harvard Medical School), we explored the relevance of mTORC1-
induced PPP in a Ras-driven cancer, Nf1-deficient malignant peripheral nerve sheath 
tumors (MPNSTs). It was found that three ER stress-inducing agents, including the 
HSP90 inhibitor IPI-504, triggered rapid tumor regression in the MPNST mouse model, 
but only when combined with the mTOR inhibitor rapamycin [63]. Consistent with cellular 
studies showing that SREBP1 is regulated by mTOR (Chapter 2; [1, 2]), rapamycin 
significantly decreased the expression of known SREBP targets including SREBP1 itself, 
ACC, and FASN in MNPSTs within 7 hours of treatment (Figure 4-5A,B). Treatment with 
IPI-504 alone slightly suppressed SREBP1, but together both agents reduced SREBP1 
expression by 92% and effectively suppressed ACC and FASN (Figure 4-5A,B). 
Rapamycin also potently suppressed G6PD mRNA levels in MPNST tumor tissue 
(Figure 4-5C). However, rapamycin alone had inconsistent effects on G6PD protein 
levels (Figure 4-5B), perhaps reflecting a slower turnover of G6PD protein within this  
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Figure 4-5. Oxidative stress plays a critical role in mediating the therapeutic 
response to IPI-504 and rapamycin. 
(A) SREBP1 mRNA levels in tumors from animals that were treated for 7 hr as indicated. 
(B) Immunoblots showing expression of FASN, ACC, and G6PD in tumors from animals 
treated for 7 hr as indicated. Actin serves as a loading control. 
(C) G6PD mRNA levels in individual tumors treated as described in (B). 
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short time frame. Nevertheless, rapamycin and IPI-504 together dramatically suppressed 
both G6PD mRNA and protein expression in MPNSTs in vivo (Figure 4-5B,C). 
Accordingly, rapamycin/IPI-504 caused a 34% decrease in reduced glutathione levels in 
these tumors, demonstrating the functional consequence of this suppression of SREBP-
driven G6pd [63]. Rapamycin and IPI-504 synergize by promoting irresolvable ER 
stress. The drug combination causes catastrophic ER and mitochondrial damage. This 
process is further fueled by oxidative stress, induced by the IPI-504-dependent 
production of reactive oxygen species (ROS) and the simultaneous rapamycin-
dependent suppression of an important endogenous antioxidant pathway. The 
mechanism by which these agents cooperate reveals a therapeutic paradigm that can be 
expanded to develop additional combinations for Ras-driven malignancies.  
Our findings demonstrate that mTORC1 activation alone is sufficient to drive 
specific metabolic processes that are frequently detected in human cancers. Aberrant 
activation of mTORC1 occurs in the most common human cancers, suggesting that 
mTORC1 signaling contributes to the metabolic reprogramming of cancer cells, thereby 
affording survival and proliferative advantages. Targeting these downstream metabolic 
pathways may provide effective therapeutic approaches for mTORC1-driven tumor 
syndromes (e.g., Tuberous Sclerosis Complex) and sporadic cancers. Inhibitors 
targeting the metabolic enzymes comprising these pathways are unlikely to elicit the 
same unwanted feedback signaling events that have been proposed to limit the 
usefulness of rapamycin and its analogs in the clinic. Therefore, it is possible that such 
metabolic inhibitors would elicit selective cytotoxic responses in the tumor, rather than 
the cytostatic effects routinely seen with rapamycin [64].  
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Future Directions 
We and others have recently identified a role for mTORC1 in the regulation of 
SREBPs and lipid metabolism, which has implications for disease states in which 
mTORC1 is aberrantly activated and de novo lipogenesis is misregulated, including 
cancer and type 2 diabetes. In cultured and tumor cells characterized by TSC deficiency, 
mTORC1 activation is both necessary and sufficient to stimulate expression of lipogenic 
and pentose phosphate pathway SREBP targets. Future studies are required to 
understand the molecular mechanism(s) by which mTORC1 regulates SREBP. It will 
also be important to understand which oncogenes and tumors suppressors drive SREBP 
activation and lipogenesis through mTORC1 and to determine which tumorigenic 
settings require activation of SREBPs for cell growth, survival, and proliferation. 
Understanding which SREBP targets are required for tumorigenic properties will offer 
insights into novel therapeutic approaches targeting tumor cell metabolism. Importantly, 
we found that the regulation of SREBP1c and lipogenesis in hepatocytes is different than 
cultured cells, as parallel mTORC1-dependent an independent pathways downstream of 
Akt are required for hepatic lipogenesis. Future mechanistic studies are needed to define 
both the signaling pathway by which Akt suppresses Insig2a expression and the 
molecular target of mTORC1 signaling involved in promoting hepatic SREBP1c 
activation. Our findings that SREBP is a major transcriptional effector or mTORC1 will be 
enhanced by the proposed future studies to ultimately better understand and ideally treat 
disease characterized by aberrant mTORC1 signaling.  
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SUMMARY 
Tumor cells undergo a metabolic shift toward specific bioenergetic (glycolysis) 
and anabolic (protein and lipid synthesis) processes that promote rapid growth.  Nomura 
et al. (2010) now demonstrate that an increase in monoacylglycerol lipase (MAGL) 
drives tumorigenesis through the lipolytic release and remodeling of free fatty acids [1]. 
 
DISCUSSION 
The re-emergence of the field of tumor cell metabolism has yielded important 
new insights into the metabolic reprogramming of cells that accompanies their oncogenic 
transformation (for recent reviews, see [2, 3]).  The fundamental differences in both the 
catabolic and anabolic properties of a tumor cell relative to its tissue of origin could 
provide opportunities for selective therapeutic approaches.  How cancer cells sense and 
use nutrients also impacts our understanding of dietary influences on tumor 
development and progression.  To date, the majority of research on cancer metabolism 
has focused on the nearly ubiquitous catabolic switch of tumor cells (and other rapidly 
proliferating cells) from oxidative to glycolytic metabolism even in the presence of 
oxygen. This is referred to as aerobic glycolysis or, more popularly, the Warburg effect.  
However, tumor cells also commandeer anabolic processes resulting in elevated rates of 
protein, nucleic acid, and lipid biosynthesis.  For instance, tumor cells exhibit a 
pronounced increase in de novo fatty acid synthesis, whereas normal cells are thought 
to acquire fatty acids primarily from dietary sources [4, 5]. Nomura et al. demonstrate an 
unexpected role for lipolytic remodeling of lipid species in promoting the tumorigenic 
properties of cancer cells [1]. 
A functional screen for differences in the activity of serine hydrolases in a small 
number of human cancer cell lines revealed that the activity of monoacyglycerol lipase 
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(MAGL) was elevated in those lines classified as more aggressive [1].  MAGL activity 
was also elevated in ovarian tumor tissue from patients with more advanced disease.  
This enzyme hydrolyzes monoacyl glycerols (MAGs) to release glycerol and a free fatty 
acid (FFA), and its best-characterized substrate is 2-arachidonoylglycerol, an 
endocannabinoid MAG [6].  Interestingly, the more aggressive cancer cell lines and high-
grade primary tumors contained elevated FFA levels, which could be substantially 
reduced by pharmacological and short-hairpin RNA-mediated attenuation of MAGL 
activity. This surprising finding suggests that MAGL-dependent hydrolysis of MAGs is a 
major source of intracellular FFAs in aggressive cancer cells. 
The MAGL-dependent remodeling of lipids appears to contribute to the 
transformed properties of tumor cells [1].  Using in vitro cell-based assays, the authors 
found that inhibition of MAGL activity impaired the enhanced migration and invasive 
capabilities of aggressive cancer cells and diminished their survival upon growth factor 
withdrawal.  Interestingly, exogenous addition of the saturated FFAs palmitate (C16) or 
stearate (C18) to MAGL-inhibited cells rescued the migration defects.  Reciprocally, 
overexpression of MAGL or addition of FFAs could enhance these phenotypes in less 
aggressive cancer cell lines exhibiting low MAGL activity.  MAGL knockdown or 
pharmacological inhibition also blunted xenograft tumor growth in mice, and this was 
accompanied by a significant decrease in FFA levels within the tumors.  Strikingly, these 
in vivo effects of MAGL inhibition on tumor growth and lipid levels were reversed by 
feeding the mice a high-fat diet.  Collectively, these data demonstrate that MAGL 
promotes the oncogenic properties of tumor cells by increasing FFA levels. 
To determine the mechanism of action of the FFA products of MAGL activity, the 
investigators took a lipidomics approach to identify lipid species sensitive to increases or 
decreases in MAGL activity in cancer cells [1].  This profile revealed that MAGL activity 
not only decreases MAGs and increases FFAs, but also leads to an increase in specific 
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FFA-derived signaling lipids, such as phosphatidic acid (PA), lysophosphatidic acid 
(LPA), and prostaglandin E2 (PGE2).  The authors propose that these lipids activate 
tumor-promoting signaling events, and they demonstrate that LPA and PGE2 can rescue 
the migration defects of cancer cells with attenuated MAGL activity.  Interestingly, both 
LPA and PGE2 stimulate G protein-coupled receptor-mediated signaling events and 
promote multiple oncogenic properties in tumor cells [7]. This study suggests that MAGL 
activity plays a major role in the production of signaling lipids, which then stimulate tumor 
cells in an autocrine manner.  
The relationship between the synthesis, storage, and use of FFAs in tumor cells 
is poorly understood.  Most cancer cells express elevated levels of fatty acid synthase, a 
multi-functional enzyme that converts malonyl-CoA to palmitate, thereby explaining the 
increase in de novo lipogenesis in these cells [4, 5].  However, the Nomura et al. study 
makes a compelling case that hydrolysis of acylglycerols, such as MAG, is a major 
source of FFAs in tumor cells (Figure A-1).  The authors propose that newly synthesized 
FFAs are immediately converted into neutral lipid stores and that the use of FFAs is 
dependent on their lipolytic release, with MAGL being the critical lipase.  However, 
further investigation regarding the fate of newly synthesized FFAs versus those released 
by hydrolysis of acylglycerols in tumor cells is needed.  Through in vitro assays, Nomura 
et al. focus primarily on the contribution of MAGL-derived lipid mediators to cancer cell 
migration.  However, the tumor-promoting effects of MAGL in the in vivo xenograft model 
are more likely to depend on increased cell growth and proliferation.  These are 
processes predicted to rely on lipid remodeling for new membrane biosynthesis and, 
perhaps, beta-oxidation for energy production to support accompanying anabolic 
processes.  Although the bioenergetic needs of cancer cells are predominantly met 
through glycolysis, the oxidation of FFAs offers an alternative route (e.g., [8, 9]).  Again, 
the question is whether the in vivo fates of FFAs derived from de novo synthesis versus  
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Figure A-1. Free fatty acids in tumor cells.  Tumor cells display elevated rates of de 
novo free fatty acid (FFA) synthesis due, in large part, to their increased expression of 
fatty acid synthase (FASN).  Newly synthesized FFAs are believed to be converted to 
neutral lipid stores, including mono- (MAG), di- (DAG), or tri- (TAG) acylglycerols.  The 
activity of monoacylglycerol lipase (MAGL), which catalyzes the lipolytic release of FFAs 
from MAGs, is elevated in more aggressive tumor cells (Nomura et al., 2010).  MAGL 
plays a critical role in maintaining the increase in FFAs in such cells and in promoting the 
production of FFA-derived signaling lipids, such as phosphatidic acid (PA), 
lysophosphatidic acid (LPA), and prostaglandin E2 (PGE2).  Other potential fates of 
newly synthesized or released FFAs include conversion to specific lipid species for 
incorporation into cellular membranes or β-oxidation for the production of ATP.  FFA 
remodeling and utilization contribute to tumor cell proliferation, growth, and migration.   
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lipolytic release differ or whether FFAs ultimately enter the same pool for remodeling or 
catabolic use. 
Many exciting new questions arise from the findings reported by Nomura and 
colleagues regarding the role of both MAGL and exogenous lipids in tumor development 
and progression.  For instance, how is MAGL expression and activity regulated in tumor 
cells, and how widespread is its activation in cancer?  Is MAGL a metastasis factor and 
can its activity be used as a biomarker to predict the influence of dietary fats and obesity 
on tumor progression? Although MAGL was found to increase cell migration and 
invasion in vitro, the effects on tumor metastasis were not examined in this study 
(Nomura et al., 2010).  Interestingly, the inhibitory effects of MAGL attenuation on tumor 
growth were reversed by feeding the mice a high fat diet, which has been shown to 
promote metastasis in other xenograft tumor models (e.g., [10]).  It will be interesting to 
determine whether conditions of obesity lead to increased levels of FFA-derived 
signaling lipids, such as LPA, within tumors.  Finally, the antitumor effects of the MAGL-
selective inhibitor used in this study suggest that MAGL is a promising therapeutic target 
for treating cancer.  However, the critical role of MAGL in attenuating endocannabinoid 
signaling in the brain could lead to behavioral side effects that are unique amongst 
cancer drugs [6].  It is clear that we are just beginning to understand the molecular 
contributions of alterations in lipid metabolism to the pathology of cancer. 
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